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Abstract
PUTATIVE ROLES OF CD200 IN THE LEUKEMOGENESIS AND IMMUNE
EVASION OF LEUKEMIA STEM CELLS

Shelley Marie Herbrich, M.S.

Advisory Professor: Marina Konopleva, M.D., Ph.D.

Acute myeloid leukemia (AML) stem cells (LSC) are capable of surviving
current standard chemotherapy and are the likely source of deadly, relapsed
disease. While stem cell transplant serves as proof-of-principle that AML LSCs can
be eliminated by the immune system, the translation of existing immunotherapies
to AML have been met with limited success. Consequently, understanding and
exploiting the unique immune mechanisms of AML LSCs is critical. To identify
novel immunotherapeutic targets, we sourced multiple large, publicly available
datasets and identified CD200 as a potential stem-cell specific immune checkpoint
in AML. We hypothesized that CD200 was a stem-cell specific mechanism of
evading immune detection and destruction and that anti-CD200 antibody therapy
could effectively eliminate AML LSCs by engaging the patient’s immune system.
To study the functional role of CD200 in AML, we established and characterized
two isogenic cell line models of CD200 expression. Utilizing these cells, we
investigated the effects of CD200+ leukemia on the effector functions of isolated T
cells, NK cells, and macrophages in vitro. To study CD200 in a physiological
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setting, we established a PBMC-humanized mouse model, in which we could
characterize progression of CD200+ and CD200- AML in the presence of an
activate human immune response. Further, we used this model to compare the
effects of CD200+ AML on the transcriptional activity and functional capacity of the
human T cells. To therapeutically target CD200+ leukemia, we developed a novel,
humanized CD200-IgG1 antibody. We investigated the potential of this antibody to
both inhibit the immunosuppressive signaling through the CD200 receptor and
initiate an antibody-mediated response. By comparing the therapeutic efficacy in
both immunocompromised and PBMC-humanized mice, we confirmed that
CD200-IgG1 could effectively eliminate CD200+ AML only in the presence of T
cell-mediated response. Taken together, we conclude that CD200 is a marker of
functional AML stem cells that aids in the escape of immune detection and
destruction. Furthermore, these studies lay the groundwork for CD200-targeted
therapeutic strategies to specifically eliminate LSCs and prevent relapse of AML.
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Chapter I
Introduction

1

1.1

Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a clonal malignancy of the bone marrow

derived from immature hematopoietic cells. Accumulation of mutations and genetic
translocations result in malignant transformation of hematopoietic stem cells and
early myeloid progenitor cells that maintain the ability to self-renew and propagate.
The rapidly expanding leukemia cells commandeer the available resources in the
bone marrow and outcompete healthy hematopoiesis. The severe reduction of
healthy red blood cells, platelets, and neutrophils, result in anemia,
thrombocytopenia, and neutropenia. These systemic conditions lead to symptoms
such as lethargy, bruising, and frequent infection. Due to the rapid onset of disease
and the nondescript symptoms, most AML patients are diagnosed after the blast
count, or abundance of disease, is high1,2.
While age is typically considered the biggest “risk factor” for developing
AML, there are few specific genetic and environmental components that
predispose individuals to disease. Familial or genetic predisposition include
inherited mutations in the telomerase complex3, germline chromosomal
abnormalities, like Down Syndrome4, and bone marrow failure syndromes, such
as Fanconi anemia5, Shwachman syndrome6, and Diamond-Blackfan syndrome7.
Patients with myeloid dysplastic syndrome (MDS) are also at higher risk of
developing AML8.
Certain environmental exposures also increase the odds of developing
AML. A meta-analysis of 22 studies found a consistent link between high benzene
exposure and acute myeloid leukemia across various industry sectors9.
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Unfortunately, exposure to radiation and chemotherapy, used for the treatment of
other neoplasms can also increase the odds of developing AML. In fact, therapyrelated AML (t-AML) makes up approximately 10% of all AML cases and have
been shown to have inferior outcomes when compared to de novo leukemia10.
Frontline chemotherapy results in remission in up to 80% of patients,
however, the 5-year survival rate for those with AML is only 50% for younger
patients and <30% for the elderly patients; statistics that have remained relatively
unchanged for more than a decade2. This discrepancy is due to the fact that most
patients relapse and relapsed disease is deadly11. It has been postulated that
therapy-resistant leukemia stem cells (LSCs) are the most probable source of
relapse, implicating LSCs as the critical target for curing AML.

1.2

Acute Myeloid Leukemia Stem Cells
The cancer stem cell controversy began in the 19th century when a German

pathologist, Robert Virchow, remarked on the similarities between cancerous cells
and cells of embryonal origin12. Since then, there have been numerous variations
of the cancer stem cell hypothesis that all converge upon the notion that there must
exist a cell, or subset of cells, that represent the origin of disease. The first
experimental evidence of a cancer stem cell came when it was demonstrated that
certain subsets of acute myeloid leukemia cells could engraft and recapitulate
disease in immunocompromised mice13.
Normal hematopoiesis follows a hierarchical, albeit fluid, structure with a
well-established, well-characterized hematopoietic stem cell (HSC) residing at the
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apex. Thus, it was hypothesized that the malignant versions of these stem and
progenitor cells would also mimic a hierarchical structure by maintaining selfrenewal while also producing more differentiated, nonfunctional blast cells (Figure
1)14. Work by John Dick and colleagues confirmed the existence of such cells,
eventually named leukemia stem cells (LSCs), using a series of clonogenic and
transplantation studies13,14.
Now, LSCs are functionally defined as those cells capable of engrafting and
giving rise to disease in sub-lethally irradiated immunodeficient mice13. In AML,
LSCs are generally defined by their immunophenotype as being positive for CD34
and negative for CD38, with an ever-growing list of exceptions. In most patients,
LSCs are thought to comprise only a small fraction of the overall disease, however,
their unique biological properties implicate them as both the initiators of disease
as well as the most likely source of relapse. Patients with genetic signatures similar
to LSCs have significantly worse overall survival in multiple patient cohorts15,16.
Further molecular characterization of AML LSCs has demonstrated that
they, similar to their health HSC counterparts, are largely quiescent, and capable
of both long-term self-renewal and production of more differentiated cells17. Their
relatively dormant cell cycle make LSCs less vulnerable to therapeutic agents that
preferentially target dividing cells, like chemotherapy or radiation18. LSCs have
also been shown to selectively upregulate anti-apoptotic proteins, such as BCL-2,
as an added layer of protection19. Taken together, this evidence implicates LSCs
as the cells most likely to evade standard therapy and give rise to relapsed
disease.
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Figure 1. Schematic of normal hematopoiesis and leukemogenesis. Normal
hematopoiesis follows a hierarchical structure with hematopoietic stem cells
residing at the apex. Acquisition of mutations and translocations in myeloid stem
and progenitor cells give rise to the leukemia stem cell, capable of self-renewal
and production of blast cells. HSC= hematopoietic stem cell, MPP= multipotent
progenitor cell, CLP= common lymphoid progenitor. CMP= common myeloid
progenitor, LSC= leukemia stem cell.
4

1.3

Current therapy
Standard of care for acute myeloid leukemia has remained relatively

unchanged since the introduction of the “3+7” strategy over 30 years ago. Upon
diagnosis of AML, patients receive induction chemotherapy which consists 3 days
of an anthracycline (typically either daunorubicin or idarubicin) and 7 days of
continuous infusion of cytarabine. This approach results in morphological complete
remission in 60-80% of patients between 18-60 years of age and only 30% in those
60 and older. Post-remission strategies vary by patient and response and can
include continued maintenance therapy, intensive chemotherapy, or ablative
therapy followed by hematopoietic stem cell transplant2.
One of the few recent changes in frontline care for AML came in 2018, when
the FDA approved venetoclax, a potent BCL-2 inhibitor, in combination with
hypomethylating agents (HMA) for the treatment of newly diagnosed AML in older
patients20. This came as a result of the multicenter Phase 1B clinical that
demonstrated deep, durable responses that significantly outcompeted standard
chemotherapy20. The profound success of venetoclax plus HMA was attributed to
the disruption of energy metabolism specific to AML LSCs21.

1.4

Immunotherapy in AML
While immunotherapy has gained a great deal of recent publicity for the

unparalleled successes seen with checkpoint inhibitor therapy in melanoma22 and
non-small cell lung cancer23, cancer immunotherapy is no new concept. Curing
cancer with the immune system was actually first described in AML over 40 years
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ago24. It was demonstrated that immune cells reconstituted from donor marrow
were capable of eliminating residual leukemia cells and curing patients. Allogeneic
stem cell transplant (allo-SCT) after myeloablative chemotherapy is still the best
option for reducing the likelihood of relapse25. The graft-versus-leukemia (GvL)
response induced by the introduction of foreign immune cells demonstrates that
LSCs are vulnerable to destruction by the immune system. However, the
mechanism of allo-SCT success can also be hazardous, resulting in high rates of
treatment-related mortality and morbidity. Despite this knowledge, immunotherapy
has not yet been optimally exploited for the treatment of AML. Popular checkpoint
inhibitors are now being explored in combination therapies in AML patients with
limited sucess26. Immunotherapy clinical trials in AML are broadening to include
monoclonal antibodies, both drug-conjugated and naked, bispecific engager
antibodies and chimeric antigen receptor (CAR) T and NK cells to target specific
leukemia antigens like CD33 and CD12327. However, many of these antigenspecific approaches focus on the bulk disease rather than the stem cell biology.
Therefore, there is a need for novel approaches to exploit the immune system to
explicitly eliminate LSCs while limiting toxicity.

1.5

CD200 in Immunology
Cluster of differentiation 200, or CD200, is a type-1 transmembrane

glycoprotein that is a member of the immunoglobulin superfamily. CD200 is
broadly expressed in neurons, B cells, and subsets of endothelial cells28. This
small 41-47kD protein consists of two extracellular immunoglobulin superfamily
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domains, a single transmembrane domain, and a short cytoplasmic tail29-31.
Because the intracellular portion of CD200 contains no known signaling motifs or
consensus binding sites for adapter molecules, it has been hypothesized that the
primary role of CD200 is through its interaction with the CD200 receptor32.
The CD200 receptor, CD200R1, is the only established binding partner for
CD20033. Unlike its ligand, CD200R is almost exclusively expressed on subsets of
myeloid and lymphoid cells. This pattern of expression has led to the belief that the
CD200/CD200R signaling axis primarily acts as a local regulator of immune
response. Like CD200, the receptor consists of two extracellular immunoglobulin
superfamily domains and a single transmembrane domain. However, the
intracellular tail is longer and contains 3 tyrosine residues34. Most inhibitory
receptors on lymphocytes, including Programmed cell death protein 1 (PD-1), T
cell immunoreceptor with Ig and ITIM domains (TIGIT), and T-cell immunoglobulin
domain and mucin domain 3 (TIM-3), signal by recruiting Src homology domain
containing protein tyrosine phosphatases (SHP-1 and SHP-2) to immunoreceptor
tyrosine-based inhibition or switch motifs (ITIMs or ITSMs) which directly
dephosphorylate proteins downstream of the T cell receptor35. CD200 receptor
lacks ITIM/ITSMs. Instead, upon ligation of CD200, the downstream tyrosine
kinase (Dok2) adapter protein is recruited to the distal phosphorylation residue
where it further recruits the SH2 domain containing protein, RAS p21 protein
activator (RasGAP). The Dok2/RasGAP complex is sufficient to inhibit Ras
activation, which leads to the subsequent inhibition of the mitogen-activated
protein kinase (MAPK) signaling cascade (Figure 2)36. While CD200R suppression
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has been primarily studied through MAPK, inhibition of Ras activity can also impair
the PI3K/AKT/mTOR pathway37.
Both the CD200-/- and CD200R1-/- C57BL/6 mouse models are viable. While
grossly normal, CD200-/- mice displayed an increased number of macrophages
that were more phenotypically activated upon stimulation38. These mice were also
more susceptible to experimental allergic encephalomyelitis (EAE) and collageninduced arthritis; both diseases largely regulated by myeloid cells. There was also
no evidence of abnormalities in the cells that normally expressed CD200. This
model suggested that the primary role of CD200 was the suppression of myeloid
and macrophage activity. Complimentary evidence in the CD200R1 knockout
mouse demonstrated a more potent inflammatory response, as measured by the
release of tumor necrosis factor alpha (TNFα), in response to lipopolysaccharides
(LPS), a known stimulator of myeloid cells39. These mice are also used as a model
system to study instances of chronic inflammation and infection40-42.
Functional studies using CD200R agonists reported that the primary
molecular mechanisms of CD200-mediated immunosuppression were the
inhibition of interferon gamma (IFNγ) and interleukin 17 (IL-17) cytokine secretion
from murine macrophages and downregulation of IL-5 and IL-13 cytokine
production from human monocytes43. Additionally, CD200-Ig fusion proteins
induce the production of indoleamine 2,3-dioxygenase (IDO) from dendritic cells
which promoted immunosuppressive tryptophan catabolism and suppressed
antigen-specific immune responses44.
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Figure 2. Schematic of CD200R signaling.
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1.6

CD200 in AML
The bulk of our understanding of the role of CD200 in AML has come from

the labs of Alexander Tonks and Richard Darley. First, Coles et al observed that
AML patients with high bulk CD200 expression had approximately half the
frequency of activated natural killer (NK) cells when compared to AML with low
CD200. Additionally, it was demonstrated that CD200 could have a directly
suppressive role on cell function by suppressing NK cell degranulation and
interferon production45. In the adaptive immune cell subsets, CD8+ memory T cells
from AML patients with high levels of CD200 were less capable of producing
CD107a after ex vivo stimulation. Similarly, CD200-high patients had significantly
fewer CD4+ memory T cells capable of secreting the inflammatory cytokines,
TNFα and IL-2, upon artificial stimulation46. This could indicate T cell exhaustion
in patients with high CD200 expression on leukemia cells. Within patients, CD200
expression on AML cells was also observed to correlate with the abundance of
FoxP3+CD4+ regulatory T cells, a known immunosuppressive immune cell subset
that is indicative of poor prognosis47. Finally, it was observed that CD200 on AML
blasts positively correlated with expression of the immune checkpoint PD-1 on
cytotoxic CD8+ T cells48. Taken together, there is preliminary evidence that CD200
is an important regulator of immune cell function in AML.
CD200 has also been reported to be clinically relevant in AML. High CD200
expression on bulk AML disease was associated with a 50% reduction in odds of
complete remission and significantly worse overall survival when compared to
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patients with negligible CD200 expression, excluding core-binding factor
leukemias49-51.

1.7

CD200 in Stem Cell Biology
CD200 has also been reported as a marker of both normal and cancer stem

cells. In the normal setting, CD200 has been used to accurately identify colonyforming follicular stem cells52. An unbiased screen of 240 cell-surface markers on
fat depots revealed that CD200 uniquely differentiated visceral-fat adipose-derived
stem cells from subcutaneous-fat stem cells53. In another screen of plasma
membrane proteins of mesenchymal stem cells (MSCs), CD200 was identified as
a novel MSC marker and that expression on cells decreased after adipogenic
differentiation54.
Kawasaki et al first posited that cancer stem cells may have unique
mechanisms of evading immune cell detection and destruction. Using cell lines
derived from prostate, breast, colon, and glioblastoma, they showed that CD200expressing cells were rare and almost exclusively found in the stem cell fraction of
disease55. In acute myeloid leukemia, CD200 expression was significantly
enriched in disease high for CD34, the established AML LSC marker50. Early data
also suggests that CD200 may also identify stem cells in AML that is negative for
CD3456.
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1.8

Existing CD200-targeted therapy
Samalizumab is a humanized anti-CD200 IgG2/G4 chimeric antibody

engineered to specifically block CD200 binding to the CD200R without inciting Fcmediated effector functions57. The decision to use an antibody backbone without
innate effector function was based on preliminary data suggesting that the IgG2/G4
version was just as effective at eliminating disease as the effector-engaging IgG1
version in a subcutaneous model of Non-Hodgkin’s lymphoma58,59. In the Phase
I, first-in-human, trial of single-agent samalizumab for the treatment of chronic
lymphocytic leukemia (CLL) and multiple myeloma (MM), 14 out of 21 CLL patients
experienced a dose-dependent decrease in the frequency of CD200-expressing
leukemia cells and reduction in overall disease burden. Samalizumab was well
tolerated and had a good safety profile [NCT00648739]57. Single-agent
samalizumab was also included as a therapeutic arm of the BEAT AML clinical trial
[NCT03013998] for previously untreated patients with core-binding factor
leukemias which present with high levels of bulk CD200 expression. The results of
this arm were not included in the trial summary60.
Another emerging CD200-targeted therapy involves modified T cells with
immunomodulatory fusion proteins (IFPs)61. In this unique strategy, CD8+
cytotoxic T cells are engineered to express an artificial protein that contains the
extracellular CD200 receptor domain fused to the intracellular signaling domain of
the T cell costimulatory protein, CD2862. In response to CD200-expressing
leukemia cells, the CD200R-CD28 T cells demonstrate enhanced effector function
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and proliferation by directly converting the previously suppressive CD200 ligand
into a T cell activator.

1.9

Hypothesis and Research Goals
A better understanding of the precise mechanisms employed by LSCs to

evade immune detection and destruction are critical to developing targeted
immunotherapy for curing AML. CD200 has been implicated as a stem cell marker
for certain normal and cancerous tissues. Clinically, CD200 is a poor prognostic
marker in AML. Functionally, CD200 has been shown to be immunosuppressive
by inhibiting macrophage and NK cell function and also inducing regulatory T cells.
Monoclonal antibodies against CD200, like samalizumab, are currently in Phase
I/II clinical trials. At present, CD200-mediated immunotherapy has not been
translated to specifically target AML LSCs to facilitate clearance by the patient’s
immune system.
The long-term goal of this research project is to understand the patientspecific immune evasion mechanisms of leukemia stem cell populations to
improve personalized immunotherapies and, ultimately, eradicate AML. This
dissertation investigates the intrinsic and extrinsic functions of CD200, a novel
marker of AML LSCs, and explores the potential therapeutic benefit of targeting
CD200 on LSCs using monoclonal antibodies. I hypothesize that, in a subset of
AML, high expression of CD200 is an LSC-specific mechanism for evading both
innate and adaptive immune-mediated cell death and that CD200 blockade will
result in the clearance of LSCs by the immune system.
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To address this hypothesis, I endeavored to (Figure 3):
1. Validate CD200 as a novel AML stem cell marker by
a. evaluating AML LSC gene expression datasets
b. performing clonogenic assays with CD200+ AML patient samples
c. constructing and characterizing 2 isogenic AML cell line models of
CD200 expression
2. Determine the role of CD200-expressing AML on the immune system by
a. performing isolated mixed-lymphocyte reactions with cells from
both the innate and adaptive immune systems.
b. evaluating CD200-expressing and non-expressing leukemias in
humanized mouse models.
3. Test the pre-clinical utility of a novel CD200-IgG1 antibody by
a. characterizing the antibody-mediated and CD200 blockingmediated effects of anti-CD200 therapy.
b. evaluating single-agent therapy in immunocompromised and
humanized mouse models.

Significance and Impact: This dissertation introduces CD200 as a novel marker of
acute myeloid leukemia stem cells. Further, this work reveals that AML LSCs have
unique mechanisms by which they interact with and control the neighboring
adaptive and innate immune systems. Finally, this body of work demonstrates that
specifically targeting LSCs with a proprietary anti-CD200 monoclonal antibody can
be a curative approach to AML.
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Figure 3. Graphical abstract summary.
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Chapter II
CD200 is an AML stem cell marker
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2.1

Abstract

Purpose: Accurately targeting acute myeloid leukemia stem cells, particularly with
immunotherapy, requires a better understanding of the genes and biological
processes that are uniquely employed by these cells. In this chapter, we used an
in silico approach, leveraging the wealth of publicly available data, to identify novel
AML LSC targets. We then performed a series of experiments to validate one of
these markers, CD200, in both human and murine leukemia.

Experimental design: We sourced 3 large, publicly available datasets that
contained gene expression profiling on sorted LSCs, blasts, and normal
hematopoietic subsets and identified CD200 as being uniquely overexpressed in
LSCs. Primary AML patient samples were screened for CD200 expression by flow
cytometry. Mass cytometry was performed to track CD200 in patients over the
course of immunotherapy treatment. Colony formation assay were used to
challenge AML cell subsets for in vitro repopulation potential. Stem cell function in
CD200+ murine AML was tested by transplantation assays. Two isogenic cell line
models were engineered using both CRISPR/Cas9 knockout and overexpression
to study the functional role of CD200 in AML.

Results: CD200 transcript was identified as significantly overexpressed in LSCs
compared to blasts and healthy HSCs using publicly available databases.
Subsequently, using AML patient samples, we confirmed CD200 surface protein
expression in >90% of primary AML cases. Further, CD200 more specifically
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identified human AML LSCs than CD34. In a murine model of AML, CD200 also
identified functional LSCs, which was consistent with our human data.
Manipulating human CD200 in AML cell lines did not significantly alter growth,
metabolism, or engraftment but did result in differential transcription and the
upregulation of genes involved in DNA damage response. CD200+ clones of
disease persisted in the presence of immunotherapy treatment.

Conclusions: We found that CD200 is a novel marker of LSCs in both human and
murine models of AML. While not previously described, our data suggests a
potential intrinsic role of CD200 in regulating cellular response to DNA damage.
This added protection may explain the persistence of CD200 disease in resistant
and relapsed AML.
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2.2

Introduction

History of AML LSCs. Acute myeloid leukemia (AML) was first shown to mimic a
normal hematopoietic hierarchy 50 years ago using clonogenic assays63,64. Since
then, seminal work by Dick and colleagues has demonstrated that a small fraction
of AML cells was capable of engrafting and recapitulating disease in nonobese
diabetic (NOD) severe combined immunodeficient (SCID) mice, originally termed
SCID leukemia-initiating cell (SL-IC)13,14. These SL-IC had the stem cell properties
of both long-term self-renewal and differentiation into leukemic blasts and would
later go on to be called leukemia stem cells (LSCs). While LSCs are rare, their
unique biological properties implicate them as both the initiators of disease as well
as the most likely source of relapse65. In fact, LSC gene expression signatures
have been shown to be independent predictors of worse overall survival in multiple
patient cohorts15,16. Therefore, understanding the biology of LSCs is critical to their
eradication in AML.

Biological properties of AML LSCs. Similar to their normal hematopoietic stem cell
(HSC) counterparts, LSCs are characterized by cell cycle quiescence17. Treatment
with 5-fluorouracil (5-FU) is toxic to actively cycling cells and has been traditionally
used to purify healthy hematopoietic stem and progenitor populations66. Terpstra
et al found that treating AML with 5-FU selected for cells capable of engrafting in
SCID mice, suggesting that AML stem cells were either more resistant to 5-FU
cytotoxicity or more quiescent67. By partitioning primary AML patient samples by
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cell cycle status based on 3H-thymidine incorporation or DNA content assays,
Guan et al more definitively demonstrated that the functional leukemia stem cells
were enriched in the quiescent/G0 cell fractions68. LSC quiescence is one of the
proposed mechanisms by which these cells selectively evade the effect of
chemotherapeutic agents that rely on active cell cycling for cytotoxicity18.
In contrast, HSCs and LSCs have different metabolic dependencies.
Healthy, quiescent CD34+ cells have a decreased dependence on oxidative
phosphorylation (OXPHOS) and efficiently employ glycolysis to sustain their
minimal energy requirements69. However, studies by our lab and others have
demonstrated that LSCs are uniquely metabolically dormant and rely almost
exclusively on mitochondrial respiration for survival70,71. This unique metabolic
dependency on OXPHOS was shown to be mediated by the upregulation of the
anti-apoptotic B-cell lymphoma 2 (BCL-2) protein and targeting BCL-2 with a BH3
mimetic could selectively eliminate AML LSCs19,70.

Immunophenotype of AML LSCs. A seemingly simple yet critical aspect of AML
LSC research is the ability to accurately and systematically identify these cells in
heterogeneous disease. Early xenotransplantation studies in SCID or NOD-SCID
indicated that the only cells with stem capabilities resided exclusively in the
CD34+CD38- cell fraction13,14. However, with the advent of more immunodeficient
NOD/SCID/IL2R-γ null (NSG) mouse models and careful consideration of stem cell
isolation, leukemia stem cells have been identified outside the of CD34+CD38partition72-76. In fact, it is now appreciated that approximately half of AML patient
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samples will also have functional stem cells that are either CD34+CD38+ or even
CD34-15. Goardon et al further demonstrated that 2 molecularly distinct, functional
stem cell subtypes coexist in a hierarchical relationship within approximately 80%
of AML patients77. Another notable exclusion to the CD34+CD38- stem cell rule
are AML samples with mutations in nucleophosmin (NPM1). In these samples,
which make up approximately 30% of de novo AML, the majority of functional stem
cells are CD34-78-80. Thus, CD34 no longer remains a reliable way to partition
functional leukemia stem cells. Many groups have endeavored to discover more
universal LSC markers using gene expression studies of immunophenotypically
sorted AML samples. In the past few years, numerous candidates, including
CD12381, CD2517, CD3217, CD4482, CD9683, CD9984, CLL-185, IL1RAP86, and
TIM387, have been posited as superior identifiers of AML LSCs. However, these
markers alone have not been able to consistently segregate functional LSCs ex
vivo. Beyond studying stem cell biology, having a universal AML stem cell marker
is critical for developing targeted immunotherapeutics.

In this chapter, we aimed to (1) identify, (2) validate, (3) and characterize CD200,
a novel marker of functional AML LSCs.
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2.3

Materials and Methods

In silico screen. The pre-aligned RNA-seq data from Corces et al was downloaded
through the NCBI GEO portal under accession number GSE7424688. Normalized
Illumina expression array data generated by de Jonges et al was downloaded
through NCBI GEO under accession GSE3002989. Affymetrix CEL files generated
by Jung et al were downloaded through NCBI GEO under accession GSE6327090.
Appendix A contains all scripts used to process and analyze these data.

Flow cytometry and cell sorting of primary human AML. Primary AML bone marrow
biopsies or peripheral blood draws were collected under the MD Anderson
Institutional Review Board protocol PA12-0173. PBMCs were isolated by density
gradient separation. Briefly, whole blood samples were mixed at a 1:1 ratio with
Dulbecco’s Phosphate-Buffered Saline (PBS) without calcium and magnesium
(GenDEPOT) and gently added to 15ml Lymphocyte Separation Medium (Lonza;
cat. 17-829E). Cells were centrifuged at 1,800 RPM for 20 minutes and the
lymphocyte layer was carefully extracted. If necessary, 5ml ammonium chloride
solution (Stem Cell Technologies) was used to lyse any residual red blood cells for
5 minutes on a shaker. After counting, 3x105 cells were transferred to a 5ml FACS
tube and washed twice with staining buffer (PBS + 0.5% Bovine Serum Albumin
(Sigma-Aldrich)). Cells were human Fc-blocked with 5µl anti-human Fc receptor
binding inhibitor (eBioscience Invitrogen) in 100µl staining buffer for 15 minutes
prior to the addition of CD200-APC-Cy7 (Biolegend; cat. 329221) and CD34-FITC
(Biolegend) antibodies (1µl/sample). Surface stain was incubated for 30 minutes
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at room temperature on an orbital shaker followed by 2 washes with staining buffer.
Cells were resuspended in 300µl of staining buffer plus 5ul 4',6-Diamidino-2Phenylindole, Dihydrochloride (DAPI; 2µg/ml; Invitrogen) for live/dead cell
discrimination for collection on a LSRII machine (BD). Cell sorting followed the
same staining protocol with larger cell numbers and was run on the MoFlo Astrios
cell sorter (Beckman Coulter).

CyTOF mass cytometry. Frozen primary bone marrow samples were thawed and
immediately incubated in thawing media (10ml Minimum Essential Medium Eagle,
alpha modification (a-MEM; Sigma Life Science) with 20% heat-inactivated Fetal
Bovine Serum (FBS; GenDEPOT), 10mM MgSO4, 100µg/ml Heparin, and DNAse
for 15 minutes at 37°C prior to CyTOF staining. Sample barcoding and metalconjugated antibody staining were performed according to Fluidigm’s protocols as
described below. Briefly, all antibodies were labeled with heavy metals using
Maxpar-X8 labeling reagent kits (Fluidigm DVS Sciences) according to
manufacturer’s instructions and titrated for optimal concentration determination.
For normal and AML bone marrow samples, 1x106 cells were aliquoted into
separate FACS tubes and washed twice with Maxpar PBS Buffer (Fluidigm; cat.
201058). For live/dead cell discrimination, cells were resuspended in 200µl of 5µM
cisplatin (Fluidigm; cat. 201064) for 1 minute on an orbital shaker followed
immediately by 3 washes in Maxpar Cell Staining Buffer (CSB; Fluidigm; cat.
201068). Cells were then fixed in 1ml of 1x Fix I Buffer (Fluidigm; cat. 201065) for
10 minutes followed by 2 washes with 1x Barcode Perm Buffer (Fluidigm; cat.
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201057). Each unique Palladium Barcode (Fluidigm; Cell-ID 20-Plex Pd Barcoding
Kit cat. 201060) was suspended in 100µl of Barcode Perm Buffer and immediately
transferred to cells in 800µl Barcode Perm Buffer. Cells were incubated with
barcodes for 30 minutes followed by 2 washes with 2ml CSB. Barcoded cells were
then combined into a single tube for CyTOF staining. The staining factor was
calculated as the total number of barcoded cells/3x106. Cells were blocked with 5
μL x staining factor of anti-human Fc receptor binding inhibitor (eBioscience
Invitrogen) in 45µl x staining factor of CSB for 15 minutes at room temperature.
Appropriate amount of surface antibody master mix (Table 1) was added directly
to the tube and incubated for 1 hour at room temperature before 2 washes with
CSB. For intracellular staining, cells were dissociated in 1ml of Foxp3
Fixation/Permeabilization Buffer (eBioscience; cat. 00-5523-00) and incubated
overnight at 4°C followed by 2 washes with 2ml of 1X Permeabilization Buffer. After
discarding supernatant from the final wash, appropriate amounts of intracellular
antibody master mix were added to the residual Permeabilization Buffer for 1 hour
in the dark at room temperature. For cell discrimination, a metallointercalator
working solution (2 ml Permeabilization Buffer, 125nM iridium metallointercalator
(Fluidigm; cat. 201103A)) was added to the sample and incubated overnight at
4°C. Cells were washed with a minimum of 3mL CSB, then again with 3mL ddH2O
with 0.1% BSA. Finally, cells were filtered through a 35µm filter and resuspended
in 100µl ddH2O with 0.1%BSA. The MDACC Flow Cytometry and Cellular Imaging
Core Facility prepared the antibody cocktails and acquired data on a Helios CyTOF
machine (DVS Sciences).
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Isotope

Mass Channel

Marker

Clone

Source

Custom
Catalog #

Surface /
Intracellular

89Y
139La
141Pr
142Nd
143Nd
144Nd
145Nd
146Nd
147Sm
148Nd
149Sm
150Nd
151Eu
152Sm
153Eu
154Sm
155Gd
156Gd
158Gd
159Tb
160Gd
161Dy
162Dy
163Dy
164Dy
165Ho
166Er
167Er
168Er
169Tm
170Er
171Yb
172Yb
173Yb
174Yb
175Lu
176Yb

89
139
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176

CD45
CD56
CD27
CD274 (PD-L1)
CD19
CD11b
CD4
CD8a
CD278 (ICOS)
CD34
CD223 (LAG-3)
CD86
CD123
CD137 (41BB)
CD272 (BTLA)
CD28
CD117
TIM-3
OX40
FOXP3
TIGIT
CD152 (CTLA-4)
CD80 (CTLA-4L)
CD45RA
CD15
CD200
CD41
CCR7
CD38
CD25
CD3
CD200R
CD273 (PD-L2)
CD33
HLA-DR
CD279 (PD1)
CD127

HI30
NCAM16.2
O323
MIH1
HIB19
ICRF44
RPA-T4
RPA-T8
C398.4A
581
Poly
IT2.2
6H6
4-1BB
MIH26
CD28.2
104D2
F38-2E2
ACT35
259D/C7
MBSA43
14D3
2D10.4
HI100
W6D3
OX-104
HIP8
G043H7
HIT2
2A3
UCHT1
OX-108
24F.10C12
6C5/2
L243
EH12.2H7
A019D5

DVS-Fluidigm
BD
Biolegend
eBioscience
DVS-Fluidigm
DVS-Fluidigm
Biolegend
DVS-Fluidigm
Biolegend
DVS-Fluidigm
R&D
DVS-Fluidigm
DVS-Fluidigm
BD
Biolegend
Biolegend
Biolegend
Biolegend
DVS-Fluidigm
DVS-Fluidigm
eBioscience
DVS-Fluidigm
DVS-Fluidigm
Biolegend
DVS-Fluidigm
Biolegend
Biolegend
DVS-Fluidigm
DVS-Fluidigm
DVS-Fluidigm
DVS-Fluidigm
Biolegend
DVS-Fluidigm
Abcam
BIolegend
DVS-Fluidigm
DVS-Fluidigm

3089003B
559043
302802
14-5983-82
3142001B
3144001B
300502
3146001B
313502
3148001B
AF2319
3150020B
3151001B
555955
344502
302937
313202
345002
3158012B
3159028A
16-9500-82
3161004B
3162010B
304102
3164001B
329219
303702
3167009A
3167001B
3169003B
3170001B
329302
3172014B
ab11032
307602
3175008B
3176004B

surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
inracellular
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface

Table 1. Panel of antibodies used for AML patient CyTOF staining.

Mass cytometry data analysis. Data was first demultiplexed using the Fluidigm
Debarcoder software. Individual mass cytometry data files (.fcs) were then filtered
using FlowJo to remove the normalization beads, debris, doublets, and dead cells
(Figure 4). Remaining analysis was performed in R (version 3.6.1, The R
Foundation for Statistical Computing) using the R packages ‘cytofkit’91 and
‘flowcore’92. Processed data was subjected to negative value pruned inverse
hyperbolic sine transformation and clustered based on the PhenoGraph algorithm
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(k=22) using all cell surface markers93. Dimensionality reduction was performed

Irridium 193

Irridium 191

using uniform manifold approximation and projection (UMAP) method94.

Cells

Event length

CD3

Cisplatin

Beads

Single cells

Live

CD45

CD45+
CD45

Figure 4. CyTOF gating strategy. Cells were first discriminated from
normalization beads. Doublets were removed using Irridium 193 and event length.
Cells negative for cisplatin were considered viable. Finally, CD45+ cells were
selected for analysis.
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Colony formation assays. Sorted cells were counted and suspended at a
concentration of 2.5x105 in 400µl of RPMI-1640 (Lonza) + 10% FBS in 15ml Falcon
tubes. 4ml of MethoCult™ GF M3434 (Stem Cell Technologies; cat. 3434) was
transferred to each Falcon tube using a 5ml syringe with 18g1½ gauge needle.
Cells were suspended in the methylcellulose by vortexing for 1 minute. After 15
minute of rest, 3ml of methylcellulose from each sample were equally distributed
between 3 wells of a 6-well plate (2.5x104 cells/1ml/well) using a 3ml syringe with
18g1½ gauge needle. Cells were allowed to grow for 2 weeks before colonies were
manually counted. Colonies were required to contain at least 25 cells.

Mice. NOD-SCID IL2Rgnull (NSG) and CD45.1 C57BL/6 mice were obtained from
our breeding colony with breeders originally purchased from Jackson Laboratory.
C57BL/6 mice were purchased from the MD Anderson Experimental Radiation
Oncology department. Mice were approximately 5 to 8 weeks old at the time of
use. All mice were housed in accordance with the Association for Assessment and
Accreditation of Laboratory Animal Care and NIH standards. All experiments were
conducted according to protocols 00001146-RN02 and 00001446-RN01 approved
by the University of Texas MD Anderson Cancer Center Institutional Animal Care
and Use Committee.

Murine AML model. Transplantable Tet2-/-Flt3ITDCD45.2 murine AML cells were a
kind gift from Dr. Ross Levine. Cells were expanded in lethally irradiated (950cGy)
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CD45.1 C57BL/6 mice with support marrow. Donor CD45.2 leukemic cells were
collected from the bone marrow and spleen of moribund mice.

AML transplantation assay in vivo. NSG or CD45.1 C57BL/6 mice were sublethally
irradiated 24 hours prior to injection with doses of 250cGy and 450cGy,
respectively. Cd200+CD45.2+ and Cd200-CD45.2+ leukemia cells were sorted by
FACS and 2.5x105 cells were injected i.v. per mouse. Engraftment in mice was
tracked weekly by flow cytometry assessment of peripheral blood. Briefly, 50µl of
peripheral blood was collected retro-orbitally and red blood cell-lysed using
ammonium chloride solution. Remaining leukocytes were Fc receptor blocked for
15 minutes prior to staining with CD45.1 FITC (Biolegend), CD45.2 PerCP-Cy5.5
(Biolegend), and Cd200 APC (Biolegend) for 30 minutes at room temperature.
DAPI staining was used for live/dead cell discrimination.

Electroporation optimization. For both CRISPR/Cas9 and plasmid DNA delivery,
we used the Neon electroporation device (Thermo Fisher Scientific, cat.
MPK5000). To ensure cells were growing in log phase at the time of
electroporation, cell culture medium was changed daily three days prior to the
electroporation. The optimal electroporation conditions for the OCI-AML3 and
Kasumi1 lines were determined using the 24-well plate optimization protocol
(Thermo Fisher Scientific) with 10µl electroporation volumes (Thermo Fisher
Scientific, cat. MPK1096). All experiments were carried out using 100µl of R or T
buffer (Thermo Fisher Scientific, cat. MPK10096). After 48 hours, transfection
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efficiency was determined by flow cytometry. Optimal conditions were determined
by GFP positivity and toxicity.

Transfection. OCI-AML3 cells were stably transfected to express the CD200 and
luciferase constructs using the Sleeping Beauty transposon system95. Specifically,
canonical CD200 and luciferase constructs were inserted into the donor
transposon plasmid pSBbi-Pur (Addgene plasmid #6052395), and 9µg of the
transposon plasmid was electroporated together with 5µg of the transposase
plasmid pCMV(CAT)T7-SB100 (Addgene plasmid #3487996) per 1.2 million cells
in 100µl R buffer. Cells were then re-suspended in 3mL of pre-warmed antibioticfree culture media and cultured for 48 hours without disruption. Cells were
consequently selected for integration by hygromycin B at a final concentration of
200µg/mL.

CD200 CRISPR/Cas9 knockout. To reduce any off-target effects, two unique
sgRNAs were selected to target both the canonical, full length and the shorter
isoform of CD200 (Table 2). The sgRNAs were cloned into hSpCas9 pX330
backbone vector, a kind gift from Feng Zhang (Addgene plasmid #42230)97. Cells
were transfected using the Neon electroporation device using predetermined
conditions according to optimization experiments in 100µl R buffer. Cells were resuspended in 3mL of pre-warmed antibiotic-free culture media and cultured for 48
hours without disruption. Knockout was confirmed by surface flow cytometry and
cells were sorted into CD200+ and CD200- lines by FACS sorting.
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Target

Cell Line

gRNA1 (forward)

gRNA2 (forward)

Cas9B backbone plasmid

target region

CD200

Kasumi1

CACCCCATGGTT
CTCGCTGAAGG

GGTGATCCAGC
CTGCCTATAAGG

hSpCas9 (pX330)

Common
exon

Table 2. CRISPR/Cas9 guide RNA (gRNA) sequences.
Growth assays. To assess cell proliferation, 2.5x105 cells were seeded in 1mL of
complete media in 12-well plates. At the indicated time points, 10µl from each well
were collected and viable cells were counted using trypan blue exclusion with a ViCell XR Cell Viability Analyze (Beckman Coulter).

Cell cycle assay. 5x105 cells were collected in FACS tubes and washed with cold
PBS. Cold 70% ethanol was added drop-wise to cells while vortexing. Cells were
then fixed for 30 minutes at 4°C followed by 2 washes with PBS at 800g. To
eliminate RNA, cells were treated with 5µg RNAse prior to staining with 200µl
propidium iodide (50µg/ml; Biolegend, cat. 421301) and 5ul DAPI (2µg/ml). DNA
abundance of live cells was collected by flow cytometry.

Seahorse metabolism assay. To evaluate metabolic phenotype, in particular the
impact of CD200 on mitochondrial respiration, oxygen consumption rates (OCR)
and extracellular acidification rates (ECAR) were measured in parental OCIAML3
and in OCIAML3 with CD200 overexpression as well as in parental Kasumi cells
and Kasumi with CD200 knockout, using Seahorse Mito Stress Test (Agilent

30

Technologies). In brief, cells were washed 2 times with PBS and finally
resuspended in pre-warmed (37°C) Seahorse Basal Medium supplemented with 1
mM pyruvate, 2 mM glutamine and 5 mM glucose, pH 7.4. 175µl of cells
suspension at the density of 2 million/ml were plated in 4 replicates on 96-well
plate. To allow cells to attach the bottom of the plate and create cell monolayer,
the Seahorse Cell Culture plate was previously precoated with Cell-Tak, according
to the manufacturer’s instructions and cells once plated were subjected to gentle
centrifugation for 4 minutes, at 1,000g without break and then repeated the
centrifugation counterclockwise. Subsequently, the analysis of OCR and ECAR
was performed in a Seahorse XFe96 analyzer according to the manufacturer’s
instructions for the Mito-Stress test. First, the OCR and ECAR values were
obtained during baseline (3 initial measurements) and after the injections of
Seahorse XF Mito Stress Test Kit reagents: Oligomycin (final concentration
1.5 μM), FCCP (final concentration 1.0 mM) and Antimycin/Rotenone (final
concentration 0.5 μM). All measurements were normalized to cell number after
accomplishing the assay and carried out by the Mito Stress Test Generator (Agilent
Technologies).

RNA sequencing. Total RNA was extracted from 5x106 cells using the RNeasy
Mini Kit (Qiagen; cat. 74104). RNA concentration was determined by NanoDrop
2000 (ThermoFischer Scientific) and RNA quality was assessed with an Agilent
Bioanalyzer. Approximately 100 million reads per sample were run on Illumina
Nextseq 500 using PE 75x 75 for stranded whole transcriptome sequencing. Raw
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sequencing reads were mapped to the GRCh38 human genome using STAR98
and the UCSC GRCh38.92 Known Gene reference transcript database. Analysis
of differentially expressed genes between CD200+ and CD200- cell lines was
performed using DESeq99 in R. An FDR < 0.05 was considered significant. For
GSEA, all genes were ordered according to the score obtained by multiplying the
sign of the fold change by the -log10 p-value.

Western blotting. 5x106 cells were washed twice with cold PBS and lysed with 50µl
lysis buffer: RIPA (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium
deoxycholate, 0.1% SDS; Thermo Scientific, cat. 89901) with Halt™ Protease and
Phosphatase Inhibitor Cocktail (Thermo Scientific, cat. 78440). Cells were
incubated on ice for 30 minutes, sonicated, and centrifuged at >13,000g for 13
minutes at 4°C. Protein concentration was determined using the Pierce BCA
Protein Assay Kit (Thermo Scientific, cat. 23225). A total of 30µg of protein per
sample was thoroughly mixed with 4X Protein Loading Buffer (Li-cor) with βmercaptoethanol and boiled for 5 minutes at 95°C. Samples were immediately run
on 4-20% Mini-PROTEAN TGX Gels (Bio-Rad) for 1 hour at 120V and transferred
to PVDF membrane for 45 minutes at 100V. Membranes were blocked for 1 hour
with 1X Odyssey Blocking Buffer (Li-cor). The following primary antibodies in 1:1
Odyssey Blocking Buffer to PBS were incubated overnight at 4°C on a rocker;
CD200 (goat anti-human; R&D) at 1:1,000; p53 (rabbit anti-human, Cell Signaling
Technology) at 1:1000; p-γ-H2AX (rabbit anti-human; Cell Signaling Technology)
at 1:1,000; γ-H2AX (rabbit anti-human; Cell Signaling Technology) at 1:1,000, and
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β-actin (mouse anti-human; Abcam) at 1:15,000. Following 5 3-minute PBS +
0.1%v/v TWEEN 20 (PBST) washes, membranes were incubated with the
appropriate secondary antibodies in 1:1 Odyssey Blocking Buffer to PBS for 30
minutes at room temperature in the dark; donkey anti-goat 800 (Li-cor) at 1:5,000,
donkey anti-rabbit 680 at 1:10,000 (Li-cor), donkey anti-mouse 800 (Li-cor) at
1:4,000. Again, membranes underwent 5 3-minute PBST washes followed by a
PBS wash. Membranes were imaged and analyzed using the Odyssey Infrared
Imaging System (Li-cor).
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2.4

Results

In silico discovery of CD200 as an LSC marker. To identify novel leukemia stem
cell markers, we mined 3 large, publicly available datasets which contained whole
genome expression data for paired leukemia stem cells and blasts from the same
patient, as well as healthy hematopoietic controls. The final 3 datasets used for
discovery varied slightly in the immunophenotypic definition of LSCs and were all
run on different gene quantification platforms. Jung et al used the
immunophenotyping described in Table 3 and ran all samples on Affymetrix HG
U133Plus 2.0 arrays90.
Status
AML
AML
AML
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy

Subset
LSC
LPC
Blast
HSC
LMPP
MPP
GMP
CMP
MEP

Immunophenotype
CD34+CD38CD34+CD38+
CD34LIN-CD34+CD38-CD90+CD45RA+
LIN-CD34+CD38-CD90-CD45RA+
LIN-CD34+CD38-CD90-CD45RALIN-CD34+CD38+CD123+CD45RA+
LIN-CD34+CD38+CD123+CD45RALIN-CD34+CD38+CD123-CD45RA-

Table 3. Cell type definitions from Jung et al.
RNA sequencing was performed on the cell types from Corces et al88 isolated
according to Table 4.
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Status
AML
AML
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy
Healthy

Cell Type

AML LSC
AML Blast
HSC
MPP
LMPP
CMP
GMP
MEP
Monocyte

Immunophenotype

Lin– CD34+ CD38– TIM3+ CD99+
Non-LSC; CD45-Intermediate, SSC-High
Lin– CD34+ CD38– CD90+ CD10–
Lin– CD34+ CD38– CD90– CD10–
Lin– CD34+ CD38– CD45RA+ CD10–
Lin– CD34+ CD38+ CD123+ CD45RA– CD10–
Lin– CD34+ CD38+ CD123+ CD45RA+ CD10–
Lin– CD34+ CD38+ CD123– CD45RA– CD10–
CD14+

Table 4. Cell type definitions from Corces et al.

And de Jonges et al performed Illumina expression analysis on CD34+ and CD34cells from a large number of both AML and healthy individuals89.
For each dataset, we performed 2 analyses; 1) identification of genes
significantly overexpressed in LSC compared to the patient’s corresponding blast
cells and 2) identification of genes significantly overexpressed in LSCs when
compared to un-matched healthy HSCs. This two-fold approach would ideally
detect LSC-specific genes from each dataset. We scored each gene as the product
of the fold change and –log10 p-value. Genes with scores that exceeded the
threshold defined below were deemed significant.

!ℎ#$%ℎ&'( = *$(+,- .$-$%/&#$ + 10 ∗

456 .$-$%/&#$
1.35

The final genes of interest from each dataset were those in the intersection of
genes significantly upregulated in LSCs when compared to both blasts and healthy
cells (Figure 5A). We then required that a gene survive this analysis in each of the
3 distinct datasets (Figure 5B), which gave us a final list of 43 genes (Table 5).
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From here, we implemented a biased screen for genes that were relatively novel
in AML, had known immunoregulatory properties, and, for therapeutic purposes,
were expressed on the cell surface. Through this process, we chose to focus our
following studies on CD200. Across the 3 datasets interrogated, CD200 expression
was high in early stem and progenitor cells and decreased in expression as cells
differentiated; a pattern that was mimicked at even higher levels in the leukemia
hierarchy (Figure 5C-E). This data suggested that CD200 was a novel, robust
marker of acute myeloid leukemia LSCs.
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Figure 5. CD200 expression across publicly available gene expression
datasets. A. Schematic for the cross-platform approach to detecting novel LSC
markers. B. Overlap of the 3 datasets revealed 43 novel putative LSC markers. (C
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to E) CD200 mRNA expression across immunophenotypically sorted healthy
(grey) and leukemic (red) cell populations ordered from left to right by
differentiation status mined from C. Jung et al90 D. Corces et al88, and E. de Jonges
et al89. (HSC-hematopoietic stem cells; LMPP- lymphoid-primed multipotent
progenitors,

MPP-

multipotent

progenitors;

GMP-

granulocyte-monocyte

progenitors; CMP- common myeloid progenitors; MEP- megakaryocyteerythrocyte progenitors; Mono- mature monocytes; LSC- leukemia stem cell; LPCleukemia progenitor cell; Blast- differentiated leukemia cell).
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Gene Symbol
Description
ANKRD28
ankyrin repeat domain 28
ANTXR2
ANTXR cell adhesion molecule 2
ARHGAP25
Rho GTPase activating protein 25
CALCOCO2
calcium binding and coiled-coil domain 2
CD200
CD200 molecule
CD44
CD44 molecule
CELF2
CUGBP Elav-like family member 2
CEP170
centrosomal protein 170
CMAHP
cytidine monophospho-N-acetylneuraminic acid hydroxylase
CNST
consortin connexin sorting protein
DAB2
DAB adaptor protein 2
DENR
density regulated re-initiation and release factor
DNAJC21
DnaJ heat shock protein family (Hsp40) member C21
DPYSL3
dihydropyrimidinase like 3
GTF3A
general transcription factor IIIA
HEATR5B
HEAT repeat containing 5B
IGSF10
immunoglobulin superfamily member 10
ITGA6
integrin subunit alpha 6
KDM5B
lysine demethylase 5B
KHDRBS1 KH RNA binding domain containing signal transduction associated 1
MACF1
microtubule actin crosslinking factor 1
MYO9A
myosin IXA
N4BP2L2
NEDD4 binding protein 2 like 2
NUFIP2
nuclear FMR1 interacting protein 2
OGT
O-linked N-acetylglucosamine (GlcNAc) transferase
RAB27B
member RAS oncogene family
RALA
RAS like proto-oncogene A
RNF125
ring finger protein 125
RPAP2
RNA polymerase II associated protein 2
RUNX1
RUNX family transcription factor 1
RXFP1
relaxin family peptide receptor 1
SESN1
sestrin 1
SLC25A36
solute carrier family 25 member 36
SLC38A1
solute carrier family 38 member 1
TEC
tec protein tyrosine kinase
TFPI
tissue factor pathway inhibitor
TIA1
TIA1 cytotoxic granule associated RNA binding protein
TRIM13
tripartite motif containing 13
TTC3
tetratricopeptide repeat domain 3
TTC37
tetratricopeptide repeat domain 37
UBR5
ubiquitin protein ligase E3 component n-recognin 5
UPF2
UPF2 regulator of nonsense mediated mRNA decay

Table 5. Genes identified as robustly and significantly overexpressed in
LSCs. The table lists the 43 putative LSC biomarkers. These genes were
significantly overexpressed in LSCs compared to blast cells and healthy controls
and that were common to the 3 datasets used.
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CD200 is expressed in primary AML patient samples. In order to validate our in
silico discovery, we first needed to confirm that CD200 was also expressed at the
protein level in AML patient samples. To do this, primary AML patient samples from
both peripheral blood and bone marrow were screened for CD200 surface
expression along with the classic hematopoietic stem cell marker, CD34, by flow
cytometry. Similar to the gene expression data, the frequency of CD200
expressing cells was variable across AML patients but still significantly higher than
the frequency seen in healthy bone marrow (Figure 6A; Mann-Whitney p=0.0071).
In investigating the variability of CD200 expression, we made two interesting
observations. First, while CD34 expression is the standard marker for stem cell
identification, this protein is largely lost in patients with mutated nucleophosmin
(NPM1), which represents about one-third of all primary AML78. We confirmed that
while the NPM1 mutant samples in our cohort (n=5) did lose CD34 surface
expression, maintained strong levels of CD200 (Figure 6B). Second, the only
samples observed that failed to express any subset of CD200+ cells also harbored
a rare KMT2A translocation. The low expression of CD200 in KMT2A-rearranged
leukemia separately was confirmed using the Leucegene AML cohort (Figure
6C)100. We also saw the highest expression of CD200 mRNA in core-binding factor
(CBF) leukemia. Taken together, these results confirm that CD200 is expressed at
the protein level in the majority of AML patient samples.
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Figure 6. CD200 is expressed in primary AML patients. A. Frequency of cells
expressing CD200 surface protein expression in 30 primary AML patient samples
compared to 3 normal bone marrow biopsies (mean and standard deviation; MannWhitney p<0.01). B. Representative flow cytometry plots of CD34 and CD200
expression in an NPM1 WT (left) and NPM1 mutant (right) primary patient sample.
C. CD200 RNAseq expression in the Leucegene AML cohort by genetic subgroup
(KMT2A-r (red) versus others p<0.001; CBF leukemia (blue) versus others
p<0.001; t-test)100.
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CD200 is a functional stem cell marker in human AML. CD200 gene and protein
expression is almost exclusively confined to stem cell populations as defined by
CD34+ immunophenotype. To determine whether CD200 is also a maker of
functional stem cells, CD200+ AML cells were investigated for colony forming
potential in vitro. Special consideration had to be taken to account for the variability
in CD200 expression, since in many patient samples CD200 expression correlated
with CD34, a well-established marker of cells with clonogenic potential14.
Therefore, we looked to see if CD200 could identify functional stem cells within
CD34+ AML (Figure 7A). The CD34+CD200+ cell fraction formed significantly
more colonies when compared to CD34+CD200- cells from the same patient
samples (Figure 7B; Mann-Whitney p=0.317). The gold standard for evaluating
stem cell potential is the ability of cells to engraft in immunodeficient NSG mice.
Ng et al produced the first publicly available gene expression dataset
characterizing functional LSCs by sorting patient samples by CD34/CD38 status
into 4 groups and tested engraftment in immunocompromised mice. LSC+
samples were defined as populations that engrafted in mice101. We mined this
dataset and found that CD200 was significantly overexpressed in fractions of
engrafting LSC+ cells when compared to non-engrafting LSC- cells from the same
patient sample (Figure 7C; paired t-test p<0.0001)102. Collectively, these data
suggest that CD200 is a functional AML stem cell marker and may more accurately
identify stem cells than CD34.
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Figure 7. CD200 is a marker of human AML leukemia stem cells. A.
Representative gating strategy for FACS sorting CD200+ and CD200- cells from
CD34+ AML samples. B. Number of colonies formed in the CD34+CD200- and
CD34+CD200+ fractions (lines connect paired cells from the same patient; MannWhitney). C. CD200 mRNA expression in cell fractions that either did (LSC+) or
did not (LSC-) engraft in NSG mice from the dataset generated by Ng et al
[GSE76009] (lines connect cells from the same AML patient; t-test)101. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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Cd200 is a functional stem cell marker in a syngeneic murine model of AML. To
study Cd200 in a fully immunocompetent in vivo model, we chose to utilize the
Tet2-/-Flt3ITD syngeneic mouse model of AML that faithfully mimics human AML
and is resistant to standard induction chemotherapy103. We wondered whether
Cd200 could also selectively identify functional AML LSCs in mice. Based on RNAsequencing data, Cd200 expression was significantly higher in stem cells (LSK,
Lin−Sca+cKit+) when compared to more committed granulocyte-macrophage
progenitors (GMPs, lin−cKit+Sca-1−FcγR+CD34+) in WT mice (p=0.0252). The
trend in Cd200 expression was mirrored in the Tet2-/-Flt3ITD mice at even higher
levels (Figure 8A). To test the stem cell functionality of Cd200+ cells, leukemic
CD45.2+Cd200+ and CD45.2+Cd200- Tet2-/-Flt3ITD cells were FACS sorted and
injected into sub-lethally irradiated CD45.1 C57BL/6 recipient mice (Figure 8B).
After 2 weeks, only the Cd200+ leukemia cells demonstrated engraftment potential
and, interestingly, only in male recipient mice (Figure 8C). These Cd200+ male
recipients were the only mice to die of leukemia (Figure 8D). To test whether the
difference in engraftment between male and female mice was immune related, the
same AML engraftment study was performed with NSG mice. In the absence of an
intact immune system, Cd200+ cells were capable of engrafting in both male and
female mice (Figure 8E). However, regardless of the immune status, Cd200
identified functional leukemia stem cells in this murine model (Figure 8F). These
results confirm that the functional stem cell marker, Cd200, is conserved in murine
AML.
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Figure 8. Cd200 is a murine leukemia stem cell marker. A. RNA-seq gene
expression data for sorted GMP and LSK cells derived from wild type (WT) and
the Tet2-/-;Flt3ITD murine leukemia model (GSE57244)103. B. Representative gating
strategy for CD200+ leukemia (Cd45.2) stem cells. C. Frequency of circulating
leukemic burden in CD45.1 mice at 3 weeks by sex. D. Overall survival for the
mice in panel C. E. Frequency of circulating leukemic burden in NSG mice at 2
weeks by sex. F. Combined leukemic burden for NSG and C57Bl/6 mice from 2
experiments. Leukemia frequencies were compared using two-tailed t-tests;
*p<0.05, **p<0.01, ***p<0.001.

46

In vitro model systems of CD200. To more systematically understand the functional
role of CD200 in AML stem cells, we established two isogenic cell line model
systems. First, we used CRISPR/Cas9 to knockout the canonical transcript of
CD200 in the Kasumi1 cell line, an AML1-ETO model with low basal CD200
expression (the Kasumi WT cells were denoted as CD200+ cells, while the Kasumi
KO cells were denoted as CD200- cells). Second, OCI-AML3 cells, which had no
expression of CD200 at baseline, were used to make stable cells expressing
CD200 with GFP (CD200+ cells, OCI-AML3 pCD200) or GFP alone (CD200- cells,
OCI-AML3 pGFP). Frequency and intensity of cell surface CD200 in both isogenic
systems were assessed by flow cytometry (Figures 9A-B). These data indicate that
the over expressed CD200 protein is localized to the cell surface. Because CD200
is reported to function through the CD200 receptor, we next confirmed that these
cell line models lacked endogenous CD200R expression at both the gene and
protein level (data not shown). These models were used to functionally
characterize the potential intrinsic function of CD200. Because stem cells are
known to be more quiescent than their more differentiated counterparts, we first
tested the role of CD200 in AML cell cycle and proliferation. Alteration of CD200
expression had no significant effect on the growth or proliferation of either cell line
system (Figures 9C-D). Stem cells also have distinct metabolic patterns. However,
CD200 expression did not alter cellular respiration in either cell line system
(Figures

9E-F).

In

conclusion,

genetic

manipulation

of

CD200,

either

overexpression or knockout, does not intrinsically alter AML cell line proliferation
or metabolism.
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Figure 9. CD200 modulation in vitro does not alter cell growth or metabolism.
Cell surface flow cytometry of CD200 in the Kasumi (A) and OCI-AML3 (B)
engineered cell line models. C. Summary of proliferation of CD200+/- Kasumi cells.
D. Cell cycle analysis of CD200+/- OCI-AML3 cells (%cells in S/G2). E-F) Cellular
respiration of CD200+/- Kasumi and OCI-AML3 cells.
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CD200 alters DNA damage response. To determine whether CD200 has any
intrinsic role in AML, RNA sequencing was performed on the CD200+/- in both
Kasumi and OCI-AML3 lines. We determined the significantly up- and downregulated genes in the CD200+ cells within each cell line and then compared
overlapping genes between the two distinct models. The 65 common
downregulated genes had significant overrepresentation of genes involved in the
Tumor Necrosis (TNF) and NF-kB pathways (Figure 10A). The 174 common
upregulated genes had significant overrepresentation of genes involved in DNA
damage response (Figure 10B). GSEA was performed on genes with combined
scores from both cell lines. We found that DNA damage machinery, particularly in
response to DNA double strand breaks, was significantly enriched in the CD200+
cells in either cell line system (Figure 10C). To confirm alterations in DNA damage
response, we treated OCI-AML3 CD200+/- cells with a low dose of hydroxyurea
(HU) for 48 hours to induce DNA damage via replication stress. CD200+ cells show
less evidence of DNA double strand breaks indicated by the decrease in p-γ-H2AX
and MDM2 activity (Figure 10D). In summary, CD200 does appear to consistently
alter the DNA repair machinery at the transcriptional level.
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Figure 10. CD200 alters DNA repair machinery at the transcriptional level. A.
Over-representation analysis of common genes enriched in CD200- cells based
on BioPlanet 2019 (adj-p<0.01). B. Over-representation analysis of common
genes enriched in CD200+ cells based on BioPlanet 2019 (p<0.01). C. GSEA of
DNA double strand break response based on combined gene scores. D. Western
blot of DNA damage induced by hydroxyurea (HU) in OCI-AML3 CD200+/- cells.
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CD200+ cells are expressed in resistant AML. AML LSCs are also hypothesized
to be more resistant to standard chemotherapy treatment. To test this hypothesis,
we examined RNA-seq data from 19 paired diagnosis and relapse samples from
the Leucegene AML cohort100. CD200 expression was significantly higher in a
given patient’s disease after relapsing from standard therapy (Figure 11A; Wilcoxin
paired test p=0.05). We next wondered whether CD200 was overexpressed in
disease resistant to immunotherapy. To this end, bone marrow and peripheral
blood samples were collected from 6 patients prior to treatment with azacitidine
and a PD-L1 inhibitor, avelumab, and after cycles 1, 3, and 5 (as available).
Samples from a given patient were barcoded, stained with a panel of 36 antibodies
that included immunophenotypic markers to distinguish AML stem cells and blasts
from the healthy, adjacent immune cells (including T, B, NK cells and monocytes)
and analyzed by mass cytometry. Five out of the 6 patients examined had a
CD200+ AML cell clone at baseline that persisted throughout immunotherapy
treatment. In 2 cases, we saw the emergence of a new AML clone that was also
CD200+ (Figure 11B). The CD200+ AML correlated with other immune
checkpoints including TIGIT and PD-L2; indicating a potential role of CD200 in the
coordinated immunosuppression (Figure 11C). Taken together, these results
suggest that CD200 may play a role in AML resistance to both standard
chemotherapy and emerging immunotherapies.
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Figure 11. CD200 is present in therapy-resistant AML. A. RNA-seq shows
CD200 expression levels in paired patients at diagnosis and relapse. Lines
connect samples from the same patient and colored by an increase (red) or
decrease (green) in CD200 abundance. B. Representative CyTOF plots of the
same patient’s disease at baseline (top) and after 4 cycles of immunotherapy
(bottom). Dots represent individual cells colored by CD200 protein expression. C.
Heatmap showing the expression of known immunosuppressive genes across
AML and healthy sample clusters determined by PhenoGraph.
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2.5

Discussion
This study leveraged publicly available data to essentially perform

“biological replicates” of RNA expression experiments on primary patient samples
to identify novel leukemia stem cell markers. The fact that the data was generated
by multiple research teams, each using a unique set of immunophenotypic
definitions to distinguish cell subsets, and quantifying expression with 3 different
platforms, makes the discovery gene set far more robust than that of a single RNA
sequencing experiment. Of the 43 genes identified using this algorithm, CD200
was identified as the optimal first target for validation because it has been shown
have immunosuppressive function and it is expressed on the cell surface, making
it readily targetable by antibody-based therapies. In fact, an anti-CD200 antibody,
samalizumab has already been shown to be well tolerated in humans57.
In acute myeloid leukemia, CD200 has been implicated as a marker of poor
prognosis (excluding core binding factor leukemia)51. Our evaluation of primary
patient sample data was consistent with previously published assessments of bulk
CD200 expression; namely, that CD200 was highest in core binding factor
leukemias (t(8;21) and inv(16)) and that CD200 was largely absent in patients with
KMT2A translocations50. However, this study was the first to look at the
heterogeneity of CD200 at the protein expression level and across within the LSC
compartment of disease. CD200 was frequently co-expressed with the established
stem cell marker, CD34, however the mutual exclusivity of these markers varied
drastically between patients. Notably, patients with NPM1 mutations (which
constitute almost a third of all primary AML) lack CD34 expression but maintain
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high frequency of CD200 positive cells, thus potentially providing a way to identify
LSC populations in this cohort of patients.
Our study also exposed the variability in stem cell potential even within the
CD34 compartment of disease. Due to the wide range of CD200 expression within
bulk CD34+ leukemia, we were able to dissect certain patient samples into
CD34+CD200+ and CD34+CD200-. The CD200+ fraction contained more
functional stem cells than the CD200- even though CD34 levels were comparable
between the two groups. This suggests that CD200 may be a superior marker for
identifying functional stem cells.
CD200 is highly conserved between human and mouse, so we anticipated
that it would also identify LSCs in a murine model of AML. Our characterization of
the Tet2-/-Flt3ITD model demonstrated that only a small fraction (10-15%) of the
leukemic cells were positive for mouse CD200 and that this fraction was more
prevalent in the bone marrow and spleen when compared to peripheral blood;
consistent the traditional distribution of AML stem cells. We found that only the
CD200+ subset of cells was capable of engrafting in sublethally irradiated C57BL/6
male mice. Interestingly, these same cells were not able to persist in matched
female mice. Because the OCI-AML3 cells were originally derived from a male
donor, we believe this phenomenon is a result of H-Y alloimmunity104-106. In
transplant biology, mismatching gender to test graft rejection is a well
characterized model to challenge the immune system. In fact, such a model has
been utilized to show that CD200 significantly attenuates skin graft rejection107.
CD200Fc has also been implicated in regulating immune rejection of leukemia in
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C57BL/6 mice108. To confirm that the differences in engraftment seen here were
not solely immune related, we performed the same experiment in NSG mice. In
the immunocompromised model, again we saw only engraftment of the CD200+
cells but now equally across gender.
To further study the intrinsic and extrinsic function of CD200, we established
two isogenic models of CD200-high and CD200-null cells using both CRISPR
knockout and engineered overexpression. Initially, we were concerned by the lack
of any stark functional changes in cell growth, metabolism, or engraftment after
CD200 modulation. However, while cell lines are useful models, they are not a not
necessarily an accurate representation of patient stem cells. The significant and
consistent transcriptional alterations between CD200+/- cells in both lines suggest
that there is, in fact, an intrinsic role of CD200, even in the absence of the CD200
receptor. Gorczynski et al recently reported that the c-terminal tail of the surface
CD200 protein could be cleaved and potentially regulate transcription109. While the
transcriptional changes identified in our AML model do not overlap with their
proposed transcription factors, this certainly offers a possible explanation. Stem
cells, including cancer stem cells, have been intimately linked to DNA damage
pathways110. Thus, the upregulation of the DNA damage machinery could be either
a passenger effect of the CD200+ cells adopting a more stem-like phenotype or a
direct result of CD200 intrinsic function.
An increase in DNA damage surveillance and response could contribute to
the therapy resistance of CD200+ leukemia cells. These findings also support the
observational studies that found that CD200 is a predictor of poor overall survival

55

in AML patients, with the exception of core-binding factor leukemias which respond
well to standard chemotherapeutic agents.
In Chapter 2, we have identified and validated a novel marker of AML LSCs
in both human and mouse, as well as uncovered a previously unknown intrinsic
mechanism of CD200. However, the extrinsic function of CD200 in relation to the
stem cell microenvironment remains unknown. In Chapter 3, we will systematically
examine the role of CD200 on members of the innate and adaptive immune
systems both in vitro and in vivo.
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Figure 12. Graphical abstract of Chapter II.
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Chapter III
CD200 suppresses both the innate and adaptive immune
system in AML
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3.1

Abstract

Purpose: AML LSCs must be capable of evading immune detection and
destruction in order to initiate leukemia and drive relapse. We hypothesized that
LSCs were protected by upregulation of unique immune regulators, like CD200,
that allowed these cells to selectively escape immune surveillance. We have
previously identified CD200 as a novel marker of functional AML LSCs that is
significantly overexpressed when compared to normal HSCs and corresponding
blast cells and has been implicated in immune function.

Experimental design: A series of mixed lymphocyte reactions with isolated
effector T cells, NK cells, or macrophages and target isogenic AML cell lines
(CD200 knockout and CD200 overexpression) were used to mechanistically tease
out the effect of CD200 on innate and adaptive effector functions as well as AML
cell killing. PBMC-humanized mouse models with the isogenic OCI-AML3 cell lines
were employed to validate these findings in vivo.

Results: CD200 receptor expression was mutually exclusive with CD200 ligand
expression and highest in mature populations of CD4/CD8 T cells and
monocytes/macrophages. AML cell line models with CD200 expression
significantly suppressed T cell MAPK and STAT3 signaling when compared to their
non-expressing counterparts. Alterations in signaling translated functionally to
impaired T cell proliferation and cytokine production in the presence of CD200+
AML that could be restored by blocking the CD200/CD200R interaction. Ectopic
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CD200 abrogated cytokine secretion of healthy macrophages but did not
significantly affect basal phagocytic function. NK cell cytokine profiles were largely
independent of CD200 presence on AML cells, however, high levels of surface
CD200 correlated with reduced NK cell cytotoxicity. In vivo in PBMC-humanized,
CD200 protected AML cells from immune-mediated rejection. Cytokine production
in PBMC-humanized mice was significantly compromised in those with CD200expressing leukemia. T cell composition was also significantly altered in the
presence of AML with and without CD200. Transcriptome analysis revealed that T
cells from humanized mice exposed to CD200 expressing disease were
metabolically quiescent.

Conclusions: CD200 plays an important immunosuppressive role primarily in T
cells and macrophages in vitro by significantly suppressing cytokine secretion in
response to AML. In a PBMC-humanized mouse model, the presence of cellsurface CD200 was sufficient to protect AML cells from immune-mediated
clearance by driving T cells into metabolic quiescence.
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3.2

Introduction

Immune surveillance in AML. Avoiding immune-mediated destruction is now
classified as one of the emerging hallmarks of cancer111. Particularly in leukemia
where it is known that the drivers of disease come from the same source as healthy
immune cell subsets, leukemia stem cells must be capable of evading detection
and/or destruction by neighboring immune cells. AML LSCs have been reported to
both up- and down-regulate important immune regulators to evade NK cells112, T
cells27, and macrophages113.

Immunosuppression through CD200 receptor signaling. CD200 triggers robust
immunosuppression through its interaction with the CD200 receptor (CD200R) on
effector cells. As part of the original characterization of the CD200 receptor family,
Wright et al identified a single inhibitory receptor in both human and mouse
(CD200R1), a related human gene (CD200R1L), and 4 related murine genes
(CD200RLa-d)114. However, it was later demonstrated that the related proteins did
not bind CD20033. The distribution of CD200R was variable across populations of
circulating lymphocytes and reported the highest levels in peripheral T cells,
granulocytes, and monocytes. It was mentioned, but not shown, that CD200R
expression was increased in mature macrophages or dendritic cells when
compared to monocytes. It was also observed that only a small subset of NK cells
expressed any CD200R114. The CD200 receptor signaling pathway was first
described by Zhang et al in myeloid cells where it was shown that CD200R
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activation resulted in the recruitment of RasGAP which interfered downstream with
the MAPK signaling pathway115.

CD200 regulation of myeloid cells. It has been shown that CD200 knockout mice
had higher numbers of both activated and total macrophages when compared to
controls and were more susceptible to collagen-induced arthritis (CIA) and
experimental autoimmune encephalomyelitis (EAE); both autoimmune diseases
primarily regulated by monocytes38,116. In immunocompetent mice, it has been
demonstrated that macrophage production of IFNγ- and IL-17 could be inhibited
by engaging the CD200 receptor with artificial binding agents. These same
CD200R agonists could also reduce the production of IL-5 and IL-13 from human
monocytes in response to tetanus toxoid43.

CD200 regulation of T cells. In the context of chronic lymphocytic leukemia, it was
shown that cells transfected with CD200 expression plasmids were capable of
suppressing antigen specific T cell production of IFNγ and IL-2117. In the murine
setting, antibodies against the CD200RLa, but not CD200R, could activate the
differentiation of dendritic cells that recruit CD4+CD25+ Tregs118. Coles et al also
observed a correlation between CD4 Treg frequency and CD200 expression on
AML blasts. CD8+ memory T cells from AML patients with high levels of CD200
demonstrated a 50% reduction in degranulation capacity after artificial stimulation.
Similarly, CD200-high patients had significantly fewer TNFα and IL-2 producing
CD4+ T cells46. CD200 was further proposed to play an immunosuppressive role
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in AML by inducing expression of the immune checkpoint PD-1 on cytotoxic CD8+
T cells48.

CD200 regulation of NK cells. Coles et al observed that patients with high CD200
expression on AML blasts had a 50% reduction in the frequency of activated NK
cells. Additionally, they were the first to suggest that CD200 had a direct
suppressive role on NK cell function by decreasing CD107a and IFNγ45.

Humanized murine models. A significant challenge in studying CD200/CD200R
interaction in a systemic setting is the lack of adequate in vivo models, thus most
of the work the role of CD200 in AML has been done in vitro. Humanized mouse
models have gained traction as a way to mimic the interaction between human
disease and the human immune system, however these approaches are still
subject to limitations. Models of humanization involving transplantation of human
hematopoietic stem cells into neonate mice accurately recapitulate human
hematopoiesis in the mouse without causing graft-versus-host disease (GvHD)119121

. However, these murine educated T cells will be more prone to attack foreign

epitopes on leukemia derived from a human donor. On the other hand, peripheral
blood mononuclear cell (PBMC) transfer into NSG mice elicits GvHD and may
more accurately mimic the scenario observed in AML patients after bone marrow
transplantation122.
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In this chapter, we utilized our previously established isogenic AML cell line models
(CD200 knockout and CD200 overexpression) to individually characterize the
effects of AML surface CD200 on isolated members of the innate and adaptive
immune systems in vitro. Further, we employed a PBMC-humanized mouse model
to study the effects of CD200+ AML in an inflammatory, engraftment model of
leukemia.
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3.3

Materials and Methods

PBMC collection and target cell isolation. Buffy coat was obtained from healthy
donors. PBMCs were isolated by Ficoll density gradient centrifugation. Briefly,
sample was mixed at a 1:1 ratio with Dulbecco’s Phosphate-Buffered Saline (PBS)
without calcium and magnesium (GenDEPOT) and gently added to 15ml
Lymphocyte Separation Medium (Lonza; cat. 17-829E). Cells were centrifuged at
1,800 RPM for 20 minutes and the lymphocyte layer was carefully extracted. If
necessary, 5ml ammonium chloride solution (Stem Cell Technologies) was used
to lyse any residual red blood cells. CD3+ T cells were isolated using the
EasySep™ Release Human CD3 Positive Selection Kit (Stem Cell Technologies;
cat. 17751). NK cells were negatively selected from total PBMCs using magnetic
column separation (Miltenyi Biotec, cat. 130-092-657). Monocytes were negatively
selected from PBMCs using the EasySep™ Human Monocyte Isolation Kit (Stem
Cell Technoligies; cat. 19359). T and NK cells were cultured in RPMI-1640 media
with 10% heat-inactivated Fetal Bovine Serum (FBS; GenDEPOT) and 200U/ml
recombinant interleukin 2 (IL-2; Peprotech).

Macrophage differentiation and culture. Macrophages were differentiated as
previously described113. Briefly, sorted CD14+ monocytes from healthy PBMCs
were cultured in RPMI-1640 media with 10% FBS and 20 ng/mL recombinant
human macrophage colony stimulating factor (M-CSF; Peptrotech) for 7-10 days
with media changes every 3 days. Mature macrophages were detached using
StemPro Accutase Cell Dissociation Reagent (ThermoFisher Scientific) on ice for
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20 minutes and counted. Cells were re-plated at a density of 4x104 cells/well in 48well plates and allowed to reattach for 48 hours prior to use.

Flow cytometry. 3x105 cells were transferred to a 5ml FACS tube and washed twice
with staining buffer (PBS + 0.5% Bovine Serum Albumin (Sigma-Aldrich)). Cells
were Fc-blocked with either 5µl anti-human or anti-mouse Fc receptor binding
inhibitor (eBioscience Invitrogen) in 100µl staining buffer for 15 minutes prior to the
addition of anti-human CD200R (PE; Biolegend), anti-human CD47 (PerCP-Cy5.5;
Biolegend), anti-human CD45 (APC-Cy7; Biolegend), anti-human CD4 (PerCPCy5.5; Biolegend), anti-human CD8 (PE-Cy7; Biolegend), or anti-mouse CD45
(APC; Biolegend) antibody (1µl/sample). Surface stain was incubated for 30
minutes at room temperature on an orbital shaker followed by 2 washes with
staining buffer. Cells were resuspended in 300µl of staining buffer plus 5µl 4',6Diamidino-2-Phenylindole, Dihydrochloride (DAPI; 2ug/ml; Invitrogen) for live/dead
cell discrimination for collection on a LSRII machine (BD).

T cell signaling western blotting. 4x106 CD3+ T cells were co-cultured with 2 x106
AML cells in 1 ml of T cell media (RPMI-1640 + 10%FBS + 100 U/ml recombinant
human IL-2 (PeproTech; cat. 200-02)) for 24 hours at 37°C. CD3+ T cells were reselected using the same T cell positive selection marker. Isolated T cells were
washed twice with cold PBS and lysed with 30µl lysis buffer: RIPA (25 mM TrisHCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS;
Thermo Scientific, cat. 89901) with Halt™ Protease and Phosphatase Inhibitor
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Cocktail (Thermo Scientific, cat. 78440). Cells were incubated on ice for 30
minutes, sonicated, and centrifuged at >13,000g for 13 minutes at 4°C. Protein
concentration was determined using the Pierce BCA Protein Assay Kit (Thermo
Scientific, cat. 23225). A total of 30µg of protein per sample was thoroughly mixed
with 4X Protein Loading Buffer (Li-cor) with β-mercaptoethanol and boiled for 5
minutes at 95°C. Samples were immediately run on 4-20% Mini-PROTEAN TGX
Gels (Bio-Rad) for 1 hour at 120V and transferred to PVDF membrane for 45
minutes at 100V. Membranes were blocked for 1 hour with 1X Odyssey Blocking
Buffer (Li-cor). The following primary antibodies in 1:1 Odyssey Blocking Buffer to
PBS were incubated overnight at 4°C on a rocker; p-STAT3 (rabbit anti-human;
Cell Signaling Technology) at 1:1000, total STAT3 (rabbit anti-human; Cell
Signaling Technology) at 1:1,000, p-ERK1/2 (rabbit anti-human; Cell Signaling
Technology) at 1:1000, total ERK2 (mouse anti-human; Santa Cruz) at 1:1,000,
and β-actin (mouse anti-human; Abcam) at 1:15,000. Following 5 3-minute PBST
(0.1%) washes, membranes were incubated with the appropriate secondary
antibodies in 1:1 Odyssey Blocking Buffer to PBS for 30 minutes at room
temperature in the dark; donkey anti-rabbit 680 at 1:10,000 (Li-cor), donkey antimouse 800 (Li-cor) at 1:5,000. Again, membranes underwent 5 3-minute PBST
washes followed by a PBS wash. Membranes were imaged and analyzed using
the Odyssey Infrared Imaging System (Li-cor).

Peptide-specific CTL lines. Peptide-specific cytotoxic T cells (CTLs) were prepared
as previously described123-125. Briefly, T2 cells were pulsed with 20µg/ml cathepsin
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G or negative control peptide for 90 minutes at 37°C. Peptide-pulsed cells were
then irradiated with 7500 cGy and cultured with freshly isolated PBMCs from
healthy HLA-A*0201 individuals at a 1:1 ratio in RPMI-1640 medium supplemented
with 10% human serum. PBMCs were re-stimulated with peptide-pulsed T2 cells
weekly for 3 weeks. Final peptide-specific CTLs were the transferred to culture
media supplemented with 20 IU/ml of recombinant human interleukin-2 (IL-2;
Peprotech).

T cell mediated cytotoxicity assay. Calcein AM assays for cytotoxicity were
performed as previously described126,127. Briefly, target AML cells were washed 2x
with PBS and stained at a concentration of 1x106 cells/ml of calcein AM staining
media (10µg/ml calcein AM in 1ml PBS) for 90 minutes at 37°C. Residual calcein
was quenched with 3 washes in 15ml complete media. Then, 1,000 stained cells
in 10µl IL-2 media were co-cultured with 10µl of peptide-specific CTLs at varying
effector to target (E:T) ratios for 4 hours at 37°C. After which, 5μL of Trypan blue
was added to each well and fluorescence was measured using a CytoFluor II plate
reader (PerSeptive Biosystems). Percent specific cytotoxicity was calculated as
follows:
%/;!&!&<+/+!; =

1 − >'?&#$%/$-/$@ABCDEFGHHDIEJB − >'?&#$%/$-/$KDLMA
>'?&#$%/$-/$@ABCDE − >'?&#$%/$-/$KDLMA

∗ 100%

T cell growth assay. To assess T cell proliferation, 2.5x104 T cells were seeded at
a 1:1 ratio with irradiated AML cell lines in 1mL of complete media supplemented
with 100 IU/ml IL-2 in 12-well plates. Negative and positive controls included
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untreated T cells and cells treated with ImmunoCult™ Human CD3/CD28 T Cell
Activator (Stem Cell Technologies; cat. 10971), respectively. After 5 days, cells
were collected and live CD4 and CD8 T cell numbers were determined by flow
cytometry using Precision Count Beads (Biolegend; cat. 424902).

Cytokine profiling. 2x105 effector cells were co-cultured at a 1:1 ratio with desired
target cells and treatments in 200µl in 96-well U-bottom plates and incubated for
16-24 hours. Plates were spun down at 500g for 5 minutes. 25µl of supernatant
from each well was transferred to a new 96-well U-bottom plate. Secreted cytokine
abundance was determined using one of the following Legendplex kits
(Biolegend); Human CD8/NK Panel (cat. 740267), Human T Helper Cytokine
Panel (cat. 740722), Human Macrophage/Microglia Cytokine Panel (cat. 740503).
Briefly, cell supernatant was incubated with 25µl of pre-mixed analyte capture
beads and 25µl detection antibodies for 2 hours at room temperature on a shaker
(at approximately 600 RPM). Without washing, 25µl streptavidin-PE was added to
each well and incubated another 30 minutes at room temperature on a shaker.
Beads were washed twice and collected using a High Throughput Sampler (HTS;
BD). For cytokines within range, cytokine concentration was interpolated based on
the standards. For cytokines outside of the standard range, MFI was reported.

Phagocytosis. Target leukemia cells were labeled with 5µM carboxyfluorescein
succinimidyl ester (CFSE; ThermoF) for 5 minutes at 37°C followed by a 5-minute
quench with 5ml complete media at 37°C. Labeled AML cells were co-cultured at

69

a 2:1 ratio with differentiated macrophages (7-10 days old) for 4 hours at 37°C.
Cells were detached using StemPro Accutase Cell Dissociation Reagent
(ThermoFisher Scientific) on ice for 20 minutes and transferred to 5ml FACS tubes.
Cells were stained with 1µl/sample CD206 PerCP-Cy5.5 for 30 minutes at room
temperature prior to assessment by flow cytometry. Macrophages that had
undergone phagocytosis of AML cells were identified as CFSE+CD206+.
Percentage of activated macrophages was calculated as the fraction of double
positive cells to total CD206+ cells.

Calcein AM release assay for NK-cell mediated ADCC. NK cells were cultured in
RPMI-1640 media + 20% FBS + 200 IU/ml recombinant human IL-2 (PeproTech;
cat. 200-02) for no more than 24 hours before use. AML target cells were washed
2x with PBS and stained at a concentration of 1x106 cells/ml of calcein AM staining
media (2µg/ml calcein AM in 1ml PBS) for 1 hour at 37°C. Residual calcein was
quenched with 3 washes in 15ml complete media. 2.0x104 target cells were
plated/well in 96-well U-bottom plates. Varying numbers of NK cells were added in
a final volume of 100µl IL-2 media. Antibody treatments either 100nM
samalizumab, 100nM CD200-IgG1, or PBS-only were added to appropriate wells
in triplicate. 2% Triton-X was added to positive controls (maximum calcien
release). Plates were spun down at 500g for 1 minute before incubating 4 hours at
37°C. Following incubation, cells were spun down at 500g for 5 minutes. 75µl of
supernatant per well was transferred to a black bottom, black walled 96-well plate.
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Fluorescence was measured using a Victor X3 fluorescent plate reader
(PerkinElmer). Percent specific lysis was calculated as:
%';%+% =

>'?&#$%/$-/$DNODBMKDPEAQ − >'?&#$%/$-/$ROJPEAPDJSR
∗ 100%
>'?&#$%/$-/$KAN − >'?&#$%/$-/$ROJPEAPDJSR

Mice. Female NOD-SCID IL2Rgnull (NSG) mice were obtained from our breeding
colony with breeders originally purchased from Jackson Laboratory. Mice were
approximately 5 to 8 weeks old at the time of use. All mice were housed in
accordance with the Association for Assessment and Accreditation of Laboratory
Animal Care and NIH standards. All experiments were conducted according to
protocols 00001146-RN02 and 00001446-RN01 approved by the University of
Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee.

PBMC-humanized mice. Healthy PBMCs were extracted from buffy coat the day
of injection. 10x106 cells in 100µl PBS were injected intravenously and allowed
one week to engraft. T cell engraftment was confirmed day 7 by detection of human
CD45+CD3+ in peripheral blood by flow cytometry. Mice were then randomized to
receive 5x104 of either pGFP or pCD200 OCI-AML3 cells in 100µl of sterile PBS
i.v.

In vivo leukemia monitoring. Firefly luciferase was used to track the engraftment
of OCI-AML3 cells in mice. The luciferase substrate, d-luciferin (100μL of 30
mg/mL in PBS; Gold Biotechnology, Inc.), was injected i.p. 5 minutes prior to IVIS
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imaging (IVIS-Xenogen 100 system; Caliper Lifesciences). Leukemia burden was
determined to be to total flux minus the total flux of the background.

Serum collection. 100µl of whole blood was collected by retro-orbital eye bleeding
from anesthetized mice in microtainers containing K2EDTA (BD, cat. 365974).
Blood was transferred to Eppendorf tubes and centrifuged at 4°C for 20 minutes
at 500g. The top plasma layer was carefully extracted, transferred to fresh
Eppendorf tubes, and stored at -80°C until testing.

Complete blood count. 50µl of whole blood was collected by retro-orbital eye
bleeding from anesthetized mice in microtainers containing K2EDTA (BD, cat.
365974). Blood was mixed at a 1:1 ratio with 50µl PBS. CBC analysis was
performed using an ABX Pentra analyzer (Horiba).

CyTOF mass cytometry. Human CD45+ cells were collected from mouse bone
marrow and spleen and selected using the EasySep™ Mouse/Human Chimera
Isolation Kit (Stem Cell Technologies, cat. 19849). Sample barcoding and metalconjugated antibody staining were performed according to Fluidigm’s protocols as
described below. Briefly, all antibodies were labeled with heavy metals using
Maxpar-X8 labeling reagent kits (Fluidigm DVS Sciences) according to
manufacturer’s instructions and titrated for optimal concentration determination.
For each mouse evaluated, 3x106 cells were aliquoted into separate FACS tubes
and washed twice with Maxpar PBS Buffer (Fluidigm; cat. 201058). For live/dead
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cell discrimination, cells were resuspended in 200µl of 5µM cisplatin (Fluidigm; cat.
201064) for 1 minute on an orbital shaker followed immediately by 3 washes in
Maxpar Cell Staining Buffer (CSB; Fluidigm; cat. 201068). Cells were then fixed in
1ml of 1x Fix I Buffer (Fluidigm; cat. 201065) for 10 minutes followed by 2 washes
with 1x Barcode Perm Buffer (Fluidigm; cat. 201057). Each unique Palladium
Barcode (Fluidigm; Cell-ID 20-Plex Pd Barcoding Kit cat. 201060) was suspended
in 100µl of Barcode Perm Buffer and immediately transferred to cells in 800µl
Barcode Perm Buffer. Cells were incubated with barcodes for 30 minutes followed
by 2 washes with 2ml CSB. Barcoded cells were then combined into a single tube
for CyTOF staining. The staining factor was calculated as the total number of
barcoded cells/3x106. Cells were blocked with 5μL x staining factor of anti-human
Fc receptor binding inhibitor (eBioscience Invitrogen) in 45µl x staining factor of
CSB for 15 minutes at room temperature. Appropriate amount of surface antibody
master mix (Table 6) was added directly to the tube and incubated for 1 hour at
room temperature before 2 washes with CSB. For intracellular staining, cells were
dissociated in 1ml of Foxp3 Fixation/Permeabilization Buffer (eBioscience; cat. 005523-00) and incubated overnight at 4°C followed by 2 washes with 2ml of 1X
Permeabilization Buffer. After discarding supernatant from the final wash,
appropriate amounts of intracellular antibody master mix were added to the
residual Permeabilization Buffer for 1 hour in the dark at room temperature. For
cell discrimination, a metallointercalator working solution (2ml Permeabilization
Buffer, 125nM iridium metallointercalator (Fluidigm; cat. 201103A)) was added to
the sample and incubated overnight at 4°C. Cells were washed with a minimum of
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3mL CSB, then again with 3mL ddH2O with 0.1% BSA. Finally, cells were filtered
through a 35µm filter and resuspended in 100µl ddH2O with 0.1% BSA. The
MDACC Flow Cytometry and Cellular Imaging Core Facility prepared the antibody
cocktails and acquired data on a Helios CyTOF machine (DVS Sciences).

Isotope

Mass Channel

Marker

Clone

Source

Custom
Catalog #

Surface /
Intracellular

89Y
139La
141Pr
142Nd
143Nd
145Nd
146Nd
147Sm
148Nd
149Sm
150Nd
151Eu
152Sm
153Eu
154Sm
155Gd
156Gd
158Gd
159Tb
160Gd
161Dy
162Dy
163Dy
165Ho
166Er
167Er
168Er
169Tm
170Er
171Yb
172Yb
173Yb
174Yb
175Lu
176Yb

89
139
141
142
143
145
146
147
148
149
150
151
152
153
154
155
156
158
159
160
161
162
163
165
166
167
168
169
170
171
172
173
174
175
176

CD45
CD56
CD27
CD274 (PD-L1)
CD357 (GITR)
CD4
CD8a
CD278 (ICOS)
CD34
CD223 (LAG-3)
CD11c
CD123
CD137 (41BB)
CD62L
CD28
CD25
TIM-3
IFNg
FOXP3
TIGIT
CD152 (CTLA-4)
CD69
CD19
CD200
NKG2D
CCR7
CD38
CD45RA
CD3
CD200R
CD273 (PD-L2)
Granzyme B
HLA-DR
CD279 (PD1)
Ki67

HI30
NCAM16.2
O323
MIH1
621
RPA-T4
RPA-T8
C398.4A
581
Poly
Bu15
6H6
4-1BB
DREG-56
CD28.2
M-A251
F38-2E2
B27
259D/C7
MBSA43
14D3
FN50
HIB19
OX-104
ON72
G043H7
HIT2
HI100
UCHT1
OX-108
24F.10C12
GB11
L243
EH12.2H7
Ki-67

DVS-Fluidigm
BD
Biolegend
eBioscience
Biolegend
Biolegend
DVS-Fluidigm
Biolegend
DVS-Fluidigm
R&D
Biolegend
DVS-Fluidigm
BD
Biolegend
Biolegend
BD
Biolegend
DVS-Fluidigm
DVS-Fluidigm
eBioscience
DVS-Fluidigm
DVS-Fluidigm
Biolegend
Biolegend
BD
DVS-Fluidigm
DVS-Fluidigm
Biolegend
DVS-Fluidigm
Biolegend
DVS-Fluidigm
DVS-Fluidigm
BIolegend
DVS-Fluidigm
Biolegend

3089003B
559043
302802
14-5983-82
311602
300502
3146001B
313502
3148001B
AF2319
337221
3151001B
555955
304802
302937
555430
345002
3158017B
3159028A
16-9500-82
3161004B
3162001B
302202
329219
A08934
3167009A
3167001B
304102
3170001B
329302
3172014B
3173006B
307602
3175008B
350502

surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
inracellular
inracellular
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
surface
inracellular

Table 6. Panel of antibodies used for lymphocyte CyTOF staining.

Mass cytometry data analysis. Data was first demultiplexed using the Fluidigm
Debarcoder software. Individual mass cytometry data files (.fcs) were then filtered
using FlowJo to remove the normalization beads, debris, doublets, and dead cells
(Figure 4). Remaining analysis was performed in R (version 3.6.1, The R
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Foundation for Statistical Computing) using the R packages ‘cytofkit’91 and
‘flowcore’92. Processed data was subjected to negative value pruned inverse
hyperbolic sine transformation and clustered based on the PhenoGraph algorithm
(k=22) using all cell surface markers93. Dimensionality reduction was performed
using uniform manifold approximation and projection (UMAP) method94.

RNA sequencing. Human CD45+ cells were collected from mouse bone marrow
and spleen and selected using the EasySep™ Mouse/Human Chimera Isolation
Kit (Stem Cell Technologies, cat 19849). Total RNA was extracted from 5x106 cells
using the RNeasy Mini Kit (Qiagen; cat. 74104). RNA concentration was
determined by NanoDrop 2000 (ThermoFisher Scientific) and RNA quality was
assessed with an Agilent Bioanalyzer. Approximately 100 million reads per sample
were run on Illumina Nextseq 500 using PE 75x 75 for stranded whole
transcriptome sequencing. Raw sequencing reads were pseudoaligned using
Kallisto v0.44.0128 with 30 bootstrap samples to a transcriptome index based on
the human GRCh38.92 release (Ensembl). Abundance data was further analyzed
with Sleuth v0.30.0129 using models with covariates for condition. Gene-level
abundance estimates were calculated as the sum of transcripts per million (TPM)
estimates of all transcripts mapped to a given gene. For GSEA, all genes were
ordered according to the score obtained by multiplying the sign of the fold change
as determined by the Wald test by the -log10 p-value obtained from the likelihood
ratio test.
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Statistics. Unless otherwise specified, data analysis performed using GraphPad
Prism version 8. Statistical tests and methods for correcting for multiple testing
are reported in-line.

76

3.4

Results

CD200 receptor is expressed in subsets of mature lymphocytes. The primary role
of CD200 is thought to be through its interaction with the suppressive CD200
receptor on effector cells114. To begin to better characterize the role of CD200
expressed on AML cells with the immune system, we first looked at the distribution
of the CD200 receptor across healthy immune cell subsets using the RNA-seq
data generated by Corces et al88. In contrast to the pattern seen with CD200
expression, CD200R mRNA levels increased throughout differentiation and were
highest in mature T cells and monocytes (Figure 13A). In fact, looking at CD200
and CD200R expression within the same cell fractions revealed almost complete
mutual exclusivity of these genes (Figure 13B). This suggests that the
CD200/CD200R signaling pathway is not utilized in an autocrine fashion but,
rather, to communicate with or control neighboring cell types, which may be in
different states of differentiation. To confirm this pattern of expression at the protein
level, CyTOF analysis was performed on 3 pooled normal bone marrow biopsies.
CD200 receptor expression was highest on the surface of subsets of CD4 and CD8
T cells (Figure 14A). We were also interested in the CD200R expression of cell
types not present at an appreciable abundance in PBMCs, namely, differentiated
macrophages. We saw a significant increase in CD200R expression on paired
monocytes after 7 days of differentiation into mature macrophages (Figure 14B).
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Figure 13. CD200R is expressed in mature leukocytes. A. CD200R1 mRNA
expression across immunophenotypically sorted healthy hematopoietic subsets
ordered left to right by differentiation status from Corces et al88. B. Mutual
exclusivity of CD200 and CD200R1 mRNA in healthy hematopoietic cells.
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Figure 14. CD200R protein expression in healthy immune cells. A. CD200
receptor expression, at the protein level, by CyTOF analysis of 3 pooled normal
bone marrow samples. B. Flow cytometry analysis of CD200R expression on
paired monocytes and differentiated macrophages.
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CD200 expression on leukemia cells alters T cell signaling in vitro. Based on the
high levels of CD200R in mature T cell subsets, we first asked whether T cell
signaling was altered in the presence of leukemia cells that expressed CD200
compared to the same cells without CD200. The engineered cell lines described
in Chapter II provide two isogenic systems with either moderate (Kasumi1 WT) or
high (OCI-AML3 pCD200) cell-surface CD200 expression that can be used to more
precisely determine the role of CD200 in immune cell interaction. Healthy T cells
were co-cultured with either the CD200+ or CD200- version of each cell line at a
1:1 ratio for 24 hours before reselecting T cells for western blot analysis (Figure
15A). T cell signaling through the MAPK pathway, as measured by ERK1/2
phosphorylation, was activated in response to co-culture with both OCI-AML3 cell
lines but significantly attenuated in the presence CD200, consistent with the
proposed CD200R signaling pathway (representative donor; Figure 15B). T cells
failed to signal through the MAPK pathway in response to either Kasumi1 cell line.
However, both Kasumi1 and OCI-AML3 AML models invoked T cell STAT3
signaling that was consistently suppressed, in a dose dependent manner, in the
presence of either moderate or high CD200 expression.
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Figure 15. AML-CD200 suppresses CD3+ T cell signaling in vitro. A.
Schematic of the T cell:AML co-culture system. B) Representative western blot
analysis of healthy T cells purified after 24-hour co-culture at a 1:1 ratio with AML
cells. Primary antibodies against phosphorylated and total STAT3 and ERK were
used.
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CD200 does not directly alter T cell-mediated killing in vitro. Because CD200
expression on AML cells was sufficient to alter multiple intracellular signaling
pathways, we next asked if CD200 expression was also sufficient to influence T
cell killing of AML cells. We chose to test both peptide-specific killing (to model the
interaction within a patient’s own immune system) and allogeneic killing (to model
graft-vs-leukemia as a result of bone marrow transplant). The OCI-AML3 cell line
expresses the minor histocompatibility antigen HLA-A*0201, which has been
shown to present a novel peptide derived from the cathepsin G protease130. Zhang
et al further demonstrated that these peptide-presenting cells can be selectively
eliminated by cathepsin G- cytotoxic T lymphocytes (CG-CTL)123. These same CGCTLs in the presence of a leukemia without HLA-A*0201, like Kasumi1, will be
limited to allogeneic killing in response to recognition of foreign antigens. Peptidespecific and allogeneic T cell killing of OCI-AML3 and Kasumi cells, respectively,
was measured by calcein AM release. There was no significant, reproducible
difference in T cell-mediated killing of AML cells with or without CD200 expression
in either the peptide-specific (Figure 16A) or the allogeneic setting (Figure 16B). In
fact, even at the highest effector to target ratios, we saw less than 50% AML cell
killing. We further employed other T effector cells, including artificially stimulated T
cells, CD123 CAR-T cells, and bulk PBMCs, in an attempt to improve AML
cytotoxicity (data not shown). However, the AML cell lines were consistently
resistant to killing by T cells in these in vitro assays.
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Figure 16. Ectopic CD200 expression does not significantly alter T cell killing
of AML. Calcein AM retention in AML cells exposed to increasing numbers of CGCTLs relative to a spontaneous release control. A. Peptide-specific cell killing of
the HLA-A2 OCI-AML3 cell line by CG-CTLs from two donors. A. Allogeneic cell
killing of Kasumi1 cell lines by CG-CTLs cells from two donors.
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CD200 suppresses T cell proliferation in vitro. We next asked whether the
differences in T cell signaling in response to CD200 resulted in altered T cell
proliferation. To examine T cell cycle response to AML cells with or without CD200
expression, growth-arrested AML cell lines were co-cultured with healthy T cells
for 4 days. CD4 and CD8 T cells were counted by flow cytometry. Across 3 healthy
donors of varying gender and age, we only saw consistent expansion of CD4 and
CD8 T cells exposed to AML cells without CD200 expression (OCI-AML3 pGFP),
albeit to differing degrees (Figure 17). T cell proliferation in the co-cultures with the
CD200 overexpressing cell line (OCI-AML3 pCD200) could be partially restored
using a nanobody (Nb) to block the interaction between CD200 on the AML cells
and the CD200 receptor on the T cells in both donors that received treatment.
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Figure 17. CD200 abrogates T cell proliferation. Bulk T cells from 3 healthy
donors were cultured at a 1:1 ratio with proliferation-blocked CD200+ (pCD200) or
CD200- (pGFP) OCI-AML3 AML cells for 4 days prior to counting the number of
CD4 and CD8 T cells by flow cytometry.
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CD200 suppresses T cell cytokine production in vitro. Signal transducer and
activator of transcription (STAT) family proteins are important regulators of
cytokine production and response131. Based on the differences in STAT3 signaling,
we next wondered if CD200 expression functionally suppressed T cell cytokine
production in vitro. Again, the isogenic models of moderate and high CD200
expression were co-cultured with healthy T cells for 24 hours before measuring
cytotoxic enzyme and cytokine secretion by flow cytometry. First, we observed that
the same T cells appeared to mount unique cytokine responses to either OCIAML3 or Kasumi cells. Cytokines including IL-6, IL-4 and TNFα were produced
predominantly in response to Kasumi cells, while cytotoxic enzymes like
granzymes and perforin and important pro-inflammatory cytokines including IFNγ
were exclusively secreted in response to the OCI-AML3 model (Figure 18). Similar
to the western blot profiling, T cells appeared to be more activated when exposed
to the OCI-AML3 model. This inflammatory cytokine response was almost
completely blocked in the presence of high CD200 and could be partially restored
using the blocking CD200 nanobody. In the Kasumi model, only IL-6, IL-4, and IL21 appeared to be differentially secreted based on CD200 status.
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Figure 18. CD200 expressing AML suppresses T cell cytokine secretion.
Cytokines were compared pairwise between groups using multiple t-tests with the
two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli to correct
for multiple comparisons. Comparisons with a q-value < 0.05 were considered
significant and denoted with an asterisk.

87

CD200 does not alter phagocytosis in vitro. CD200 has been implicated as a
regulator of macrophage function and had been posited to play a similar role to
CD47 in marking cells as safe from phagocytosis132. Based on these observations
and the high levels of CD200R on mature macrophages, we next investigated
whether ectopic CD200 was sufficient to inhibit phagocytosis of AML cells. To test
this hypothesis, we first needed to confirm that the established “don’t eat me”
signal, CD47, was not differentially expressed between AML cells with and without
CD200. Both OCI-AML3 and Kasumi1 model systems had comparable frequency
and intensity of cell surface CD47 regardless of CD200 status (Figure 19A).
It is now appreciated that one of the undesirable consequence of
tumorigenic cellular stress is the upregulation of damage-associated molecular
patterns

(DAMPs).

These

markers

activate

effector

functions,

namely

phagocytosis, of innate immune scavengers. Thus, we next looked at wellcharacterized immunogenic cell death signal genes in both cell systems133. While
not statistically significant after correcting for multiple testing, in both models there
was an increase in pro-phagocytic markers, at the mRNA level, in the CD200+
versions of both cell line (Figure 19B).
Finally, we co-cultured CFSE labeled target cells with differentiated
macrophages and determined phagocytosis by flow cytometry. At baseline, we
saw no significant difference in phagocytosis, suggesting that presence or absence
of CD200 alone is not enough to induce phagocytosis.
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Figure 19. CD200 does not significantly alter phagocytosis of AML. A. Flow
cytometry assessment of CD47 expression. B) Immunogenic gene expression by
RNA-seq. C. Functional phagocytosis of AML cell lines by healthy macrophages
(OCI-AML3 n=7 donors; Kasumi n=3 donors).
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CD200 suppresses macrophage cytokine production in vitro. Although we did not
see substantial basal phagocytosis, we next challenged macrophage cytokine
production in response to the CD200-expressing and non-expressing OCI-AML3
cells (Figure 20). Healthy macrophages were capable of mounting a robust
inflammatory response in the presence of wild type leukemia cells. Production of
all cytokines profiled was significantly abrogated by ectopic CD200 expression.
Interestingly, only secretion of a subset of these inflammatory cytokines and
chemokines, including IL1-Ra, IL-12p70, CXCL10, and CCL17, could be restored
by blocking of the CD200/CD200R interaction using the CD200 nanobody.

90

Figure 20. Macrophage cytokine secretion suppressed in response to
CD200+ AML cells. Cytokines secreted by healthy macrophages in the presence
of CD200- (pGFP) or CD200+ (pCD200) OCI-AML3 cell lines were profiled by flow
cytometry.
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CD200 may affect NK cell-mediated cytotoxicity in vitro. Previous work by Coles
et al showed a correlation between high AML CD200 surface expression and
reduction in the frequency of activated NK cells, as well as impaired cytolytic
capacity of CD16/CD56+ NK cells in the presence of ectopic CD20045. However,
a major limitation of this study was the lack of isolated NK cell co-culture
experiments to explicitly determine NK cell-mediated killing of AML. Using calcein
release assays with purified NK cells from 2 donors, we found no consistent,
significant difference in NK cell-mediated cell lysis between the CD200- (KO) and
CD200+ (WT) Kasumi cells (Figure 21A). However, in 3 out of 4 donors, CD200(pGFP) OCI-AML3 cells were killed at a significantly higher rate than the
corresponding CD200+ (pCD200) cells (two representative donors; Figure 21B).
The fourth donor had low overall cytotoxicity against both OCI-AML3 cell line
variants.
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Figure 21. High CD200 expression on AML cells may protect cells from NK
cell-mediated killing in vitro. A. Specific cell lysis of Kasumi WT and CD200KO
cells at varying NK:AML cell ratios with two different NK cell donors. B. Specific
cell lysis OCI-AML3 pCD200 and pGFP cells at varying effector NK:AML cell ratios
with two different NK cell donors. Two-sample t-tests; *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.
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CD200 suppresses a subset of NK cell cytokine secretion in vitro. Next, we
checked the ability of NK cells to mount an inflammatory response after exposure
to CD200+ and CD200- OCI-AML3 cells. In contrast to the pattern seen in T cells
and macrophages, the majority of cytokines and cytotoxic enzymes were secreted
in response to AML, regardless of CD200 status (Figure 22). However, IFNγ, IL10, and IL-6 secretion were mildly attenuated by CD200 and restored by blocking
the CD200/CD200R interaction with a CD200 nanobody.
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Figure 22. NK cell cytokine response to AML is independent of CD200
expression. Cytokines secreted by healthy NK cells in the presence of CD200(pGFP) or CD200+ (pCD200) OCI-AML3 cell lines were profiled by flow cytometry.
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CD200 prevents T cell-mediated leukemia rejection in vivo. We next sought to
confirm the CD200-mediated effects in vivo. First, we checked that the isogenic
AML model systems had similar properties in NSG mice. Briefly, 50,000 luciferase
labeled pGFP or pCD200 OCI-AML3 cells were injected intravenously into
immunodeficient NSG mice and monitored without intervention by weekly
luciferase imaging (Figure 23A). We saw no significant difference in the
engraftment or progression of disease (Figure 23B) or overall survival (Figure 23C)
between lines based on CD200 status. However, when the NSG mice were
humanized with healthy human PBMCs one week prior to leukemia introduction
(Figure 24A), we then saw significant differences in the progression of leukemia
with CD200 expression (Figure 24B). While all mice had comparable engraftment
at days 4 and 7 as measured by bioluminescent imaging, around day 14 the
system began to diverge with CD200+ OCI-AML3 cells progressing while CD200OCI-AML3 cells were eliminated. In fact, in this experiment, all mice receiving
CD200- leukemia died without detectable disease. This translated to a significant
increase in overall survival (Figure 24D), however all mice eventually succumbed
to symptoms of histologically confirmed graft-versus-host disease (Figure 25).
Expansion of human CD45+ lymphocytes (>90% CD3+) was also tracked over the
course of the experiment (Figure 24C). There was no significant difference in the
fraction of human CD45+ cells between the two groups, though at day 18, when
the leukemia models began to diverge, there was a trend towards suppressed
human lymphocytes in the mice with CD200+ leukemia.
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Figure 23. Ectopic CD200 expression does not alter AML engraftment or
progression in immunocompromised NSG mice. A. Schematic of murine
transplant model. B. Leukemia burden determined by luciferase imaging. C.
Overall survival.
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Figure 24. CD200 enables AML progression in PBMC-humanized mice. A.
Schematic of the humanized mouse model. B. Total leukemia burden by
bioluminescence imaging. C. Frequency of circulating human lymphocytes in
peripheral blood (human CD45/total CD45+). D. Overall survival (Mantel-Cox logrank test).
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Figure 25. PBMC-humanized mice develop GvHD. Representative H&E
sections from organs of healthy NSG and PBMC-humanized mice.
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Cytokine secretion in humanized mice. We performed the PBMC-humanized
mouse model experiments again in order to monitor cytokine production in vivo. At
7 days post leukemia injection, mice from both the pGFP and pCD200 models
were confirmed to have equal engraftment as determined by luciferase imaging
(Figure 26A, B). At this time point, mice also had comparable fractions of human
CD45+ lymphocytes in peripheral blood, however both leukemia models had
significantly more human lymphocytes when compared to the humanized-only
control mice (Figure 26C). Serum from peripheral blood of each mouse was
profiled for secreted inflammatory cytokines by flow cytometry (Figure 26D).
Despite the similar frequency of human lymphocytes, mice with leukemia cells
expressing CD200 had significantly reduced IFNγ, granzyme A (GZMA),
granulysin (Gran), and IL-10 abundance when compared to those without (t-tests
with two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli
correction for multiple testing, q-value<0.05). Humanized-only controls also had
high variability of inflammatory cytokine production, indicative of heterogeneous
amounts of graft-versus-host disease across mice.
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Figure 26. CD200+ AML suppresses cytokine production in vivo. A. Luciferase
image of mice at day 7. B. Total flux summary of luciferase image. C. Frequency
of circulating human lymphocytes in peripheral blood (human CD45/total CD45+).
D. Normalized cytokine production for each mouse. Multiple t-tests compared
cytokine production in pGFP vs pCD200 mice. *q<0.05.
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CD200+ AML alters T cell composition in vivo. We next asked whether the
significant alterations in cytokine production could be explained by differential T
cell composition in the presence of CD200+ AML. To test this hypothesis, another
PBMC-humanized mouse model was established following the schematic
described in Figure 24A with a different healthy donor. At day 10 after leukemia
cell injection, comparable disease burden in both pGFP and pCD200 mice was
confirmed by luciferase imaging (Figure 27A). Complete blood count (CBC) and
flow cytometry was performed on peripheral blood. While mice from both leukemia
groups had the same frequency of human CD45+ lymphocytes (Figure 27C), there
was a trend, albeit not statistically significant, towards higher white blood cell
numbers in mice with CD200-expressing disease (Figure 27B). Based on flow
cytometry analysis of CD4 and CD8 expression, pGFP mice tended to have a
higher ratio of CD4/CD8 T cells when compared to pCD200 or humanized-only
controls (Figure 27D).
High resolution immune profiling of the lymphocytes in these mouse models
was performed using mass cytometry (CyTOF) analysis to simultaneously profile
the 35 proteins in Table 6. The majority of human lymphocytes present across all
mice were CD4 and CD8 T cells. The residual non-T cell fraction of lymphocytes
was comprised of B and plasma cells. There was no evidence of NK cell presence
in these models (Figure 28A). Further partitioning CD4 and CD8 T cells into
functional subsets, we found that pGFP mice had a significantly higher fraction of
CD4+CD45RA-CCR7+ central memory cells while pCD200 and humanized only
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mice were enriched for CD8+CD45RA-CCR7- effector memory cells (Figure 28B;
*q<0.05).
CyTOF profiling also allowed for the interrogation of checkpoint expression,
markers

of

activation

and

exhaustion,

and

cell

cycle

among

the

immunophenotypically defined subset. There were no significant differences in
classical markers of activation across T cells in the presence of CD200+ leukemia.
There were, however, significantly fewer actively cycling T cells (as measured by
Ki67 expression) in mice with CD200+ disease.
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Figure 27. Characteristics of humanized mouse model. A. Representative
bioluminescence image of mice at day 7. B. Summary of total flux in these mice.
C. WBC from all mice at time of collection. D. Fraction of human CD45+ cells in
circulation. E. CD4/CD8 ratio in circulating human T cells.
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Figure 28. T cell profile of humanized mice by CyTOF. A. UMAP projection of
T human CD45+ lymphocytes in the humanized mice from Figure 25. B. Cell
fraction frequency by model type. ANOVA; *p<0.05.
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CD200 significantly alters T cell transcription. With the same cells used for CyTOF
profiling, we also performed bulk RNA sequencing to look for specific
transcriptional pathways altered by CD200-expressing leukemia. We expected to
see differentially expressed genes in primarily pathways involved in cytokine
production and response. We did see an upregulation of genes involved in T cell
response and inflammation in T cells from mice with CD200-expressing leukemia
(Figure 29). More strikingly, however, was the observation that T cells from mice
with CD200-expressing disease had significantly downregulated metabolically
related genes (Figure 30). In fact, based on gene set enrichment analysis, these
cells were significantly devoid of active metabolic signaling through glycolysis and
oxidative phosphorylation.
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Figure 29. Heatmap of differentially expressed genes between T cells from
mice with CD200+ or CD200- OCI-AML3 leukemia.
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Figure 30. GSEA analysis of genes enriched in T cells from mice CD200+
leukemia compared to T cells from mice with CD200- leukemia. A. Summary
of a subset of enriched pathways. B. Individual enrichment plots.
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3.4

Discussion
Our data showed that the highest expression of CD200 receptor, at both the

protein and gene level, seen in CD4 T cells, followed by CD8 T cells, and then
monocytes, in line with the findings of Wright et al114. We showed, for the first time,
that CD200R increases during monocyte differentiation into macrophages. Based
on these results, and previous reports by Coles et al, we chose to focus our in vitro
studies on the interaction of AML-bound CD200 with T cells, NK cells, and
macrophages.
CD200 was originally discovered as a regulator of myeloid cell
function38,116,43. By directly challenging macrophages with leukemia cells both with
and without CD200 expression, we confirmed that CD200 significantly abrogated
their effector cytokine production. A subset of the cytokines interrogated, including
IL1-Ra, IL-12p70, CXCL10, and CCL17, could be restored by blocking the
CD200/CD200R interaction using a CD200 nanobody without Fc receptormediated effects. However, the expression of the remaining cytokines, including
Arginase, TNFα, and IL-1β, could not be restored. This suggested that the isogenic
pCD200 model may have additional layers of immunosuppression (independent of
CD200 status) or that the CD200 is suppressive through an additional unknown
mechanism in macrophages. We also found that CD200 alone does not act as a
“don’t eat me” signal as no significant differences were seen in phagocytosis of the
isogenic cell lines. It would be interesting to explore whether CD200 could
suppress phagocytosis in scenarios of AML cell duress, such as chemotherapy
treatment or hypoxia.
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CD200 has also been implicated in directly suppressing NK cell
degranulation and IFNγ production45. While we did find that ectopic CD200
reduced NK cell cytotoxicity, this finding was restricted to the OCI-AML3 model.
Further studies would be required to determine whether this difference in NK cellmediated killing was the direct result of CD200 dose or an unrelated intrinsic
difference between the cell line models. Additionally, CD200 appeared to only
regulate a subset of NK cell cytokines, including TNFα, IL-10, and IL-6, rather than
the global cytokine shifts seen with macrophages and T cells.
Co-culture experiments with T cells showed a strong activation of the MAPK
signaling pathway, as measured by p-ERK, in response to OCI-AML3 leukemia
cells. However, this activity was significantly diminished in the presence of ectopic
CD200. This demonstrated that the signaling pathway originally identified in mast
cells is conserved in lymphoid cells115. Interestingly, there was no activation of
MAPK in response to Kasumi leukemia cells. However, in both isogenic models,
we saw consistent downregulation of the STAT3 signaling pathway with CD200.
Whether this was a direct result of CD200 suppression through an uncharacterized
mechanism or a feedback loop would require further investigation.
We next tested whether this altered signaling translated functionally to
changes in T cell proliferation, cytokine production, or cytotoxicity. Based on the
isolated co-culture systems, T cell cytokine production was the most significantly
impacted by the presence or absence of CD200 on AML cells. These findings were
consistent with previous reports that CD200 was capable of suppressing
inflammatory cytokines from T cells46,117. However, unlike previous reports, this
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suppression appeared to be universal and also include the downregulation of antiinflammatory cytokines including IL-6, IL-10, and IL-13134. This suggests that
CD200R signaling in T cells does not selectively regulate pro-inflammatory
cytokines but, rather, may act as a master regulator of all cytokine production. The
partial restoration of cytokine production upon treatment with a CD200 nanobody
that selectively blocks the CD200/CD200R interactions without any potential Fcmediated effects substantiates the claim that CD200 directly regulates cytokine
production through interaction with the CD200 receptor. The substantial shift in
cytokine production could also contribute to the subtle changes in T cell
proliferation; however, this requires further investigation.
Based on the low levels of AML cell killing in vitro, we were surprised to see
that CD200-expressing AML was spared from immune-mediated destruction in
vivo. The 2-week lag time in the clearance of AML cells in the PBMC-humanized
mouse model suggests a more complex mechanism by which CD200 alters the
immune microenvironment. Kretz-Rommel et al previously demonstrated that
subcutaneous co-injection of PBMCs and CD200-null chronic lymphocytic
leukemia (CLL) resulted in significant reduction in the rate of tumor growth but no
difference in outcome was seen in this CD200-expressing CLL model59. However,
subcutaneous models for leukemia are highly criticized as they do not accurately
represent the disseminated nature of the disease. We show here, for the first time,
that CD200 expression alone is sufficient to protect AML cells in a physiologicallyrelevant humanized mouse model of GvHD.
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Using the PBMC-humanized mouse model, we were also able to confirm
that CD200-expressing leukemia was also capable of suppressing T cell cytokine
secretion in vivo. The delayed clearance of CD200-null disease provided a window
where we could study the cytokine profiling of T cells in the presence of equal
disease burden. We were also able to confirm that differential cytokine production
was not confounded by differences in human CD45+ abundance.
Previous reports suggested that CD200 can alter the T cell repertoire,
specifically by allowing for Treg expansion47,118 and increases in exhausted PD-1+
cytotoxic T cells. Based on our humanized in vivo system, we were unable to
confirm either of these results with no significant differences seen in either
CD4+FOXP3+ Tregs nor CD8+PD-1+ T cells between the two leukemia groups.
We did, however, observe that the T cell profile of mice with CD200-expressing
leukemia was made up of more effector memory CD8 T cells and fewer central
memory CD4 T cells when compared to those from the CD200-null leukemic mice.
Taken together with the T cell signaling data, our findings are consistent with
previous studies that STAT3 signaling is indispensable for the maturation of central
memory cells135.
The most unexpected finding of this study was the transcriptional profile of
T cells extracted from humanized mice after one week of exposure to either
pCD200 or pGFP leukemia. While T cells from the CD200-expressing leukemia
mice did show evidence of upregulation of genes involved in inflammatory
response, these cells were almost completely metabolically quiescent when
compared to T cells obtained from the mice exposed to CD200-null leukemia. This
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corroborates the diminished cell cycle activity, as measured by Ki67, seen in the T
cells exposed to CD200+ leukemia by CyTOF analysis. Tumor metabolism can
significantly alter T cell function by manipulating pH, nutrient availability, and
oxygen abundance in the tumor microenvironment136. Further studies are
necessary to understand the contribution of CD200 to T cell metabolism.
In Chapter III, we have shown that CD200 suppresses members of both the
innate and adaptive immune systems, primarily by impeding cytokine production
in vitro. Further, we demonstrated, for the first time, that CD200 rescued AML cells
from immune clearance in a humanized model and that this effect was largely due
to altering the cytokine milieu and driving T cells into metabolic quiescence. In
Chapter IV, we will examine the clinical utility of CD200 antibody therapy.
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Figure 31. Graphical abstract of Chapter III.
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Chapter IV
CD200 antibody efficacy in AML
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4.1

Abstract

Purpose: We have now demonstrated that CD200 is a robust marker of AML LSCs
that provides direct immunosuppression to subsets of T cells, NK cells, and
macrophages through interaction with the CD200 receptor. To exploit these
findings therapeutically, a fully humanized IgG1 antibody against CD200 (CD200IgG1) was developed to specifically target AML LSCs by (1) reversing the
immunosuppressive effects by blocking its interaction with the CD200 receptor and
(2) inducing potent antibody-dependent cellular cytotoxicity and phagocytosis.

Experimental design: A series of mixed lymphocyte reactions with isolated
effector T cells, NK cells, or macrophages and target isogenic AML cell lines
(CD200 knockout and CD200 overexpression) treated with CD200-antibodies and
nanobodies were used to assess the contribution of CD200-receptor blocking
versus Fc-mediated effects. Both immunodeficient and immunocompetent mouse
models with the isogenic OCI-AML3 cell lines were employed to evaluate the
efficacy of anti-CD200 antibody therapy in vivo.

Results: Both CD200-IgG1 and the clinically available benchmark IgG2/G4
antibody, samalizumab, partially restored inflammatory cytokine production by T
cells in response to CD200+ leukemia. CD200-IgG1, but not samalizumab,
induced NK cell cytokine secretion and CD200-specific antibody-dependent cell
cytotoxicity. With macrophages, both CD200-IgG1 and samalizumab stimulated
inflammatory cytokine production and promoted phagocytosis of AML cells with
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surface CD200 expression. In immunocompromised NSG mice, anti-CD200
therapy selectively reduced engraftment of CD200+ AML and prolonged overall
survival. In the PBMC-humanized model, graft-versus-host activity combined with
antibody therapy could completely eliminate disease and substantially alter the
composition of the T cell compartment.

Conclusions: The novel CD200-IgG1 antibody improves anti-leukemic response
from components of both the innate and adaptive immune system by both reducing
the immunosuppressive effects of CD200 and by stimulating NK cells and
macrophages in vitro. Only in the immunocompetent model could CD200expressing leukemia be completely eliminated with CD200-IgG1 therapy.
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4.2

Introduction

Antibody therapy in AML. Since the approval of the first monoclonal antibody for
the treatment of Non-Hodgkin’s lymphoma in 1997137, there has been a rapid influx
of targeted therapies aiming to use antibodies to eliminate AML. Currently,
antibody therapy can be classified into 3 different types; unconjugated, multivalent,
and toxin-conjugated138. Within the unconjugated antibody category, there exist
two unique strategies.
The first is to exploit the powerful cytotoxic properties of naturally occurring
antibodies. When a cell is flagged by an antibody, the primary mechanism of cell
clearance is NK cell antibody-dependent cellular cytotoxicity (ADCC). During this
process, Fc-receptors on the NK cells recognize the constant regions of the
antibody on the target cell and initiate the production of inflammatory cytokines
and release of cytotoxic granules containing perforin and granzymes139. These
enzymes pierce the membrane of the target cell and initiate apoptosis through both
caspase-dependent140

and

caspase-independent141

pathways.

Cell-bound

antibodies can also be recognized by Fc-receptors on macrophages and
neutrophils that trigger antibody-dependent cellular phagocytosis, or ADCP.
During ADCP, antibody-labeled cells are engulfed, degraded within internal
phagosomes, and presented as antigens to further enhance adaptive immune
response142. Finally, antibody-coated cells can also induce the classical pathway
of complement-dependent cellular cytotoxicity (CDC). Briefly, complement
recognizes antibody and forms membrane attack complexes that result in osmotic
cell lysis143. Such antibodies currently in trial for AML include the anti-CD47
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magrolimab144, anti-CD123 talcotuzumab145, anti-CD33 BI 836858146, and antiCD38 Daratumumab147 and Isatuximab148
The second unconjugated antibody strategy is used when Fc-mediated
effector functions are unwanted or could be deleterious. In this case, antibodies
are employed as tool compounds to specifically cross-link or disrupt the
interactions between cell surface molecules. Ablation of Fc-receptor or
complement binding can be accomplished by introducing point mutations at
various residues in the constant region of the antibody149.

Another common

approach is to leverage the properties of different IgG subclasses to engineer
cross-subclass Fc regions150. For example, the IgG2/G4 chimera combines the
constant domain of IgG2 which has weak affinity for Fc-receptor binding with the
constant domain of IgG4 that has low affinity for complement binding to create a
full-sized, immunologically quiet antibody151.

IgG

subclasses.

Humans

have

four,

highly

conserved

subclasses

of

immunoglobulin G; IgG1, IgG2, IgG3, and IgG4, that differ in their constant
domains152. These differences are sufficient to alter their affinity for various Fc
receptors and complement activity. Generally, IgG1 and IgG3 are reported to be
the most potent activators of both Fc-mediated effector function and complement
cascades, while IgG2 and IgG4 incite little to no effector activity153.

Samalizumab. Samalizumab is a humanized anti-CD200 IgG2/G4 antibody that is
currently being used as a checkpoint inhibitor in clinical trials of chronic
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lymphocytic leukemia and multiple myeloma57. The choice to develop the clinical
antibody without effector function was based on work by Kretz-Rommel et al who
demonstrated in a subcutaneous mouse model of Burkitt’s lymphoma that the
IgG2/G4 anti-CD200 antibody was moderately more effective at reducing solid
tumor size when compared to the IgG1 version58. This was believed to be caused
by the off-target destruction of activated T cells that upregulated CD200. However,
this mechanism was not validated in the murine model. Additionally, reports from
the same group had previously shown that the IgG1 and IgG2/G4 antibodies
derived from the same anti-CD200 Fab B7 had identical efficacy in vivo59.
Samalizumab was recently included as a therapeutic arm of the BEAT AML clinical
trial [NCT03013998] for the treatment of previously untreated leukemia with high
levels of bulk CD200 expression, however, the results were not included in the trial
summary60.

MD Anderson anti-CD200. In light of these results, we chose to develop our
therapeutic antibody using a fully humanized IgG1 backbone. Using the same
variable region as samalizumab, we ensure that this novel antibody binds the same
epitope that is characterized to block CD200 receptor binding while also
harnessing the potent Fc-mediated effector functions of an IgG1 antibody.
In this chapter, we sought to characterize the effect of the novel CD200IgG1 antibody on isolated innate and adaptive effector cell subsets when
compared to samalizumab. We also tested the efficacy of CD200-IgG1 as a single
agent against CD200-expressing leukemia in the context of immunodeficient and
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immunocompetent mouse models. We hypothesized that the IgG1 backbone of
the new antibody would enhance anti-leukemic potency of immune cells and that
CD200-IgG1 antibody therapy would aid in AML eradication in humanized mice.
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4.3

Materials and Methods

PBMC collection and target cell isolation. Buffy coat was obtained from healthy
donors. PBMCs were isolated by Ficoll density gradient centrifugation. Briefly,
sample was mixed at a 1:1 ratio with Dulbecco’s Phosphate-Buffered Saline (PBS)
without calcium and magnesium (GenDEPOT) and gently added to 15ml
Lymphocyte Separation Medium (Lonza; cat. 17-829E). Cells were centrifuged at
1,800 RPM for 20 minutes and the lymphocyte layer was carefully extracted. If
necessary, 5ml ammonium chloride solution (Stem Cell Technologies) was used
to lyse any residual red blood cells. CD3+ T cells were isolated using the
EasySep™ Release Human CD3 Positive Selection Kit (Stem Cell Technologies;
cat. 17751). NK cells were negatively selected from total PBMCs using magnetic
column separation (Miltenyi Biotec, cat. 130-092-657). Monocytes were negatively
selected from PBMCs using the EasySep™ Human Monocyte Isolation Kit (Stem
Cell Technologies; cat. 19359). T and NK cells were cultured in RPMI-1640 media
with 10% heat-inactivated Fetal Bovine Serum (FBS; GenDEPOT) and 200 IU/ml
recombinant interleukin 2 (IL-2; Peprotech).

Macrophage differentiation and culture. Macrophages were differentiated as
previously described113. Briefly, sorted CD14+ monocytes from healthy PBMCs
were cultured in RPMI-1640 media with 10% FBS and 20ng/mL recombinant
human macrophage colony stimulating factor (M-CSF; Peprotech) for 7-10 days
with media changes every 3 days. Mature macrophages were detached using
StemPro Accutase Cell Dissociation Reagent (ThermoFisher Scientific) on ice for
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20 minutes and counted. Cells were re-plated at a density of 4x104 cells/well in 48well plates and allowed to reattach for 48 hours prior to use.

Flow cytometry. 3x105 cells were transferred to a 5ml FACS tube and washed twice
with staining buffer (PBS + 0.5% Bovine Serum Albumin (Sigma-Aldrich)). Cells
were Fc-blocked with either 5µl anti-human or anti-mouse Fc receptor binding
inhibitor (eBioscience Invitrogen) in 100µl staining buffer for 15 minutes prior to the
addition of anti-human CD200R (PE; Biolegend), anti-human CD47 (PerCP-Cy5.5;
Biolegend), anti-human CD45 (APC-Cy7; Biolegend), anti-human CD4 (PerCPCy5.5), anti-human CD8 (PE-Cy7; Biolegend), or anti-mouse CD45 (APC;
Biolegend) antibody (1µl/sample). Surface stain was incubated for 30 minutes at
room temperature on an orbital shaker followed by 2 washes with staining buffer.
Cells were resuspended in 300µl of staining buffer plus 5µl 4',6-Diamidino-2Phenylindole, Dihydrochloride (DAPI; 2µg/ml; Invitrogen) for live/dead cell
discrimination for collection on a LSRII machine (BD).

Cytokine profiling. 2x105 effector cells were co-cultured at a 1:1 ratio with desired
target cells and treatments in 200µl in 96-well U-bottom plates and incubated for
16-24 hours. Plates were spun down at 500g for 5 minutes. 25µl of supernatant
from each well was transferred to a new 96-well U-bottom plate. Secreted cytokine
abundance was determined using one of the following Legendplex kits
(Biolegend); Human CD8/NK Panel (cat. 740267), Human T Helper Cytokine
Panel (cat 740722), Human Macrophage/Microglia Cytokine Panel (cat. 740503).
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Briefly, cell supernatant was incubated with 25µl of pre-mixed analyte capture
beads and 25µl detection antibodies for 2 hours at room temperature on a shaker
(at approximately 600 RPM). Without washing, 25µl streptavidin-PE was added to
each well and incubated another 30 minutes at room temperature on a shaker.
Beads were washed twice and collected using a High Throughput Sampler (HTS;
BD). For cytokines within range, cytokine concentration was interpolated based on
the standards. For cytokines with concentrations outside of the standard range,
MFI was reported.

Calcein AM release assay for NK-cell mediated ADCC. NK cells were cultured in
RPMI-1640 media + 20% FBS + 200 IU/ml recombinant human IL-2 (PeproTech;
cat. 200-02) for no more than 24 hours before use. AML target cells were washed
2x with PBS and stained at a concentration of 1x106 cells/ml of calcein AM staining
media (2µg/ml calcein AM in 1ml PBS) for 1 hour at 37°C. Residual calcein was
quenched with 3 washes in 15ml complete media. 2.0x104 target cells were
plated/well in 96-well U-bottom plates. Varying numbers of NK cells were added in
a final volume of 100µl IL-2 media. Antibody treatments either 100nM
samalizumab, 100nM CD200-IgG1, or PBS-only were added to appropriate wells
in triplicate. 2% Triton-X was added to positive controls (maximum calcein
release). Plates were spun down at 500g for 1 minute before incubating 4 hours at
37°C. Following incubation, cells were spun down at 500g for 5 minutes. 75µl of
supernatant per well was transferred to a black bottom, black walled 96-well plate.
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Fluorescence was measured using a Victor X3 fluorescent plate reader
(PerkinElmer). Percent specific lysis was calculated as:
%';%+% =

>'?&#$%/$-/$DNODBMKDPEAQ − >'?&#$%/$-/$ROJPEAPDJSR
∗ 100%
>'?&#$%/$-/$KAN − >'?&#$%/$-/$ROJPEAPDJSR

Phagocytosis by flow cytometry. Target leukemia cells were labeled with 5uM
carboxyfluorescein succinimidyl ester (CFSE; ThermoFisher) for 5 minutes at 37°C
followed by a 5-minute quench with 5ml complete media at 37°C. Labeled AML
cells were co-cultured at a 2:1 ratio with differentiated macrophages (7-10 days
old) for 4 hours at 37°C. Cells were detached using StemPro Accutase Cell
Dissociation Reagent (ThermoFisher Scientific) on ice for 20 minutes and
transferred to 5ml FACS tubes. Cells were stained with 1µl/sample CD206 PerCPCy5.5 for 30 minutes at room temperature prior to assessment by flow cytometry.
Macrophages that had undergone phagocytosis of AML cells were identified as
CFSE+CD206+. Percentage of activated macrophages was calculated as the
fraction of double positive cells to total CD206+ cells.

Phagocytosis by Incucyte. Cell lines were labeled with pH-sensing fluorescent dye
using the IncuCyte® pHrodo® Red Cell Labeling Kit for Phagocytosis (IncuCyte
Sartorius; cat 4649). Prior to functional studies, optimal staining concentration was
determined for each cell line. Antibody-mediated cellular phagocytosis assays
were performed by following the IncuCyte non-apoptotic phagocytosis protocol.
Briefly, 48 hours prior to the experiment, effector macrophages were detached
using StemPro Accutase Cell Dissociation Reagent (ThermoFisher Scientific) on
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ice for 20 minutes and counted. Macrophages were re-plated at a density of 4x104
cells/well in 48-well plates. On the day of experimentation, target AML cells were
washed once with IncuCyte pHrodo Cell Wash Buffer and resuspended in
IncuCyte pHrodo Cell Labeling Buffer to a density of 1x106/ml. Cells were stained
with the optimal concentrations of IncuCyte pHrodo Red Cell Labeling Dye for 1
hour at 37 °C followed by 2 washes in complete media. 8x104 target cells and
antibody treatments (10µg/ml) were added simultaneously to effector cells and
immediately placed in the IncuCyte Live-Cell Imaging System (IncuCyte Sartorius).
Red fluorescence and bright field images were collected every 15 minutes for 4
hours. The number of engulfed AML cells was determined using the IncuCyte LiveCell Analysis Software.

Mice. Female NOD-SCID IL2Rgnull (NSG) mice were obtained from our breeding
colony with breeders originally purchased from Jackson Laboratory. Mice were
approximately 5 to 8 weeks old at the time of use. All mice were housed in
accordance with the Association for Assessment and Accreditation of Laboratory
Animal Care and NIH standards. All experiments were conducted according to
protocols 00001146-RN02 and 00001446-RN01 approved by the University of
Texas MD Anderson Cancer Center Institutional Animal Care and Use Committee.

PBMC-humanized mice. Healthy PBMCs were extracted from buffy coat the day
of injection. 10x106 cells in 100µl PBS i.v. were injected and allowed one week to
engraft. T cell engraftment was confirmed day 7 by detection of human
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CD45+CD3+ in peripheral blood by flow cytometry. Mice were then randomized to
receive 5x104 of either pGFP or pCD200 OCI-AML3 cells in 100µl sterile PBS i.v.

In vivo leukemia monitoring. Firefly luciferase was used to track OCI-AML3 disease
progression in mice. The luciferase substrate, d-luciferin (100μL of 30mg/mL in
PBS; Gold Biotechnology, Inc.), was injected i.p. 5 minutes prior to IVIS imaging
(IVIS-Xenogen 100 system; Caliper Lifesciences). Leukemia burden was
determined to be to total flux minus the total flux of the background.

Serum collection. 100µl of whole blood was collected by retro-orbital eye bleeding
from anesthetized mice in microtainers containing K2EDTA (BD, cat 365974).
Blood was transferred to Eppendorf tubes and centrifuged at 4°C for 20 minutes
at 500g. The top plasma layer was carefully extracted, transferred to fresh
Eppendorf tubes, and stored at -80°C until testing.

CyTOF mass cytometry. Human CD45+ cells were collected from mouse bone
marrow and spleen and selected using the EasySep™ Mouse/Human Chimera
Isolation Kit (Stem Cell Technologies, cat 19849). Sample barcoding and metalconjugated antibody staining were performed according to Fluidigm’s protocols as
described below. Briefly, all antibodies were labeled with heavy metals using
Maxpar-X8 labeling reagent kits (Fluidigm DVS Sciences) according to
manufacturer’s instructions and titrated for optimal concentration determination.
For each mouse evaluated, 3x106 cells were aliquoted into separate FACS tubes
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and washed twice with Maxpar PBS Buffer (Fluidigm; cat. 201058). For live/dead
cell discrimination, cells were resuspended in 200µl of 5µM cisplatin (Fluidigm; cat.
201064) for 1 minute on an orbital shaker followed immediately by 3 washes in
Maxpar Cell Staining Buffer (CSB; Fluidigm; cat. 201068). Cells were then fixed in
1ml of 1x Fix I Buffer (Fluidigm; cat. 201065) for 10 minutes followed by 2 washes
with 1x Barcode Perm Buffer (Fluidigm; cat. 201057). Each unique Palladium
Barcode (Fluidigm; Cell-ID 20-Plex Pd Barcoding Kit cat. 201060) was suspended
in 100µl of Barcode Perm Buffer and immediately transferred to cells in 800µl
Barcode Perm Buffer. Cells were incubated with barcodes for 30 minutes followed
by 2 washes with 2ml CSB. Barcoded cells were then combined into a single tube
for CyTOF staining. The staining factor was calculated as the total number of
barcoded cells/3x106. Cells were blocked with 5μL x staining factor of anti-human
Fc receptor binding inhibitor (eBioscience Invitrogen) in 45µl x staining factor of
CSB for 15 minutes at room temperature. Appropriate amount of surface antibody
master mix (Table 6) was added directly to the tube and incubated for 1 hour at
room temperature before 2 washes with CSB. For intracellular staining, cells were
dissociated in 1ml of Foxp3 Fixation/Permeabilization Buffer (eBioscience; cat. 005523-00) and incubated overnight at 4°C followed by 2 washes with 2ml of 1X
Permeabilization Buffer. After discarding supernatant from the final wash,
appropriate amounts of intracellular antibody master mix were added to the
residual Permeabilization Buffer for 1 hour in the dark at room temperature. For
cell discrimination, a metallointercalator working solution (2ml Permeabilization
Buffer, 125nM iridium metallointercalator (Fluidigm; cat. 201103A)) was added to
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the sample and incubated overnight at 4°C. Cells were washed with a minimum of
3mL CSB, then again with 3mL ddH2O with 0.1% BSA. Finally, cells were filtered
through a 35µm filter and resuspended in 100µl ddH2O with 0.1%BSA. The
MDACC Flow Cytometry and Cellular Imaging Core Facility prepared the antibody
cocktails and acquired data on a Helios CyTOF machine (DVS Sciences).

Mass cytometry data analysis. Data was first demultiplexed using the Fluidigm
Debarcoder software. Individual mass cytometry data files (.fcs) were then filtered
using FlowJo to remove the normalization beads, debris, doublets, and dead cells
(Figure 4). Remaining analysis was performed in R (version 3.6.1, The R
Foundation for Statistical Computing) using the R packages ‘cytofkit’91 and
‘flowcore’92. Processed data was subjected to negative value pruned inverse
hyperbolic sine transformation and clustered based on the PhenoGraph algorithm
(k=22) using all cell surface markers93. Dimensionality reduction was performed
using uniform manifold approximation and projection (UMAP) method94.

Statistics. Unless otherwise specified, data analysis performed using GraphPad
Prism version 8. Statistical tests and methods for correcting for multiple testing
are reported in-line.
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4.4

Results

Development of a blocking CD200 antibody. The anti-CD200 IgG1 antibody
(CD200-IgG1) was developed in collaboration with UT MD Anderson’s Oncology
Research for Biologics & Immunotherapy Translation platform. This antibody was
engineered to bind to the same epitope as the clinically available antibody,
samalizumab, and thus similarly block the interaction between CD200 and its
receptor. In addition, CD200-IgG1 was hypothesized to enhance AML LSC
clearance by inducing potent ADCC and ADCP with the humanized IgG1 constant
region. Before studying the effector function of the CD200-IgG1 antibody, a series
of biomolecular binding kinetics assays using the Octet platform were performed
to characterize the interactions between CD200, CD200R and the anti-CD200
antibody (Figure 32A-B; Figure 32A courtesy of MDACC ORBIT). First, we
validated that CD200-IgG1 efficiently bound to the CD200 ligand with a KD of
0.38nM (Figure 32C). It was also confirmed that the CD200 ligand interacted with
the CD200 receptor at a lower avidity, with a KD of 14nM (Figure 32D). By
screening the binding of CD200R-Fc protein to antibody treated CD200 ligand, it
was also demonstrated that the CD200-IgG1 effectively blocked ligand/receptor
interaction (Figure 32E).
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Figure 32. CD200-IgG1 antibody development. A-B. Identity and biophysical
characterization of CD200-IgG1. C. Kinetics of CD200 binding to the CD200-IgG1
antibody. D. CD200/CD200R interaction kinetics. E. Kinetics of CD200-IgG1 ligand
blockage.
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CD200-IgG1 restores the production of a subset of inflammatory cytokines in T
cells. In Chapter III, we demonstrated that healthy T cells mounted inflammatory
responses in the presence of AML cells that were abrogated in AML cells with
ectopic CD200 expression. The suppression of cytokine production could be
partially restored by a CD200-blocking nanobody that inhibited the interaction with
the CD200 receptor without invoking any Fc-mediated immune responses. We
hypothesized that the two blocking antibodies, CD200-IgG1 and samalizumab,
would have similar effects on T cell cytokine production compared to the blocking
nanobody (represented by the pattern of IL-4 expression in response to OCIAML3; Figure 33). However, the data indicated that different cytokines were
preferentially restored in the presence of either CD200-blocking nanobody or
antibodies. In the presence of CD200+ OCI-AML3 cells, only IL-4, IL-6, granulysin,
and TNFα were restored by both the nanobody and antibody treatments.
Granzyme A, IL-9, and IL-10 were only produced after treatment with the IgG1
version of the antibody. The T cells co-cultured with CD200+ Kasumi cells offered
a completely different cytokine pattern. Here, IFNγ, IL-9, and IL-21 were
preferentially restored upon either nanobody or antibody treatment, while IL-6
production partially returned only after nanobody treatment. This may suggest a
more complex interaction between T cells and various antibodies as well as a less
direct role of CD200 alone in the regulation of cytokine production.
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Figure 33. CD200-IgG1 partially restores T cell cytokine production in
response to AML. Profile of inflammatory cytokines secreted in response to
various co-cultures with either OCI-AML3 (top) or Kasumi (bottom) cells in the
presence or absence of blocking antibodies or nanobodies.
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CD200-IgG1 induces robust, antibody-dependent cytokine production in NK cells.
NK cells express high levels of the Fc receptor CD16 that trigger effector functions
against antibody-flagged cells or pathogens. We previously showed that NK cells
upregulated cytokine production in response to AML cells regardless of CD200
status. We next wondered whether CD200 antibody therapy could increase the
inflammatory response by enhancing cytokine secretion. Healthy NK cells were
co-cultured with CD200+ cells and either the chimeric IgG2/4 samalizumab or IgG1
anti-CD200 antibody for 24 hours. Most of the cytokines profiled increased in the
presence of either antibody, independent of IgG isotype (Figure 34A). However,
the IgG1 antibody significantly outcompeted samalizumab in the production of the
critical inflammatory proteins TNFα, IFNγ, and granzyme B (Figure 34B, KruskalWallis with Dunn’s multiple comparisons test; p<0.05)
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Figure 34. CD200-IgG1 induces NK cell-mediated cytokine production. A.
Relative NK cell cytokine production in response to co-culture with OCI-AML3 cells
in the presence or absence of blocking antibodies or nanobodies. B. MFI of specific
inflammatory cytokines across treatment groups. Kruskal-Wallis with Dunn’s
multiple comparison test; *p<0.05.
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CD200-IgG1 induces NK cell-mediated ADCC. In addition to regulation of
cytokines, engagement of the Fc receptor on NK cells also initiates a cytotoxic
response. Thus, we next wondered whether the CD200-IgG1 could enhance the
destruction of CD200+ leukemia cells by inducing NK cell-mediated ADCC in vitro.
Using the OCI-AML3 isogenic cell system, we found that the CD200-IgG1 antibody
induced potent ADCC only in the cells expressing the surface CD200 protein
(Figure 35A). By design, samalizumab should not engage antibody-dependent
cell-mediated cytotoxicity due to the cross-subclass Fc region. Therefore, we next
asked if the IgG1 version of the antibody could outcompete samalizumab by
augmenting NK cell killing via ADCC. When treated with the same concentration
of antibody targeting the same epitope, the IgG1 version of the anti-CD200
antibody resulted significantly more cell lysis compared to samalizumab at all
effector-to-target ratios in both Kasumi WT (Figure 35B) and OCI-AML3 pCD200
(Figure 35C) cells, in a dose dependent manner.
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Figure 35. CD200-IgG1 antibody induces potent, CD200-specific NK cellmediated ADCC. A. Specific cell lysis of OCI-AML3 pGFP and pCD200 cells with
and without 100nM CD200-IgG1 antibody at varying NK:AML cell ratios (t-tests
compare treated vs untreated pCD200 (red) and pGFP (green) cells. B-C. Specific
cell lysis of Kasumi WT (B) and OCI-AML3 pCD200 (C) treated with either 100nM
samalizumab or 100nM CD200-IgG1 at varying effector NK:AML cell ratios (t-tests
compare

CD200-IgG1

vs

samalizumab).

*q<0.05,
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***q<0.001,
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CD200

antibodies

induce

antibody-dependent

cytokine

production

in

macrophages. As macrophages also express a wide range of Fc receptors and
are known players in antibody-mediated responses, we next examined the
cytokine secretion from these cells in the presence of anti-CD200 treated AML
cells. All cytokines profiled were upregulated in the presence of antibody-treated
leukemia cells but not nanobody-treated cells (Figure 36A-B). This suggests that
the mechanism of action is through potential Fc interactions rather than blocking
of the CD200 receptor. The cross-subclass Fc design of samalizumab precludes
Fc receptor engagement. However, the data here shows an almost identical
cytokine response to either antibody treatment, regardless of Fc design. The
cytokine abundance from macrophages in the presence of antibodies was
significantly higher than in the presence of leukemia alone.
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Figure 36. Anti-CD200 antibodies induces macrophage-mediated cytokine
production. A. Relative macrophage cytokine production in response to co-culture
with OCI-AML3 cells in the presence or absence of blocking antibodies or
nanobodies. B. MFI of specific inflammatory cytokines across treatment groups.
Kruskal-Wallis with Dunn’s multiple comparison test; *p<0.05.
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CD200-IgG1 induces robust phagocytosis of CD200-expressing AML. One of the
primary mechanisms of action of monoclonal antibodies is to engage macrophages
and induce antibody-dependent cellular phagocytosis (ADCP). To test whether
both anti-CD200 antibodies were capable of inducing specific ADCP, CFSElabeled CD200+ and CD200- leukemia cells were co-cultured with mature
macrophages and treated simultaneously with equal concentrations of
samalizumab and CD200-IgG1. We first used microscopy to manually look for
evidence of phagocytosis after 4 hours of co-incubation. In the presence of the
CD200 antibodies, we saw numerous CFSE+ leukemia cells within the perimeter
of a given macrophage (Figure 37A). This suggested that the macrophages were
capable of engulfing the AML cells and that these cells maintained fluorescence
immediately after phagocytosis. These observations allowed for the development
of a more high-throughput assay to evaluate phagocytosis by flow cytometry. Now,
cells that stained positive for both the mannose receptor (CD206), which was
exclusively expressed on macrophages, as well as CFSE, could be counted as
macrophages that had phagocytosed at least one AML cell. This method was
limited in that it could only indicate evidence of phagocytosis and could not
estimate how many cells were consumed per macrophage. Using the OCI-AML3
isogenic cell lines, we found that anti-CD200 antibody treatment significantly
increased the fraction of phagocytosing macrophages exclusively with CD200expressing leukemia (Figure 37B). Similar to the macrophage cytokine data, even
with the cross-subclass Fc region, samalizumab was still capable of inducing
phagocytosis, albeit with less intensity than its IgG1 counterpart. CD200-IgG1 also
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induced phagocytosis of wild type Kasumi cells with low basal CD200 expression
(Figure 37B).
The interpretation of these results relies on the assumption that engulfment
of cells ultimately results in AML destruction by lysosomal degradation. To test this
hypothesis, we employed a novel phagocytosis assay that directly measures cell
entry into lethal phagosomes. Cells were labeled with a pH-sensing fluorescent
dye that increased in intensity as the acidity of the environment also increased.
This allowed for visualization of cells migrating from a relatively pH neutral
extracellular environment to the highly acidic phagosomes (Figure 37C). Liveimage software was used to capture these events over 4 hours. Interestingly, with
this approach, only the CD200-IgG1 antibody induced phagocytosis. However,
more replicates are required to rule out donor-specific macrophage variability.
Live-cell imaging also provided a time-course of phagocytosis, with peak
engulfment seen at 2.5 hours (Figure 37D).
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Figure

37.

CD200-IgG1
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CD200-specific

ADCP.

A.

Representative images of phagocytosed CFSE-labeled leukemia at baseline (left)
and with CD200-IgG1 treatment (right) after 4-hour co-incubation with healthy
macrophages. B. Flow cytometry analysis of phagocytosis of OCI-AML3 (left) or
Kasumi (right) cells. C. Representative images of phagocytosed pHrodo redlabeled leukemia at baseline (left) and with CD200-IgG1 treatment (right) after 4hour co-incubation with healthy macrophages. D. Time course of phagocytosis by
live cell imaging over 4 hours.
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CD200-IgG1 delays and redistributes CD200+ leukemia. Based on the ability of
CD200-IgG1 to induce potent phagocytosis of CD200+ cells, we next assessed
the efficacy of single-agent antibody therapy in the immunocompromised NSG
mouse model. While NSG mice lack B, T, and NK cells, it has been reported that
these mice retain functional effector phagocytes, including macrophages154. Mice
were engrafted with either the CD200+ (pCD200) or CD200- (pGFP) OCI-AML3
cell line and randomized to receive 6 doses of CD200-IgG1 (10 mg/kg) or vehicle
control starting 1 week after injection (Figure 38A). Before antibody administration,
both cohorts had similar disease burden. After 2 doses (i.e. one week), there was
a significant decrease in the disease burden of CD200+ CD200-IgG1-treated mice.
However, the remaining 4 doses appeared largely ineffective, as the disease
burden began to increase at the same rate as the control treated mice (Figure
38B). This delay in leukemia expansion translated to significantly prolonged
survival (p<0.0001), with a 74% increase in median survival (Figure 38C).
Interestingly, all mice in the pCD200 antibody treated group died as a result of
large, intraperitoneal chloromas.
Because the leukemia cells were luciferase-labeled, we could use
bioluminescent imaging to track the distribution of disease. In the untreated model,
OCI-AML3 cells preferentially engrafted in the liver and progressed to the bone
marrow (Figure 39A). After 2 doses of CD200-IgG1, there was essentially
complete clearance of disease in these locations and a concentrated disease
burden in the spleen (Figure 39B). This area is where leukemia cells remained for
the duration of the experiment. Post-mortem investigation revealed that the
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disease in the treated pCD200 mice was exclusively in the spleen and the adjacent
solid tumor. In some instances, leukemia can evade targeted therapy by downregulating the protein of interest. Therefore, we performed flow cytometry on
single-cell suspensions from the spleen and chloroma from these mice. Human
CD45+ cells maintained CD200 expression (Figure 39C), negating this potential
mechanism of resistance.
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Figure 38. CD200-IgG1 delays CD200+ leukemia progression. A. Schematic of
the humanized mouse model. B. Total leukemia burden by bioluminescence
imaging (ANOVA with Dunnett’s test for multiple comparisons; ****p<0.0001). C.
Overall survival (Mantel-Cox log-rank test; ****p<0.0001).
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Figure 39. CD200-IgG1 alters CD200+ leukemia distribution. Representative
bioluminescent images of pCD200 OCI-AML3 mice after two doses of the vehicle
control (A) or CD200-IgG1 (B). Flow cytometry analysis of CD200 expression in
human CD45+ cells (c) and H&E (d) of a CD200-IgG1-treated chloroma.
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CD200-IgG1 can eliminate disease in the presence of graft-vs-leukemia. To test
whether the presence of adaptive immune cells could improve antibody-therapy,
we next assessed the efficacy of single-agent antibody therapy in two PBMChumanized NSG mouse models using two different healthy donors. Human
PBMCs were engrafted into NSG mice one week before injection of AML cells.
Seven days after the introduction of leukemia, mice were treated with 6 doses of
CD200-IgG1 (10 mg/kg) or vehicle control. In the first donor, which had potent
graft-versus-leukemia potential, anti-CD200 therapy resulted in significant
reduction in disease burden (Figure 40A-B) and ultimate clearance of leukemia (as
assessed by flow cytometry at time of death). While strong GvL/GvHD was
beneficial in anti-leukemia activity in this model, it made overall survival
uninterpretable, as mice died almost immediately upon disease elimination. In a
second humanized model with significantly less GvHD, we still saw that CD200IgG1 single-agent therapy significantly reduced the disease burden (Figure 40B).
This translated to a significant improvement in overall survival (p=0.028) with an
increase in median survival of 33.5 days (117.5% increase) (Figure 40D).
Interestingly, the leukemia treated mice also survived significantly longer than the
humanized only controls. Using this model, we also confirmed that the CD200IgG1 treatment had no significant effect on the expansion of humanized cells in
these mice (Figure 40C).
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Figure 40. CD200-IgG1 significantly reduces leukemia in humanized mice. A.
Bioluminescent images of humanized mice over the course of CD200-IgG1
treatment. B. Total leukemia burden in 2 humanized models (ANOVA with
Dunnett’s test for multiple comparisons). C. Flow cytometry of human PBMC
expansion in humanized mice (ANOVA with Dunnett’s). D. Overall survival for mice
humanized with PBMCs from Donor 2 (Mantel-Cox log-rank test). *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001.
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CD200-IgG1 treated mice revert to an anti-inflammatory state after treatment.
Based on the observation that humanized-mice, after CD200-IgG1 treatment, lived
significantly longer than the humanized-only control mice, we next investigated the
human immune cell composition in a representative mouse from each
experimental arm by mass cytometry (Figure 41A). Based on the amount of
residual leukemia at this time point, we hypothesized that the CD200-IgG1 treated
mice would resemble the mice with CD200- disease (pGFP). However, we found
that the composition of T cells present in the antibody treated mouse was
drastically different from either leukemic mouse or humanized control (Figure 41B).
After treatment with anti-CD200 antibody, there was little evidence of activated
CD8+ T cell subsets and an enrichment of both naïve and Treg CD4+ cells. This
unique pattern of T cells suggests that the CD200-IgG1 antibody has functional
properties beyond blocking CD200 receptor interaction in vivo.
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Figure 41. CD200-IgG1 alters T cell composition in humanized mice. A.
Bioluminescent images of humanized mice at time of PBMC collection. B.
Composition of human lymphocytes present in a representative mouse from each
group based on CyTOF analysis.
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4.5

Discussion
Antibody design. Samalizumab is a clinically available, anti-CD200

humanized monoclonal antibody engineered with a cross-subclass IgG2/G4
backbone to minimize Fc-mediated effector functions. This design was based on
the hypothesis that blocking the CD200/CD200R interaction alone would produce
therapeutically favorable response. We believed we could enhance the therapeutic
efficacy of the CD200 antibody by replacing the chimeric Fc region with that of the
potent IgG1 subclass. This would allow us to specifically target AML cells by (1)
blocking the immunosuppressive activity of CD200 while simultaneously (2)
engaging Fc-mediated effector cells for AML destruction.
T cell response to antibody treatment. While our data consistently show that
CD200-expressing cells abrogate cytokine production in the isogenic cell line
setting, the data pertaining to the restoration of cytokine production has proved to
be more complicated to interpret. If the reversal of T cell cytokine suppression was
as simple as disrupting the ligand/receptor interaction, the blocking nanobody,
samalizumab, and CD200-IgG1 should have had similar effects on T cell cytokine
secretion in response to CD200 expression on AML. However, the data indicated
that different cytokines were preferentially secreted in the presence of either the
CD200-blocking nanobody or antibodies. This could suggest that the interaction
kinetics between the various blocking agents are different. Still, it is more likely that
the different types of blocking agents (i.e. foreign nanobodies, or antibodies with
differential Fc regions) have their own independent ability to alter T cell cytokine
secretion. In other experiments, we have shown that nanobodies against CD200
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without receptor blocking properties may also partially “restore” cytokine
production, which may suggest that nanobody presence alone is capable of
inducing a T cell-mediated cytokine response. Despite early reports of low-affinity
Fc receptor expression on subsets of T cells, their functional role remains relatively
unstudied155. However, recent studies have suggested that Fc receptors on CD4+
cells may provide costimulatory signals in the absence of the classical
costimulatory pathway through CD28156-158. Direct signaling through the Fc
receptor on CD4+ T cells in response to antibody treatment may confound our
ability to interpret the CD200 receptor blocking with antibody therapy. Taken
together, we believe that CD200+ cells potently suppress T cell cytokine
production; however, this process does not seem to be restored by attempting to
competitively block receptor interaction with antibodies or nanobodies. In fact,
these biological agents have their own effects on T cell cytokine production.
Innate immune system response to CD200-IgG1 treatment. In the previous
chapter, we showed that AML cells with CD200 expression could also abrogate
the cytokine production in NK cells and macrophages. This dampened
inflammatory response did not directly translate to impaired cytotoxic or phagocytic
function. Yet, the inherent benefit of antibody therapy is that these functions can
be explicitly invoked by design. The clinically available anti-CD200 antibody,
samalizumab, was constructed with an IgG2/G4-kappa constant region. Such
chimeric antibodies, termed “benign blockers”, were originally engineered to target
protein interactions where effector function would be undesirable, or even fatal.
Studies indicate that such antibodies should have little to no Fc-receptor binding
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and, thus, no subsequent effector activity151. However, data presented here
suggest that this chimeric antibody is still capable of activating components of the
innate immune system to different degrees. Samalizumab was able to induce
moderate cytokine production in NK cells but did not induce ADCC. In
macrophages, samalizumab induced both potent inflammatory cytokine secretion
as well as low levels of ADCP.
Here, we show that by changing the constant region of the same antibody
from an IgG2/G4 to an IgG1, we can significantly enhance inflammatory cytokine
production from both NK cells and macrophages specifically in the presence of the
cell-bound anti-CD200 antibody. CD200-IgG1 antibody treatment also induced
potent, specific antibody-dependent NK cell cytotoxicity of CD200+ AML cells. We
also demonstrated, for the first time, that the CD200-IgG1 antibody can be used to
specifically flag CD200+ cells for phagocytosis.
Antibody clearance of AML requires the adaptive immune system. Next, we
evaluated the utility of the CD200-IgG1 antibody as a single agent in vivo. By
design, NSG mice lack critical immune components including B, T, and NK cells
but maintain macrophages and dendritic cells. Due to the non-obese diabetic
genetic background of this model, it was originally reported that these remaining
members of the innate system were defective159. However, more recent studies
have reported phagocytic potential of NSG derived macrophages ex vivo154,160.
Therefore, we speculated that the primary mechanism of AML clearance as a
result of CD200-IgG1 antibody treatment was through phagocytosis. What we did
not anticipate was the re-distribution of leukemia cells upon antibody therapy. The
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OCI-AML3 cells rarely take up residence in the spleen until the mouse is overcome
by disease burden. However, upon administration of CD200-IgG1, we saw disease
that was concentrated in the spleen. This disease did not disseminate after
cessation of treatment, instead, it led to the formation of solid AML tumors that
branched off of the spleen.
In humanized models, we saw a very similar pattern where disseminated
disease converged on the spleen after antibody treatment. However, in the
presence of human T cells-mediated graft-versus-host, this residual disease was
cleared from the spleen and did not go on to form solid tumors. In the second
donor, where GvHD was mild, there were antibody-treated mice that did not
completely eradicate disease. In these cases, disease appeared to be restricted
to organs in the genitourinary tract. Taken together, these findings suggest that
clearance of CD200+ AML by targeted antibody therapy requires components of
both the innate and adaptive immune systems.
Lastly, our data suggests that CD200-IgG1 antibody treatment not only aids
in eliminating CD200+ leukemia, but also considerably alters the T cell composition
in these mice. Further studies need to be performed to validate these findings and
link changes in T cell composition to changes in the cytokine milieu.
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Figure 42. Graphical Summary of Chapter IV.

157

Chapter V
Discussion
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5.1 Overall Summary
Acute myeloid leukemia is a deadly cancer of the blood that affects both
children and adults. Using traditional chemotherapies, up to 80% of patients will
achieve remission, a state when disease is no longer detectable. However, the
majority of these patients will relapse and no longer be responsive to traditional
treatment. Leukemia, and the subsequent relapsed disease, are hypothesized to
arise from rare, primitive cells that are capable of evading chemotherapies known
as leukemia stem cells (LSCs). Thus, LSCs are the critical target for curing AML.
Stem cell transplantation is a proof-of-principle that AML LSCs can be eliminated
by a functional immune system. However, the mechanisms by which AML LSCs
escape immune surveillance and destruction remain largely unknown. The work
presented in this thesis aims to bridge this gap in knowledge by identifying and
characterizing CD200 as a novel marker of functional LSCs, demonstrating its role
as a master regulator of both the innate and adaptive immune systems, and
translating this scientific discovery into a potential therapeutic strategy for AML.
In Chapter I, we summarized our current understanding of the biology of
acute myeloid leukemia and the available treatment regimens. The controversial
history of the cancer stem cell hypothesis and its experimental validation with the
discovery of the leukemia stem cell was discussed. In particular, we focused on
the concept of eliminating LSCs as the crux for curing AML. We provided evidence
that some of the earliest implementations of “immunotherapy” in the form of stem
cell transplant could eradicate AML LSCs. We then introduced the novel AML LSC
marker, CD200, and summarized existing literature pertaining to its role in stem
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cell biology and immunology. Emerging immunotherapeutic strategies designed to
specifically target CD200-expressing cells was also reviewed.
We hypothesized that, in the majority of AML, CD200 expression was
ectopically expressed specifically in LSCs as a mechanism for evading members
of both the innate and adaptive immune system. In order the address this
hypothesis, we had to (1) establish CD200 as a novel marker of functional AML
LSCs, (2) characterize the interaction between CD200+ AML and important
immune cell subsets, including T-, NK-cells, and macrophages, and (3) assess the
feasibility of therapeutically targeting CD200+ AML with a novel antibody.
In Chapter II, we sourced the wealth of publicly available data to generate
a master AML LSC database that contained genome-wide expression from 3
different publications.

By treating each dataset as an independent biological

replicate, we were able to robustly identify CD200 as a novel marker of AML LSCs
at the gene expression level. We independently confirmed that >90% of AML cases
contained a subset of leukemia cells that expressed cell-surface CD200 protein
and that expression of CD200 largely correlated with the established stem cell
marker, CD34. We further demonstrated that even within CD34+ cells, CD200
more accurately identified functional AML LSCs using colony formation assays.
The ability of CD200 to identify LSCs was conserved in a model of murine AML.
To study CD200 more systematically, we generated 2 isogenic cell lines
models. In one of the only AML cell lines to express CD200 at appreciable levels
in the wild type setting, Kasumi1, we performed CRISPR/Cas9 to knockout
expression. In the OCI-AML3 model, which lacked detectable CD200 expression
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at both the gene and protein level, we introduced high levels of the canonical
CD200 isoform using electroporation integration. In cell lines, manipulation of
CD200 resulted in no obvious phenotypic changes in cell growth or metabolism;
negating CD200 as an essential gene. This is consistent with the observation that
Cd200 null mice are viable. However, RNA-seq of both isogenic cell systems
revealed that the CD200+ version of each line transcriptionally upregulated genes
involved in the double-strand DNA repair response. This translated to differential
response to DNA-damaging agents; a novel observation that needs to be studied
in greater detail.
Finally, leveraging mass cytometry clinical trial data of refractory/relapsed
AML treated with hypomethylating agents in combination with an anti-PD-L1
inhibitor, we observed that CD200 was present in subsets of disease resistant to
this particular immunotherapy. Upon further investigation, CD200 was also found
to correlate with critical immune checkpoints including PD-L2 and TIGIT,
implicating CD200 as a relevant marker of immunosuppression. In light of these
findings, we next set out to methodically characterize the role of CD200 in the
interaction between AML and immune cells.
In Chapter III, we first prioritized subsets of immune cells with high levels of
the CD200 receptor at both the gene and protein level. Based on these results, we
then focused on the isolated interactions between CD200+ and CD200- leukemia
cell lines and (1) T cells, (2) NK cells, and (3) macrophages. Using co-culture
experiments, we confirmed that CD200+ AML suppressed the MAPK signaling
pathway in adjacent T cells. We also found that CD200+ leukemia robustly
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abrogated signaling through the STAT3 pathway; a major regulator of cytokine
production. Functionally, altered T cell signaling translated to a significant
suppression of T cell production of inflammatory cytokines and cytotoxic enzymes
as well as stunted proliferation. However, this did not directly result in differential
killing of AML cells.
In the interaction of AML and innate immune cells, we demonstrated that
CD200

significantly

suppressed

inflammatory

cytokine

production

from

macrophages but did not appear to regulate basal phagocytosis. CD200+ OCIAML3 cells were significantly protected from NK cell-mediated cytotoxicity,
however, CD200 did not appear to play a critical role in regulating NK cell cytokine
production.
CD200 expression on OCI-AML3 AML cells does not alter the ability of cells
to engraft and expand in an immunocompromised NSG mouse model. However,
when the same NSG mice were humanized one week prior to leukemia exposure
using healthy human PBMCs, CD200 presence became critical. While both
CD200+ and CD200- OCI-AML3 cells were capable of engrafting in humanized
mice, only CD200+ AML was able to persist in the presence of graft-versusleukemia and graft-versus-host disease. In fact, this response could completely
eliminate AML cells lacking CD200. CD200 status did not significantly alter the
expansion of healthy human CD45+ cells. However, cytokine secretion in mice
exposed to CD200+ AML was significantly reduced. Further, these same T cells
were universally metabolically quiescent at the transcriptional level. Based on
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these results, we next asked whether anti-CD200 antibody therapy could mimic or
even enhance the anti-leukemic effects seen in the CD200- cell lines.
In Chapter IV, we developed and characterized a novel, fully-humanized
anti-CD200 antibody with an IgG1 backbone. We chose to leverage the variable
region of the existing anti-CD200 antibody, samalizumab, well characterized to
block the interaction of CD200 with its cognate receptor. However, replacing the
chimeric IgG2/G4 constant region with that of IgG1 allowed for a therapeutic that
would (1) remove the suppressive CD200 signal while (2) potently engaging
members on the innate immune system.
CD200-IgG1 bound the CD200 antigen with sub-digital nanomolar avidity
and could efficiently block binding to CD200R. While there was evidence of
cytokine secretion from T cells in the AML co-cultures treated with both CD200IgG1 and samalizumab, neither antibody was capable of completely restoring
cytokine production in the presence of CD200+ AML. CD200-IgG1, but not
samalizumab, potently induced NK cell cytokine secretion and CD200-specific
ADCC. In macrophages co-cultured with AML, both CD200-IgG1 and
samalizumab promoted cytokine production and induced phagocytosis of CD200+
AML cells.
In immunocompromised NSG mice, anti-CD200-IgG1 therapy selectively
reduced and redistributed CD200+ AML from the liver and bone marrow to the
spleen, that translated to prolonged overall survival. In the PBMC-humanized
model,

graft-versus-host

combined

with

anti-CD200-IgG1

therapy

could

completely eliminate disease and substantially alter the T cell composition. In
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summary, novel CD200-IgG1 therapy improves anti-leukemic efficacy by both
removing the immunosuppressive effects of CD200 and by stimulating NK cells
and macrophages in vitro. Only in the humanized mouse model could CD200+
leukemia be completely eliminated with CD200-IgG1 therapy, suggesting the
requirement of a cooperative effort from both innate and adaptive immune cells.
Taken together, these experiments suggest that CD200 is a novel AML
stem cell-specific regulator of immune function. CD200+ AML robustly suppressed
cytokine production from various members of immune cells including T cells, NK
cells, and macrophages. Importantly, anti-CD200 antibody therapy, combined with
cellular immune response, could completely eradicate CD200+ disease in a
murine model of leukemia.
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5.2 Future Investigations
Confirm CD200 is a functional stem cell marker in vivo.
Our data indicates that even within CD34+ cells, CD200 can further refine
AML LSCs in vitro. However, the definite test of functional AML LSCs is the ability
of cells to engraft in sublethally irradiated NSG mice. While published data from
Ng et al suggest that CD200 expression is significantly higher in functional stem
cells in vivo, this needs to be explicitly tested. Preliminary experiments by Ho et al
showed that in AML cases where CD200 was expressed at appreciable levels
(>5% of blasts), all cells capable of engrafting in mice were CD200+56,161. This
included cells that were both CD34+ and CD34-. In accordance with our findings,
they also observed the utility of CD200 as a marker for LSCs in cytogenetically
normal NPM1 mutant AML cases that lack CD34 expression. To better understand
the molecular mechanisms that differentiate functional AML LSCs, single-cell
RNA-seq should be performed on paired CD200+CD34+, CD200-CD34+,
CD200+CD34-, and CD200-CD34- cells from the same patient. It would also be of
interest to collect human AML cells immediately after engraftment and assess the
distribution of known and predicted stem cell markers by CyTOF.

Elucidate the intrinsic function of CD200.
The cell line models used for in vitro characterization of CD200 function
lacked endogenous CD200 receptor expression, therefore, we did not expect to
see any intrinsic phenotype. Indeed, we saw no obvious differences in the growth,
metabolism, or engraftment potential of cells with or without CD200 expression.
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However, we were surprised find that in both isogenic models, CD200+ cells were
enriched for gene signatures associated with the DNA damage response. Genetic
components of the Fanconi Anemia pathway and double-strand DNA repair
response were consistently upregulated in CD200+ AML regardless of the cell line
background or the method used to genetically modify CD200 (i.e. CRISPR/Cas9
or electroporation integration), largely negating the likelihood of technical artifacts.
In a preliminary experiment, our results demonstrated that these transcriptional
differences did, in fact, translate to functional changes in the response to DNA
damaging agents like hydroxyurea. The precise mechanism by which CD200
participates in the control of these pathways remains to be discovered. We
hypothesize that CD200 regulates the transcription of DNA damage machinery by
either (1) autocrine signaling through an undiscovered binding partner or (2) a
novel mechanism of signaling through the cytoplasmic tail of the CD200 protein.
Identify of novel CD200 binding partners. The majority of existing literature
indicates that the CD200 receptor is the exclusive binding partner of the CD200
ligand. However, emerging data suggests that there may be other, wellcharacterized receptors that can recognize and signal in response to CD200
ligation. In the central nervous system, recombinant CD200 has been shown to
induce neurite outgrowth and survival162. The growth phenotype could be reversed,
in a dose dependent manner, using an inhibitor of the fibroblast growth factor
receptor (FGFR) or by introducing a dominant negative FGFR. These results,
along with the discovery of an FGFR binding motif in the first Ig-like module of
CD200, suggest that CD200 functions as a novel ligand for FGFR in neurons.
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Based on our RNA-seq data, Kasumi cells express high levels of the FGFR1
transcript while OCI-AML3 cells have very little. To confirm if FGFR1 is also a
receptor of CD200 in AML, first, protein expression of the receptor needs to be
confirmed in the cell line model systems and primary AML patient samples by flow
cytometry or western blot analysis. Next, activity of components of the FGFR1
signaling pathway, including MAPK, PI3K-AKT, PLCγ, and STAT, should be
assessed by western blot in the CD200+ and CD200- cell lines. If there is
differential activity at baseline that can be reversed using an FGFR1 inhibitor, this
would indicate that CD200 may induce autocrine signaling through FGFR1 in AML.
In light of these results, the possibility that even more unidentified CD200
binding partners exist should further investigated. This could be pursued by
multiple avenues. Binding motif analysis could be performed to identify a number
of receptor candidates for in vitro validation. Alternatively, we could employ a
genome-wide CRISPR activation screen to unbiasedly identify all potential
activating receptors for the CD200 ligand163.
Determine signaling potential of the CD200 cytoplasmic tail. Until recently,
the only reported role of CD200 was through its extracellular interaction with
neighboring immune cells. This exclusive functionality was based on the
observation that the short, intracellular portion of the CD200 protein lacked an ITIM
or docking site for other signaling molecules. Chen et al have now offered an
alternative signaling mechanism by which the CD200 cytoplasmic domain, or Ctail, can act directly as a transcription factor in chronic lymphocytic leukemia109.
More specifically, they proposed that upon γ-secretase cleavage, C-tail could
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translocate to the nucleus where it directly binds DNA and alters expression of 6
transcription factors; KLF5, DACH1, TSSC1, ARGLU1, POTEA and PLEKHG4B.
While compelling, this study had numerous limitations. First, this phenomenon was
not present at baseline but required external stimulation in the form of phorbol 12myristate 13-acetate (PMA). PMA is a potent activator of protein kinase C (PKC)
that results in the release of Ca++ and initiation of a non-specific T cell signaling
cascade164. Thus, the transcriptional alterations reported cannot necessarily be
attributed to the C-tail. Second, induction of constitutive C-tail expression in CLL
cells alone did not appear to have a significant functional effect. Finally, the readout
of C-tail activity was strictly confined to the expression of the 6 genes identified
using ChIP-seq. However, the ChIP-seq screen was performed without an
appropriate antibody-only control. Therefore, the true functional effect of the C-tail
may not have been adequately captured by these experiments. Despite these
limitations, there is strong evidence that CD200 can be cleaved and result in a
small intracellular protein fragment whose precise role requires further
investigation.
Understand the interaction between CD200 and cathepsin G. We
performed

preliminary

co-immunoprecipitation

experiments

with

mass

spectrometry to identify potential CD200-interacting proteins that might play a role
in cleavage and subsequent internal signaling. These experiments unbiasedly
identified cathepsin G (CTSG) as a potential protein of interest. CTSG is a
azurophil granule protease that is broadly expressing in AML and has been well
characterized as an immunotherapeutic target123,165. CTSG is traditionally thought
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to function as part of the innate host defense and neutrophil-mediated immune
response166. However, cathepsin G also plays an important role in cleaving a
variety of proteins to produce functionally unique substrates. For example, CTSG
has been reported to cleave full length IL-33 to produce more highly bioactive
forms that may function as signals of endogenous danger167. CTSG is also
responsible for producing the cleaved form of STAT5 (STAT5 γ) that contributes
to myeloid cell differentiation168. In AML, CTSG has also been reported to cleave
the AML1 portion of the AML1-ETO fusion protein, resulting in proteasomal
degradation and partial recovery of differentiation169.
In a preliminary experiment, we found that recombinant human CD200 was
cleaved by CTSG to produce a fragment protein <10kDa similar to the previously
reported C-tail (Figure 43). To confirm this cleavage product is in fact a peptide of
CD200, the low molecular weight protein should be confirmed by mass
spectrometry. Next, the isogenic cell lines with and without CD200 should be
examined by western blot analysis to look for presence and abundance of CTSG
and CD200 cleavage products. Further, the CD200+ cells could also be treated
with recombinant CTSG to confirm that cleavage can be induced exogenously.
These same western blot experiments should also be repeated with primary AML
patient samples that express appreciable levels of CD200.
While the above experiments are focused on CTSG, there exist numerous
other proteases, including granzymes170 and matrix metalloproteases171, that have
been implicated in pre-processing full-length cytokines and proteins. The potential
interaction of the proteases with CD200 warrants further investigation.
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To functionally characterize the C-tail fragment of CD200, I would propose
the following experiments. First, confocal microscopy should be performed on AML
cell lines and patient samples to detect the presence and distribution of CD200 Ctail in the cytoplasm and nucleus. Next, we could perform ChIP-seq with
appropriate controls to determine whether CD200 does, in fact, directly bind DNA.
I would also propose that co-immunoprecipitation with mass spectrometry be
performed on both a CD200+ cell line and patient sample to more definitively
identify potential interacting partners. Together, these experiments would provide
insight on the potential role of CD200 as part of a transcriptional complex and as
to whether CD200 C-tail is directly responsible for the changes seen in DNA
damage machinery. To confirm these findings, we could construct cell lines
engineered to conditionally express either full-length CD200 or C-tail protein. The
functional contribution of each version of CD200 would be compared using cell
growth assays, metabolism profiling, and transcriptional assessment by RNA-seq.
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Figure 43. Cathepsin G cleaves CD200. Recombinant human CD200 was
incubated with increasing concentrations of CTSG and assessed by western blot
for the detection of CD200 cleavage. The same membrane was probed first for
anti-CTSG (left) followed by anti-CD200 (right).
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Investigate AML cell resistance to cytotoxic lymphocytes.
The two primary mechanisms of NK- and T cell-mediated cytotoxicity are
(1) through activation of the FAS receptor pathway on target cells or (2) by the
production of granules containing cytotoxic enzymes172. In the first, FAS ligand,
both effector cell-bound and soluble, binds the FAS receptor on target cells and
leads to trimerization, activation of the FAS-associated death domain signaling
pathway, and subsequent apoptosis via caspase 8173. The second, more dominant
mechanism of cytotoxicity involves the exocytosis of granules equipped with
perforin and granzymes174. The perforin released from cytotoxic effectors can
either aggregate at the surface of target cells causing osmolysis or act as a
transport medium through the cell membrane for the adjacent granzymes175. Once
inside the cell, granzymes, particularly granzyme B, activate programmed cell
death through the activation of caspase 8 and caspase 3176.
Our data presented in Chapter III indicate that the AML cell lines OCI-AML3
and Kasumi appear largely resistant to T and NK cell cytotoxicity, with the highest
effector to target ratios achieving only roughly 50% killing. Other groups have also
demonstrated that leukemia, in general, is largely resistant to FAS-mediated cell
death, while myeloid leukemias are uniquely perforin-resistant177,178. In line with
previous reports, RNA-seq data of the AML cell lines indicated very low levels of
FAS receptor, suggesting downregulation of the receptor as a potential mechanism
of resistance179. The nature of AML resistance to perforin-mediated cytotoxicity
may be attributable to the underlying myeloid biology. As first responders of the
innate immune system, polymorphonuclear cells, derived from monocytes, are
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involved in the inflammatory response and constitutively express perforin180,181.
Thus, such cells must have intrinsic defenses in place to protect them from their
own cytotoxic response.
Previous studies have attempted to elucidate the molecular mechanisms by
which cytotoxic cells escape self-killing. Early biochemical experiments suggested
the presence of an inhibitory protein on the surface of perforin-resistant cells that
was capable of inducing a conformational change in the perforin that rendered it
inactive and prohibited the membrane pore formation182,183. Multiple proteins have
since been proposed to fulfill this protective role in cytotoxic lymphocytes including
cathepsin B (CTSB)184, serpin B9 (SERPINB9)185, and LAMP1 (CD107a)186. While
now studied in the lymphoid compartment, their contribution to perforin-resistance
of myeloid cells, including myeloid leukemias remains unknown. Using the publicly
available RNA-seq data from Corces et al88, we assessed the gene expression of
CTSB (Figure 44A), SERPINB9 (Figure 44B), and CD107a (Figure 44C) in healthy
hematopoietic cells, AML LSCs, and blasts. Although identified in cytotoxic
lymphocytes, all 3 genes had the highest expression in monocytes. Myeloid
leukemia cells also expressed high levels of the reported perforin-resistance
genes. In a preliminary flow cytometry experiment, we confirmed that CD107a was
expressed at the protein level in the Kasumi AML cell lines at a log-fold higher
abundance than activated T cells (Figure 44D). Taken together, our data suggests
that AML cells may be inherently resistant to the perforin-mediated cytotoxicity
invoked by effector T and NK cells.
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To test this hypothesis, we should first generate and characterize CTSB,
SERPINB9, and CD107a knockout AML cell lines using CRISPR/Cas9. Differential
AML cell killing could then be evaluated using the mixed lymphocyte assays
described in detail in Chapter III. To confirm that the effect is specifically though
the inactivation of cell-bound perforin, cell lines could be treated with isolated
cytotoxic granules or recombinant perforin protein to assess cell membrane
integrity and lysis. Novel mechanisms of perforin resistance specifically to AML
should be identified by performing a CRISPR/Cas9 screen. Briefly, a custom-made
library of guide RNAs targeting AML cell surface proteins and known
immunoregulators will be delivered by lentivirus to the AML cell line. Cells will then
be treated with recombinant perforin or cytotoxic granules. Surviving cells will be
sequenced to back calculate which guide RNAs resulted in increased perforin
sensitivity. Clinically, it would be of interest to know if expression of these perforinresistant proteins on primary AML patient samples act as poor prognostic markers
or identify cases that fail to respond to existing immunotherapies. The results of
such studies would be critical to consider in the context of emerging
immunotherapies that attempt to eliminate AML by directly engaging cytotoxic
lymphocytes, such as chimeric antigen receptor T and NK cells or T cell engaging
bispecific-antibodies.
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Figure 44. Perforin-resistant genes are expressed in healthy monocytes and
AML. A-C. RNA-seq gene expression of CTSB (A), SERPINB9 (B), and CD107a
(C) across healthy components of hematopoiesis (green) as well as AML (red),
ordered by increasing differentiation. D. Flow cytometry analysis of cell surface
CD107a expression in WT and CD200ko Kasumi cells compared to artificially
activated CD3+ T cells.
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Determine the role of CD200 and anti-CD200 therapy in humanized mouse models
without GvHD.
To study the interactions between human AML and components of the
human immune system in a physiological setting, we chose to use a PBMChumanized mouse model. It has been previously shown that transplantation of
healthy, human mononuclear cells into NSG mice results in the almost exclusive
(>93% of hCD45+ cells) expansion of polyclonal T cells187. These human-educated
T cells homed to various organs where they become activated and mediated
GvHD. Translationally, this model mimics the scenario seen in AML patient
samples after allogeneic stem cell transplant. In this setting, our data showed that
CD200 played a critical role in protecting AML cells from immune-mediated
clearance in the presence of aggressive GvHD and that effective antibody therapy
against CD200+ AML required human T cells.
To understand the interaction between the immune system and CD200+
leukemia cells without the GvHD component, we need to employ a different form
of humanized mice. The Hans-Peter lab has developed a system in which human
CD34+ hematopoietic stem and progenitor cells are transplanted into the livers of
irradiated neonatal NSG mice, essentially replacing the murine hematopoietic
system for human121. With this approach, human T cells, B cells and monocytes
are differentiated and educated within the mice and persist without attacking the
host for more than 8 months. In a preliminary experiment in this in vivo system, we
confirmed that both CD200+ and CD200- OCI-AML3 cells were capable of
engrafting and expanding in the presence of a murine-raised human immune
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system. To see if the pattern of cytokine inhibition was similar to that in the PBMChumanized model, we performed flow cytometry analysis on the serum of a
representative mouse from each group, using a CD34-humanized mouse without
leukemia as a control. In contrast to the PBMC-humanized model where we saw
global inhibition of cytokine production, the CD34-humanized mice demonstrated
a distinct immune response to either CD200+ or CD200- leukemia (Figure 45).
While critical inflammatory cytokines including IL-4, IL-6, IL-17a, and TNFα were
suppressed in the presence of CD200+ leukemia, there appeared to be an
enrichment of cytotoxic enzymes like perforin, granzyme A, and soluble Fas. This
suggests that murine-raised T cells are capable of activation in response to human
AML cells but that CD200 still suppresses cytokine secretion.
To complete this investigation, we plan to expand this study and engraft
CD34-humanized mice with either CD200+ or CD200- OCI-AML3 cells (20 mice
per group with 10 control mice). After engraftment is confirmed by bioluminescence
imaging, we will treat a subset of each leukemia group (10 mice each) with the
CD200-IgG1 similar to the design presented in Chapter IV. At the end of the
antibody administration, 3 mice per cohort will be sacrificed to characterize the
immune cell composition by both CyTOF and single-cell RNA-seq. For the
remaining mice, circulating lymphocytes and serum cytokine concentrations will be
monitored weekly by flow cytometry and overall disease burden will be assessed
by bioluminescence. We anticipate that CD200 will provide an immune advantage
for the leukemia cells and anti-CD200 antibody therapy will similarly result in
disease clearance and prolonged overall survival.
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Figure 45. Secreted cytokines in CD34-humanized mice. A. Bioluminescence
imaging of CD34-humanized mice with OCI-AML3 leukemia at the time of blood
collection. B. Summary flow cytometry data of secreted cytokines in the plasma
of each mouse in panel A.
178

Assess the role of CD200 in reprogramming immune cell metabolism.
One of the most surprising findings of this study was the universal
suppression of lymphocyte metabolism in humanized mice exposed to pCD200
OCI-AML3 leukemia when compared to those exposed to pGFP cells. Despite
similar abundance and composition of T cells, human cells harvested from mice
exposed to the CD200+ leukemia showed evidence of inhibited oxidative
phosphorylation (OXPHOS), glycolysis, glucogenesis, pyrimidine metabolism, and
fatty acid metabolism (Chapter III). The ability of T cells to proliferate and perform
appropriate effector functions is dependent on a significant increase of
bioenergetic production. In order to meet these vast energy demands, activated T
cells undergo metabolomic reprogramming from OXPHOS and fatty acid oxidation,
sufficient for naïve cell maintenance, to glycolysis and glucogenesis188. However,
our data suggests that both naïve and activated lymphocytes in mice with CD200+
leukemia are metabolically impaired. Insufficient T cell metabolism could explain
the diminished cytokine production in these mice. The alterations in
immunometabolism could be explained by either (1) a direct mechanism through
CD200/CD200R signaling or (2) unique differences in the tumor microenvironment
created by CD200+ leukemia.
To address the first regulatory mechanism, I would propose the following
experiments. T cells will be treated with either excess blocking CD200 antibody or
a control IgG prior to exposure to either CD200+ of CD200- OCI-AML3 cell lines.
After 24 hours, T cells will be reselected and tested for metabolic fitness using
Seahorse technology. If the primary regulator of T cell metabolism is through
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CD200R signaling, we will see impaired T cell function only in those exposed to
CD200+ leukemia without blocking antibody. If the effect is due to leukemic
contribution to the microenvironment, we will see impaired metabolism in T cells
exposed to CD200+ leukemia with or without blocking antibody therapy.
Tumors can also have significant effects on lymphocyte function even
without direct interaction through nutrient deprivation, waste accumulation, pH
alterations, and oxygen availability189. To determine if CD200+ cells differentially
alter the microenvironment, metabolomics profiling should be performed on the
supernatant from the AML:T cell co-culture experiments as well as serum obtained
from the humanized mice. Similarly, pH and oxygen concentrations of these
samples should also be evaluated. Taken together, this data could provide
evidence that CD200 plays a novel in modifying the metabolic microenvironment.
Furthermore, the discussion above focuses primarily on the metabolic
reprogramming of T cells, as those were the most abundant cell population
evaluated by RNA-seq. However, all effector cells are regulated by the systemic
metabolic changes induced by leukemia. For instance, macrophage differentiation,
polarization, and activation can be directly influenced by nutrient availability190.
Similarly, NK cells rely significantly on glycolysis and OXPHOS for cytokine
production and cell-mediated cytotoxicity191. Thus, I would propose similar coculture experiments of CD200+ and CD200- leukemia with isolated NK cells and
macrophages to specifically investigate metabolic capacity by both Seahorse and
RNA-seq.
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Compare and contrast the roles of CD200 and CD47 in AML.
CD200 and CD47 have been both reported as negative regulators of
macrophage function through the binding of their respective receptors, CD200R
and SIRPα, that share structural similarities192,193. The unique patterns of
ligand/receptor distribution are also similar for CD200/CD200R and CD47/SIRPα,
with broad expression of the ligand and receptor expression restricted to myeloid
and a subset of lymphoid cells132. However, using publicly available gene
expression datasets, we found that the pattern of CD200 and CD47 differs within
the hematopoietic compartment (Figure 46A). More specifically, CD200 is
expressed at appreciable levels only in undifferentiated stem/progenitor cells and
B cells, while CD47 is ubiquitously expressed across all hematopoietic cell
subsets, including mature myeloid cells like macrophages.
In AML, only CD47 has been investigated as a therapeutic target for
leukemia stem cells. The lab of Irving Weissman was the first to demonstrate that
hematopoietic stem and progenitor cells from CD47-null mice were incapable of
engrafting in wild type recipient mice as a result of increased phagocytosis of these
cells194. Interestingly, and consistent with the original study identifying CD47 as a
regulator of phagocytosis, this phenomenon appeared to occur only when CD47null target cells interacted with CD47-expressing phagocytes195. Furthermore, they
showed that monoclonal antibodies against CD47 could preferentially lead to
targeted phagocytosis of AML cells and impaired engraftment113. These
discoveries have since been translated to the development of the clinical antiCD47 antibody, Hu5F9-G4, that is now in a variety of clinical trials for leukemias,
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lymphomas, and other solid tumors196. While generally well-tolerated, many
patients experienced transient anemia as a result of the elimination of CD47+
erythrocytes197. The ubiquitous expression of CD47 also mandated that antibody
therapy be administered at higher doses for a longer duration than other antibody
strategies.
Taken together, we hypothesize that anti-CD200 is a more rational
therapeutic strategy for specifically targeting AML LSCs. In Chapter III, we
confirmed that CD200 expression does not alter CD47 levels. We performed
preliminary experiments to compare the efficacy of our CD200-IgG1 antibody
against the clinically available Hu5F9-G4 (5F9). In the Kasumi cells, that
expressed low levels of CD200 in the wild type setting, we found the same
frequency of phagocytosis of CD200+ cells after treatment with either antibody
(Figure 46B). This result was surprising as Kasumi cells express much higher
levels of CD47 when compared to CD200. However, in the OCI-AML3 line, with
substantial over-expression of CD200, we found significant phagocytosis only of
CD200+ cells treated with the CD200-IgG1 antibody (Figure 46C). The variability
in response to either antibody suggests that there are other intrinsic factors that
contribute to phagocytosis of AML that are differentially regulated between
CD200+ and CD200- cells as well as between different AML subtypes. Elucidating
these unknown factors and understanding potential interactions between CD200IgG1 and 5F9 therapy remain to be understood.
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Figure 46. Comparison of CD200 and CD47 expression and antibody
therapies. A. RNA-seq gene expression of either CD47 (green) or CD200 (red)
across healthy components of hematopoiesis ordered by increasing differentiation
from Corces et al88. CD200+ and CD200- Kasumi (B) or OCI-AML3 (C) cells were
co-cultured with monocyte-derived human macrophages and treated with 10
μg/mL or either CD200-IgG1 or 5F9. Phagocytosis was assessed by flow
cytometry after 4 hours.
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Assess the contribution of complement to CD200+ AML protection and CD200IgG1 therapy.
While Chapter IV investigated the role of CD200-IgG1 in NK cell-mediated
ADCC and macrophage-mediated ADCP, complete characterization of this
antibody requires the evaluation of complement dependent cytotoxicity (CDC). The
complement system is comprised of over 30 proteins that function as one of the
primary mechanisms of antibody-mediated immunity198. The classical complement
pathway is activated when C1q proteins recognize and bind the constant region of
IgG1, IgG3, or IgM antibodies resulting in the formation of membrane attack
complexes and ultimate cell lysis199. To assess CDC in vitro, we will treat CD200+
and CD200- AML cells with either the CD200-IgG1, samalizumab, or control
antibodies in the presence or absence of human serum. Cell membrane integrity
will be assessed by propidium iodide uptake200. We expect that only the CD200IgG1 antibody will result in specific CD200+ AML cell lysis, as the constant region
of samalizumab will not be recognized by complement. In vivo validation of CDC
will be more challenging as the majority of immunocompromised mice, including
the NSG utilized in this body of work, do not produce functional complement
proteins201.
Unrelated to antibody function, we were surprised to find that the
complement component 3 gene, C3, was one of the most significantly
downregulated genes in pCD200 OCI-AML3 cells when compared to pGFP OCIAML3 by genome-wide RNA-seq (Figure 47A). While this pattern was consistent
in Kasumi, neither CD200+ nor CD200- cells expressed high levels of the C3
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transcript. C3 is a critical member of both the classical and alternative complement
activation pathways. We attempted to confirm this finding in OCI-AML3 at the
protein level by measuring one of the prominent cleavage products, C3b, using
cell surface flow cytometry (Figure 47B). In media with heat-inactivated serum,
there was negligible detection of surface C3b protein in either cell line model.
However, when cultured in media with activated human serum, pGFP OCI-AML3
cells bound significantly more surface C3b than pCD200 cells. C3b is a potent
opsonizing agent that contributes to enhanced phagocytosis of flagged
antigens202. Again, using the Corces et al RNA-seq dataset, we observed that C3
transcript is expressed exclusively in healthy monocytes and leukemia blast cells
(Figure 47C)88. The almost complete lack of C3 expression in LSCs when
compared to blasts is consistent with the pattern seen in OCI-AML3 cells where
the introduction of the stem cell marker, CD200, results in downregulation of C3.
The mechanisms by which CD200 regulates C3 transcription as well as the
interaction between CD200 and C3b protein at the cell surface both require further
investigation.

185

Figure 47. Complement C3 is altered in CD200+ AML. A. C3 RPKM levels in
CD200+ (red) and CD200- (green) in Kasumi and OCI-AML3 cells. B. Cell surface
C3b protein expression in pCD200 (red) and pGFP (green) OCI-AML3 cells
cultured with inactive (baseline) and active (+serum) human serum. C. RNA-seq
C3 gene expression in healthy (green) and leukemia (red) cell populations.
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Investigate alternative CD200 antibody therapeutics strategies.
Bi-specific antibodies. While the CD200-IgG1 initiated potent and specific
antibody-mediated cytotoxicity of CD200 positive leukemia cells, there are
emerging avenues that allow for the strategic improvement of antibody-alone
therapy. One such strategy involves fusing the binding regions of two antibodies
to one common IgG backbone, thus allowing for the simultaneous targeting of two
epitopes with a single antibody. This can be used to target multiple AML LSC
markers at once; for example, dual targeting of CD200 along with another known
leukemia specific marker like CLEC12A203. However, bi-specific antibodies are
more commonly employed to bridge together AML cells and effector T or NK cells.
AMG330 is an example of a bi-specific T cell engager (BiTE) antibody against AML
that functions by simultaneously binding the CD3 epitope on T cells and CD33 on
AML and encouraging a cytotoxic synapse204. There are two immediate
shortcomings of the engager antibody approach. First, for this therapy to effective
as a single agent, it requires that all leukemia cells express the same target
epitope. While this may be applicable in lymphoid malignancies, like B cell
leukemia where all cells express CD19, we now appreciate that such strategies
are not feasible in AML due to the vast heterogeneity of disease. Second, this
therapeutic strategy relies on the assumption that the engaged effector cell alone
is capable of killing leukemia cells. The data presented in this dissertation suggests
that not all AML cells are sensitive to T cell mediated cytotoxicity.
Toxin-conjugated antibodies. The epitope-specificity of antibodies can also
be harnessed for targeted drug delivery. By conjugating a drug to a known

187

antibody, we can better guarantee that the drug makes it to the cell of interest while
limiting off-target effects. Gemtuzumab ozogamicin is a calicheamicin-conjugated
CD33 antibody that aims to specifically deliver the chemotherapeutic payload to
CD33+ cells that is FDA approved for the treatment of AML205. While this approach
is also limited by the ability to deliver to only a single epitope, it does allow for a
higher dose of delivery than could be achieved by administering the chemotherapy
systemically. In the context of the data presented here, I would propose
conjugating a known AML LSC-specific therapeutic agent, like the BCL-2 mimetic,
venetoclax, to the CD200-IgG1 antibody. We have preliminary data suggesting
that CD200+ leukemia cells are more sensitive venetoclax than CD200- cells from
the same patient. This therapeutic could be administered after induction
chemotherapy to specifically eliminate residual AML LSCs and reduce likelihood
of relapse.

Investigate novel uses for CD200-antibody therapy.
This body of work demonstrates the rationale and utility of therapeutically
targeting CD200 in the context of AML. However, the inhibitory mechanisms and
CD200 antibody efficacy described here could likely be extrapolated to any tumor
type with overexpression of CD200 including melanoma, glioblastoma, colon,
prostate, and breast cancers55,206-208. However, we also posit that CD200 therapy
could be utilized outside the context of cancer alone.
CD200 antibody as checkpoint therapy in activated T cells. While PD-1 and
CTLA-4 are the most well-understood checkpoints of immune activation, control of
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adaptive T cell response complex and involves many emerging players209. It was
previously reported that CD200 and CD200R were both upregulated on T cells in
response to stimulation by mesenchymal stromal cells in vitro but were not
involved in T cell proliferation210. Furthermore, Zappasodi et al identified a
population of CD4+FOXP3-PD1hi cells that transcriptionally resembled follicular
helper T cells and significantly impaired T cell effector functions211. This novel
immune cell subset exclusively upregulated CD200 in both human and mice.
These data point to CD200 as a novel immune checkpoint with uncharacterized
function.
Using western blot and flow cytometry, we independently confirmed that
CD200 expression is upregulated in T cells, particularly those of CD4 lineage, upon
CD3/CD28 stimulation (Figure 48A-B). To determine the functional effect of CD200
upregulation on activated T cells, we treated both resting and stimulated cells with
either a blocking CD200 antibody or nanobody and measured secreted cytokine
abundance (Figure 48C). As expected, T cells exposed to CD3/CD28 activating
beads almost universally upregulated inflammatory cytokines and cytotoxic
enzymes. Activated T cells treated with either the antibody or nanobody approach,
when compared to the PBS control, resulted in enhanced cytotoxic potential. The
similar results seen between antibody and nanobody treated cells indicate that
response is most likely through blocking the CD200/CD200R interaction. Further,
the functional recovery of activated T cells indicates that CD200 is induced as a
mechanism of controlling T cell response through autocrine or paracrine signaling.
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Further studies to better characterize CD200 as a novel T cell checkpoint should
be pursued.
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Figure 48. CD200 regulates T cell activity. CD200 expression in T cells artificially
activated using CD3/CD38 beads for 24 hours by western blot (A) and flow
cytometry (B). C. Cytokine production from unstimulated and CD3/CD28
stimulated T cells treated with either anti-CD200 blocking antibody or nanobody.
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CD200 therapy to neutralize viral orthologues. The evolution of viruses also
provides insight into the function and importance of CD200. Natural selection
results in viruses that are capable of avoiding detection and destruction by the host
immune system. Viruses evade the antiviral response by mimicking important host
immunosuppressive strategies. Full genomic sequencing of viruses has identified
multiple, homologous immunomodulatory genes. Viral homologs of CD200,
termed viral OX-2 (vOX-2), have now been identified in a subset of double-strand
DNA viruses including poxviruses, herpesviruses, and adenoviruses212-214. The
broad acquisition of a version of CD200 across virus families points to a strong
selective advantage provided by the protein. However, that a viral homolog of
CD200 is not found in every virus type suggests that it is likely not essential doe
viral entry or replication215. Functional studies of these homologs support the
hypothesis that viruses utilize the CD200-like genes to obtain an immune
advantage by suppressing both innate and adaptive cells through interaction with
the CD200 receptor.
The viral homolog of CD200 in myxoma viruses, M141R, is essential for
lethal infection in vivo but is dispensable for viral replication in vitro215. Further,
M141R was capable of down-regulating both macrophage and T cell activity and
suppressed IFNγ production in a rabbit model of disease. The Kaposi’s sarcomaassociated herpesvirus (KSHC) homolog, K14, shares 40% protein identity with
CD200 and binds the CD200R with high affinity213. K14 has also been shown to
directly interact with and inhibit effector functions of neutrophils, basophils,
macrophages, and antigen specific T cells213,216-218. In summary, this data
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suggests in the case of certain DNA viruses, CD200-like proteins may be
overexpressed on the surface of infected cells undergoing viral replication. This
may represent a therapeutic window whereby viral burden could be reduced by
eliminating these cells with antibody therapy targeting the CD200 homolog. Such
an antibody strategy could also eliminate the immune advantage provided these
cells by blocking CD200R interactions.
While a viral homolog of CD200 has not yet been described in severe acute
respiratory

syndrome

coronavirus,

SARS-CoV

or

SARS-CoV2,

the

CD200/CD200R axis still plays a critical role in this RNA virus setting. CD200R
has been shown to control the TLR7 response to single stranded RNA detection.
In a mouse model of hepatitis coronavirus (MHV), the existing in vivo model for
SARS-CoV, elimination of CD200R signaling resulted in a significant decrease in
viral load and had a positive effect on MHV clearance219,220. The mechanism of
viral reduction was through an unabated type I interferon response. It was further
shown that infection of a mouse-adapted strain of SARS-CoV (MA15) required the
presence of alveolar macrophages that expressed high levels of CD200R, even
though direct interaction between MA15 and the innate cell was not observed221.
Thus, CD200 antibody therapy presents a possible treatment strategy for SARSCoV2 infection by inhibiting the repressive CD200R signaling in effector cells and
promoting robust interferon production.
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5.3 Significance and Impact
Understanding the unique immune properties of hematopoietic and
leukemic stem cells is critical to developing targeted immunotherapeutic strategies
to eradicate LSCs and cure AML. In this body of work, we bridged the research
between stem cell biology and immunology to propose CD200 as an AML LSCspecific mechanism of evading detection and destruction by the neighboring
immune system. CD200+ cells uniquely demonstrate functional stem cell
properties while also directly interacting with and suppressing members of both the
innate and adaptive immune systems.
This dissertation also highlights the power of leveraging publicly available
datasets for hypothesis generation. Our initial identification of CD200 was based
on a substantial amount of data generated by labs across the world that we alone
would never have been able to produce. By agreeing to share genome-wide data,
we allow for fruit of our labors to become the seeds of scientific discovery for
others.
Finally, clinically feasible therapies for targeting AML LSCs are urgently
needed. We present here a novel CD200 antibody that could be rapidly translated
to the clinic. Our data demonstrate potent anti-leukemic activity of CD200 antibody
therapy mediated by both blocking the repressive CD200R signaling as well as
engaging effector NK cells and macrophages. Our humanized model systems
suggest that successful CD200 antibody requires the interplay between both the
innate and adaptive immune cells.
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While this body of work is focused on the role of CD200 on AML stem cells,
the implications of stem cell-specific immunobiology are extensive. It is my hope
that the studies presented in this dissertation help lay the groundwork for novel
immunotherapies specifically designed eliminate the most evasive cancer stem
cells and to, ultimately, help alleviate the heavy burden of cancer.
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Appendix A
LSC mRNA expression analysis
1 Executive Summary
1.1 Introduction
Novel immunotherapeutic targets for AML LSCs are critical. To identify such
potential candidates, we mined 3 large, publicly available datasets which contained
whole genome expression data for paired leukemia stem cells and blasts from the
same patient, as well as healthy hematopoietic controls.
1.2 Datasets
1)

Corces et al: GSE74246 This dataset contains pre-aligned RNA-seq data for
healthy hematopoietic cell subsets from 5 healthy individuals and paired
leukemia stem cells and blasts from 10 AML patient samples.

2)

Jung et al: GSE63270 This dataset contained Affymetrix HG U133Plus 2.0
array data for healthy hematopoietic cell subsets from 7 healthy bone marrow
biopsies and paired leukemia stem/progenitor cells and blasts from 21 AML
patient samples

3)

de Jonges et al: GSE30029 This dataset contains Illumina BeadChip Arrays
(HT12 v3) array data for the CD34+ and CD34- subfractions of 46 AML patient
samples and 31 normal CD34+ samples.

1.3 Analysis
For each dataset, we performed 2 ANOVA tests to;

196

1)

identify of genes significantly overexpressed in LSC compared to the patient’s
paired blast cells (using ANOVA to account for inter-patient variability) and

2)

identify of genes significantly overexpressed in LSCs when compared to unmatched healthy HSCs

We scored each gene as the product of the fold change and –log10 p-value. Genes
with scores that exceeded the threshold defined below were deemed significant.

!ℎ#$%ℎ&'( = *$(+,-(.$-$%/&#$) + 10 ∗

456(.$-$%/&#$)
1.35

1.4 Discussion
Using this approach, we identified 43 genes in the intersection of all 3 datasets.
2 Setup
#load all necessary libraries
library(Biobase)
library(GEOquery)
library(biomaRt)
library(RColorBrewer)
library(ggplot2)
library(reshape2)
#specifically for Jung analysis
library(oligo)
library(hgu133plus2hsentrezg.db)

3 Corces et al analysis
For this analysis, we can download the preprocessed RNA-seq count data from
the supplementary files through NCBI GEO. Sample annotation can be extracted
from the column names.
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## load RNA-seq data
filePaths = getGEOSuppFiles("GSE74246")
dat <- read.delim("GSE74246_RNAseq_All_Counts.txt", header = TRUE, s
tringsAsFactors = FALSE)
genes <- dat[,1]
rownames(dat) <- dat$X_TranscriptID
dat <- data.matrix(dat[,-1])
## format variable
id <- sapply(colnames(dat), function(x) strsplit(x, "\\.")[[1]][1])
cell_type <- sapply(colnames(dat), function(x) strsplit(x, "\\.")[[1
]][2])
cell_type[which(cell_type=="Blast")] <- "Blasts"
tmp_type <- cell_type
tmp_type[which(tmp_type=="rHSC")] <- "HSC"
keep_these <- which(!(tmp_type %in% c("CD4Tcell", "CD8Tcell", "NKcel
l", "Bcell", "Ery", "CLP")))
## scripts for plotting CD200 in the Corces dataset
lvls <-c("HSC","LMPP","MPP","GMP","CMP","MEP","Mono","LSC","Blasts")
df <- data.frame(mRNA=log2(dat["CD200R1",keep_these]+1),cellType=fac
tor(tmp_type[keep_these],levels=lvls))
status <- rep("normal",length=nrow(df))
status[which(df$cellType %in% c("LSC","Blasts"))] <- "AML"
df <- data.frame(df,status)
p <- ggplot(df, aes(x=cellType, y=mRNA, fill=status)) + geom_boxplot
(outlier.shape = NA) +
geom_jitter(shape=16, size=2,position=position_jitter(0.2)) + scal
e_fill_manual(values=c("#cc0000", "#999999")) +
theme(text = element_text(size=20), legend.position="none",axis.ti
tle.x=element_blank()) + theme_classic()
p

3.1 Corces et al; LSC vs Blasts
## subset cell types of interest
ind <- which(cell_type %in% c("LSC", "Blasts"))
sub_id <- id[ind]
sub_cell_type <- cell_type[ind]
sub_dat <- dat[,ind]
paired_samples <- names(table(sub_id)[which(table(sub_id)==2)])
ind <- which(sub_id %in% paired_samples)
sub_id <- sub_id[ind]
sub_cell_type <- sub_cell_type[ind]
sub_dat <- sub_dat[,ind]
aovDat <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(sub_id)
+factor(sub_cell_type)))[[1]][,5]))
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aovDat <- aovDat[,-3] #subtract empty column
colnames(aovDat) <- c("patient","lsc")
diffs <- t(apply(sub_dat,1, function(tt){
df <- data.frame(exp=tt,LSC=sub_cell_type)
mean(sapply(split(df,factor(sub_id)), function(t) diff(sapply(spli
t(t[,"exp"],t[,"LSC"]),mean))))
}))
diffs <- as.numeric(diffs)
names(diffs) <- rownames(sub_dat)
gene_score <- -log10(aovDat[,2]) * diffs
sub_gene_score <- gene_score[!is.na(gene_score)]
plot(1:length(sub_gene_score), rev(sub_gene_score[order(sub_gene_sco
re)]), ylim=c(-50000,50000))
threshold <- median(sub_gene_score) + 10*IQR(sub_gene_score)/1.35
blast_genes <- names(sub_gene_score[which(sub_gene_score>threshold)]
)

3.2 Corces et al; LSC vs HSC
## subset cell types of interest
tmp_type[which(tmp_type=="rHSC")] <- "HSC"
ind <- which(tmp_type %in% c("LSC", "HSC"))
sub_id <- id[ind]
sub_cell_type <- tmp_type[ind]
sub_dat <- dat[,ind]
aovDat_lscVhsc <- t(apply(sub_dat,1,function(x) summary(aov(x~factor
(sub_cell_type)))[[1]][,5]))
aovDat_lscVhsc <- aovDat_lscVhsc[,-2] #subtract empty column
colnames(aovDat_lscVhsc) <- c("lsc")
diffs <- as.numeric(apply(sub_dat,1, function(tt){
mean(tt[which(sub_cell_type=="LSC")]) - mean(tt[which(sub_cell_typ
e=="HSC")])
}))
names(diffs) <- rownames(sub_dat)
hsc_score <- -log10(aovDat_lscVhsc) * diffs
sub_hsc_score <- hsc_score[!is.na(hsc_score)]
plot(1:length(sub_hsc_score), rev(sub_hsc_score[order(sub_hsc_score)
]), ylim=c(-50000,50000))
threshold <- median(sub_hsc_score) + 10*IQR(sub_hsc_score)/1.35
hsc_genes <- names(sub_hsc_score[which(sub_hsc_score>threshold)])
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corces_genes <- intersect(hsc_genes, blast_genes)
save(aovDat, aovDat_lscVhsc, corces_genes, file="corces_data.RData")

4 de Jonges et al analysis
For this analysis, we download the preprocessed expression array data and
sample annotation available directly from GEO.
# load series and platform data from GEO
gset <- getGEO("GSE30029", GSEMatrix =TRUE, getGPL=FALSE)
gset <- gset[[1]]
# extract expression data and annotation
dat <- exprs(gset)
annot <- phenoData(gset)
annot <- annot@data
## deal with garbage annotation
sample_annot <- data.frame(matrix(ncol = 3, nrow = nrow(annot)))
colnames(sample_annot) <- c("year", "ID","cell_type")
for(i1 in 1:nrow(annot)){
split <- strsplit(as.character(annot$description[i1]), " ")[[1]]
if (length(split) == 3){
sample_annot[i1,] <- split
}else{
sample_annot[i1,] <- c( "NA", split[1:2])
}
}
sample_annot <- data.frame(status, sample_annot)
# construct probe annotation for illumina_humanht_12_v3
ensembl = useMart("ENSEMBL_MART_ENSEMBL",dataset="hsapiens_gene_ense
mbl", host='www.ensembl.org')
probe_annot <- biomaRt::getBM(
attributes = c("illumina_humanht_12_v3", "external_gene_name"),
mart = ensembl)
probe_annot <- dplyr::rename(probe_annot, probe_id = illumina_humanh
t_12_v3, ext_gene = external_gene_name)
probe_annot <- dplyr::select(probe_annot, c('probe_id', 'ext_gene'))
ilmn_annot <- probe_annot[which(probe_annot!=""),]
ilmn_annot <- ilmn_annot[!is.na(ilmn_annot$probe_id),]
# for now we will remove promiscuous probes
ilmn_annot <- ilmn_annot[isUnique(ilmn_annot$probe_id),]
rownames(ilmn_annot) <- ilmn_annot$probe_id
## scripts for plotting CD200 in the deJonges dataset
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pid <- ilmn_annot[which(ilmn_annot$ext_gene == "CD200"),]
lvls <-c("normal_CD34+","AML_CD34+","AML_CD34-")
df <- data.frame(mRNA=dat[pid[2,"probe_id"],],cellType=factor(status
_cell,levels=lvls),status)
p <- ggplot(df, aes(x=cellType, y=mRNA, fill=status)) + geom_boxplot
(outlier.shape = NA) +
geom_jitter(shape=16, size=2,position=position_jitter(0.2)) + scal
e_fill_manual(values=c("#cc0000", "#999999")) + theme(text = element
_text(size=20), legend.position="none",axis.title.x=element_blank())
+ theme_classic()
p

4.1 de Jonges et al; LSC vs Blasts
## subset cell types of interest
sub_dat <- dat[rownames(dat) %in% ilmn_annot$probe_id,]
ind <- which(sample_annot$status == "AML")
sub_annot <- sample_annot[ind,]
sub_dat <- sub_dat[,ind]
paired_samples <- names(table(sub_annot$ID)[which(table(sub_annot$ID
)==2)])
ind <- which(sub_annot$ID %in% paired_samples)
sub_annot <- sub_annot[ind,]
sub_dat <- sub_dat[,ind]
dj_blast_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(s
ub_annot$ID)+factor(sub_annot$cell_type)))[[1]][,5]))
dj_blast_aov <- dj_blast_aov[,-3] #subtract empty column
colnames(dj_blast_aov) <- c("patient","lsc")
bdj_blast_diffs <- t(apply(sub_dat,1, function(tt){
df <- data.frame(exp=tt,LSC=sub_annot$cell_type)
mean(sapply(split(df,factor(sub_annot$ID)), function(t) diff(sappl
y(split(t[,"exp"],t[,"LSC"]),mean))))
}))
bdj_blast_diffs <- as.numeric(bdj_blast_diffs)
names(bdj_blast_diffs) <- rownames(sub_dat)
dj_blast_score <- -log10(dj_blast_aov[,"lsc"]) * bdj_blast_diffs
dj_blast_score <- dj_blast_score[!is.na(dj_blast_score)]
plot(1:length(dj_blast_score), rev(dj_blast_score[order(dj_blast_sco
re)]))
threshold <- median(dj_blast_score) + 10*IQR(dj_blast_score)/1.35
dj_blast_genes <- names(dj_blast_score[which(dj_blast_score>threshol

201

d)])
dj_blast_genes <- ilmn_annot[dj_blast_genes,"ext_gene"]

4.2 de Jonges et al; LSC vs HSC
## subset cell types of interest
sub_dat <- dat[rownames(dat) %in% ilmn_annot$probe_id,]
ind <- which(sample_annot$cell_type == "CD34+")
sub_annot <- sample_annot[ind,]
sub_dat <- sub_dat[,ind]
dj_hsc_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(sub
_annot$status)))[[1]][,5]))
dj_hsc_aov <- dj_hsc_aov[,-2] #subtract empty column
dj_hsc_diffs <- as.numeric(apply(sub_dat,1, function(tt){
mean(tt[which(sub_annot$status=="AML")]) - mean(tt[which(sub_annot
$status=="normal")])
}))
names(dj_hsc_diffs) <- rownames(sub_dat)
dj_hsc_score <- -log10(dj_hsc_aov) * dj_hsc_diffs
dj_hsc_score <- dj_hsc_score[!is.na(dj_hsc_score)]
plot(1:length(dj_hsc_score), rev(dj_hsc_score[order(dj_hsc_score)]),
ylim=c(-50000,50000))
threshold <- median(dj_hsc_score) + 10*IQR(dj_hsc_score)/1.35
dj_hsc_genes <- names(dj_hsc_score[which(dj_hsc_score>threshold)])
dj_hsc_genes <- ilmn_annot[dj_hsc_genes,"ext_gene"]
dj_genes <- intersect(dj_hsc_genes, dj_blast_genes)
save(dj_blast_aov, bdj_blast_diffs, dj_hsc_aov, dj_hsc_diffs, dj_gen
es, file="dj_data.RData")

5 Jung et al analysis
For this analysis, we cannot use the preprocessed data available through NCBI
GEO because it uses the wrong Affymetrix CDF. Instead, we will download the
original .cel files and perform RMA to generate the expression dataset. The original
.cel file names contain descriptions adequate to extract sample annotation.
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filePaths = getGEOSuppFiles("GSE63270")
cel_files <- list.files(pattern=".CEL" ,full.names=TRUE)
cel_sample_list <- list.files(pattern=".CEL")
cel_samples <- substr(cel_sample_list,1,10)
cel_batch <- read.celfiles(cel_files[1])
dat <- rma(cel_batch)
dat <- exprs(dat)
colnames(dat) <- substr(colnames(dat),1,10)
save(dat,file="jungRMAData.RData")
load(file="jungRMAData.RData")
# grab sample id, disease state, and cell type
sample_ID <- sapply(colnames(dat),function(x) strsplit(x,"_")[[1]][2
])
cell_type <- sapply(colnames(dat),function(x) strsplit(x,"_")[[1]][3
])
cell_type <- sapply(cell_type,function(x) strsplit(x,"\\.")[[1]][1])
cell_type[which(cell_type=="L")] <- "LMPP"
disease_stat <- rep("control",length(sample_ID))
disease_stat[which(substr(sample_ID,1,2)=="SU")] <- "AML"
table(cell_type,disease_stat)
table(sample_ID,cell_type)
# construct probe annotation for Affymetrix Human Genome U133 Plus 2
.0
ensembl = useMart("ENSEMBL_MART_ENSEMBL",dataset="hsapiens_gene_ense
mbl", host='www.ensembl.org')
probe_annot <- biomaRt::getBM(
attributes = c("affy_hg_u133_plus_2", "external_gene_name","descri
ption"),
mart = ensembl)
probe_annot <- dplyr::rename(probe_annot, probe_id = affy_hg_u133_pl
us_2, ext_gene = external_gene_name)
probe_annot <- dplyr::select(probe_annot, c('probe_id', 'ext_gene'))
affy_annot <- probe_annot[which(probe_annot!=""),]
affy_annot <- affy_annot[!is.na(affy_annot$probe_id),]
# for now we will remove promiscuous probes
affy_annot <- affy_annot[isUnique(affy_annot$probe_id),]
rownames(affy_annot) <- affy_annot$probe_id
# scripts for plotting CD200 in the Jung dataset
pid <- affy_annot[which(affy_annot$ext_gene == "CD200"),]
lvls <-c("HSC","LMPP","MPP","GMP","CMP","MEP","LSC","LPC","Blast")
df <- data.frame(CD200_mRNA=dat[pid$probe_id[1],],cell_type=factor(c
ell_type,levels=lvls))
status <- rep("normal",length=nrow(df))
status[which(df$cell_type %in% c("LSC","LPC","Blast"))] <- "AML"
df <- data.frame(df,status)
p <- ggplot(df, aes(x=cell_type, y=CD200_mRNA, fill=status)) + geom_
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boxplot(outlier.shape = NA) +
geom_jitter(shape=16, size=2,position=position_jitter(0.2)) + scal
e_fill_manual(values=c("#cc0000", "#999999")) +
theme(text = element_text(size=20), legend.position="none",axis.ti
tle.x=element_blank()) + theme_classic()
p

5.1 Jung et al; LSC vs Blasts
## subset cell types of interest
ind <- which(cell_type %in% c("LSC","Blast"))
sub_cell_type <- cell_type[ind]
sub_id <- sample_ID[ind]
sub_dat <- dat[,ind]
paired_samples <- names(table(sub_id)[which(table(sub_id)==2)])
ind <- which(sub_id %in% paired_samples)
sub_cell_type <- sub_cell_type[ind]
sub_id <- sub_id[ind]
sub_dat <- sub_dat[,ind]
jung_blast_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor
(sub_id)+factor(sub_cell_type)))[[1]][,5]))
jung_blast_aov <- jung_blast_aov[,-3] #subtract empty column
colnames(jung_blast_aov) <- c("patient","lsc")
jung_blast_diffs <- t(apply(sub_dat,1, function(tt){
df <- data.frame(exp=tt,LSC=sub_cell_type)
mean(sapply(split(df,factor(sub_id)), function(t) diff(sapply(spli
t(t[,"exp"],t[,"LSC"]),mean))))
}))
jung_blast_diffs <- as.numeric(jung_blast_diffs)
names(jung_blast_diffs) <- rownames(sub_dat)
jung_blast_score <- -log10(jung_blast_aov[,"lsc"]) * jung_blast_diff
s
jung_blast_score <- jung_blast_score[ !is.na(jung_blast_score)]
plot(1:length(jung_blast_score), rev(jung_blast_score[order(jung_bla
st_score)]))
threshold <- median(jung_blast_score) + 10*IQR(jung_blast_score)/1.3
5
jung_blast_genes <- names(jung_blast_score[which(jung_blast_score>th
reshold)])
jung_blast_genes <- affy_annot[jung_blast_genes,"ext_gene"]
jung_blast_genes <- jung_blast_genes[!is.na(jung_blast_genes)]
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5.2 Jung et al; LSC vs HSC
## subset cell types of interest
tmp_type <- cell_type
tmp_type[which(tmp_type %in% c("LMPP","MPP"))] <- "HSC"
tmp_type[which(tmp_type %in% c("LPC"))] <- "LSC"
ind <- which(tmp_type %in% c("LSC","HSC"))
sub_cell_type <- tmp_type[ind]
sub_id <- sample_ID[ind]
sub_dat <- dat[,ind]
jung_hsc_aov <- t(apply(sub_dat,1,function(x) summary(aov(x~factor(s
ub_cell_type)+factor(sub_id)))[[1]][,5]))
jung_hsc_aov <- jung_hsc_aov[,-2] #subtract empty column
jung_hsc_diffs <- as.numeric(apply(sub_dat,1, function(tt){
mean(tt[which(sub_cell_type=="LSC")]) - mean(tt[which(sub_cell_typ
e=="HSC")])
}))
names(jung_hsc_diffs) <- rownames(sub_dat)
jung_hsc_score <- -log10(jung_hsc_aov[,1]) * jung_hsc_diffs
names(jung_hsc_score) <- names(jung_hsc_diffs)
jung_hsc_score <- jung_hsc_score[!is.na(jung_hsc_score)]
plot(1:length(jung_hsc_score), rev(jung_hsc_score[order(jung_hsc_sco
re)]))
threshold <- median(jung_hsc_score) + 10*IQR(jung_hsc_score)/1.35
jung_hsc_genes <- names(jung_hsc_score[which(jung_hsc_score>threshol
d)])
jung_hsc_genes <- affy_annot[jung_hsc_genes,"ext_gene"]
jung_hsc_genes <- jung_hsc_genes[!is.na(jung_hsc_genes)]
jung_genes <- intersect(jung_hsc_genes, jung_blast_genes)
save(jung_blast_aov, jung_blast_diffs, jung_hsc_aov, jung_hsc_diffs,
jung_genes, file="jung_data.RData")

5 Compute overlap
winning_genes <- intersect(intersect(corces_genes, dj_genes), jung_g
enes)
winning_genes

6 Appendix
6.1 File location
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getwd()
## [1] "/Users/smherbrich/Box Sync/Konopleva/manuscripts/thesis/scri
pts"

6.2 Session info
sessionInfo()
## R version 3.6.1 (2019-07-05)
## Platform: x86_64-apple-darwin15.6.0 (64-bit)
## Running under: macOS Sierra 10.12.6
##
## Matrix products: default
## BLAS:
/Library/Frameworks/R.framework/Versions/3.6/Resources/li
b/libRblas.0.dylib
## LAPACK: /Library/Frameworks/R.framework/Versions/3.6/Resources/li
b/libRlapack.dylib
##
## locale:
## [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8
##
## attached base packages:
## [1] stats
graphics grDevices utils
datasets methods
b
ase
##
## loaded via a namespace (and not attached):
## [1] compiler_3.6.1 magrittr_1.5
tools_3.6.1
htmltools_0.
4.0
## [5] yaml_2.2.0
Rcpp_1.0.3
stringi_1.4.5
rmarkdown_2.
1
## [9] knitr_1.27
stringr_1.4.0
xfun_0.12
digest_0.6.2
3
## [13] rlang_0.4.3
evaluate_0.14
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